
<html lang="en"     class="pb-page"  data-request-id="e9a83f07-e352-447c-8a61-0c54a7f03b50"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01955;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase" /></meta><meta name="dc.Creator" content="Christian  Markert" /></meta><meta name="dc.Creator" content="Gebhard  Thoma" /></meta><meta name="dc.Creator" content="Honnappa  Srinivas" /></meta><meta name="dc.Creator" content="Birgit  Bollbuck" /></meta><meta name="dc.Creator" content="Rainer M.  Lüönd" /></meta><meta name="dc.Creator" content="Wolfgang  Miltz" /></meta><meta name="dc.Creator" content="Rudolf  Wälchli" /></meta><meta name="dc.Creator" content="Romain  Wolf" /></meta><meta name="dc.Creator" content="Jürgen  Hinrichs" /></meta><meta name="dc.Creator" content="Christian  Bergsdorf" /></meta><meta name="dc.Creator" content="Kamal  Azzaoui" /></meta><meta name="dc.Creator" content="Carlos A.  Penno" /></meta><meta name="dc.Creator" content="Kai  Klein" /></meta><meta name="dc.Creator" content="Nathalie  Wack" /></meta><meta name="dc.Creator" content="Petra  Jäger" /></meta><meta name="dc.Creator" content="Franziska  Hasler" /></meta><meta name="dc.Creator" content="Christian  Beerli" /></meta><meta name="dc.Creator" content="Pius  Loetscher" /></meta><meta name="dc.Creator" content="Janet  Dawson" /></meta><meta name="dc.Creator" content="Grazyna  Wieczorek" /></meta><meta name="dc.Creator" content="Shin  Numao" /></meta><meta name="dc.Creator" content="Amanda  Littlewood-Evans" /></meta><meta name="dc.Creator" content="Till A.  Röhn" /></meta><meta name="dc.Description" content="The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies have validated ..." /></meta><meta name="Description" content="The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies have validated ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01955" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01955" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01955" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01955" /></link>
        
    
    

<title>Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01955" /></meta><meta property="og:title" content="Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0015.jpeg" /></meta><meta property="og:description" content="The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies have validated this enzyme as an attractive drug target in chronic inflammatory diseases. Despite several attempts, no LTA4H inhibitor has reached the market, yet. Herein, we disclose the discovery and preclinical profile of LYS006, a highly potent and selective LTA4H inhibitor. A focused fragment screen identified hits that could be cocrystallized with LTA4H and inspired a fragment merging. Further optimization led to chiral amino acids and ultimately to LYS006, a picomolar LTA4H inhibitor with exquisite whole blood potency and long-lasting pharmacodynamic effects. Due to its high selectivity and its ability to fully suppress LTB4 generation at low exposures in vivo, LYS006 has the potential for a best-in-class LTA4H inhibitor and is currently investigated in phase II clinical trials in inflammatory acne, hidradenitis suppurativa, ulcerative colitis, and NASH." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01955"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01955">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01955&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01955&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01955&amp;href=/doi/10.1021/acs.jmedchem.0c01955" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1889-1903</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01917" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c00627" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A<sub>4</sub> Hydrolase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Christian Markert</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Markert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#fa99928893898e939b94d4979b88919f888eba94958c9b888e9389d4999597"><span class="__cf_email__" data-cfemail="9bf8f3e9f2e8eff2faf5b5f6fae9f0fee9efdbf5f4edfae9eff2e8b5f8f4f6">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Markert">Christian Markert</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1857-9885" title="Orcid link">http://orcid.org/0000-0003-1857-9885</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gebhard Thoma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gebhard Thoma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gebhard++Thoma">Gebhard Thoma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Honnappa Srinivas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Honnappa Srinivas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Honnappa++Srinivas">Honnappa Srinivas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Birgit Bollbuck</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Birgit Bollbuck</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Birgit++Bollbuck">Birgit Bollbuck</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rainer M. Lüönd</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rainer M. Lüönd</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rainer+M.++L%C3%BC%C3%B6nd">Rainer M. Lüönd</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wolfgang Miltz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wolfgang Miltz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wolfgang++Miltz">Wolfgang Miltz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rudolf Wälchli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rudolf Wälchli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rudolf++W%C3%A4lchli">Rudolf Wälchli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Romain Wolf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Romain Wolf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Romain++Wolf">Romain Wolf</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jürgen Hinrichs</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jürgen Hinrichs</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J%C3%BCrgen++Hinrichs">Jürgen Hinrichs</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Bergsdorf</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Bergsdorf</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Bergsdorf">Christian Bergsdorf</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kamal Azzaoui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kamal Azzaoui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kamal++Azzaoui">Kamal Azzaoui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlos A. Penno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlos A. Penno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Analytical Sciences & Imaging, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlos+A.++Penno">Carlos A. Penno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai Klein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai Klein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PK Sciences, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Klein">Kai Klein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nathalie Wack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nathalie Wack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nathalie++Wack">Nathalie Wack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Petra Jäger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Petra Jäger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Petra++J%C3%A4ger">Petra Jäger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Franziska Hasler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Franziska Hasler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Franziska++Hasler">Franziska Hasler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Beerli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Beerli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Beerli">Christian Beerli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pius Loetscher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pius Loetscher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pius++Loetscher">Pius Loetscher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Janet Dawson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janet Dawson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Dawson">Janet Dawson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4615-4091" title="Orcid link">http://orcid.org/0000-0003-4615-4091</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Grazyna Wieczorek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Grazyna Wieczorek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Grazyna++Wieczorek">Grazyna Wieczorek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shin Numao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shin Numao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shin++Numao">Shin Numao</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6204-7117" title="Orcid link">http://orcid.org/0000-0002-6204-7117</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amanda Littlewood-Evans</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amanda Littlewood-Evans</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amanda++Littlewood-Evans">Amanda Littlewood-Evans</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Till A. Röhn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Till A. Röhn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Till+A.++R%C3%B6hn">Till A. Röhn</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01955&amp;href=/doi/10.1021%2Facs.jmedchem.0c01955" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1889–1903</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 November 2020</li><li><span class="item_label"><b>Published</b> online</span>16 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01955" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01955</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1889%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChristian%2BMarkert%252C%2BGebhard%2BThoma%252C%2BHonnappa%2BSrinivas%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D4%26contentID%3Dacs.jmedchem.0c01955%26title%3DDiscovery%2Bof%2BLYS006%252C%2Ba%2BPotent%2Band%2BHighly%2BSelective%2BInhibitor%2Bof%2BLeukotriene%2BA4%2BHydrolase%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1903%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01955"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1680</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01955" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Markert&quot;},{&quot;first_name&quot;:&quot;Gebhard&quot;,&quot;last_name&quot;:&quot;Thoma&quot;},{&quot;first_name&quot;:&quot;Honnappa&quot;,&quot;last_name&quot;:&quot;Srinivas&quot;},{&quot;first_name&quot;:&quot;Birgit&quot;,&quot;last_name&quot;:&quot;Bollbuck&quot;},{&quot;first_name&quot;:&quot;Rainer&quot;,&quot;last_name&quot;:&quot;M. Lüönd&quot;},{&quot;first_name&quot;:&quot;Wolfgang&quot;,&quot;last_name&quot;:&quot;Miltz&quot;},{&quot;first_name&quot;:&quot;Rudolf&quot;,&quot;last_name&quot;:&quot;Wälchli&quot;},{&quot;first_name&quot;:&quot;Romain&quot;,&quot;last_name&quot;:&quot;Wolf&quot;},{&quot;first_name&quot;:&quot;Jürgen&quot;,&quot;last_name&quot;:&quot;Hinrichs&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Bergsdorf&quot;},{&quot;first_name&quot;:&quot;Kamal&quot;,&quot;last_name&quot;:&quot;Azzaoui&quot;},{&quot;first_name&quot;:&quot;Carlos&quot;,&quot;last_name&quot;:&quot;A. Penno&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Klein&quot;},{&quot;first_name&quot;:&quot;Nathalie&quot;,&quot;last_name&quot;:&quot;Wack&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Jäger&quot;},{&quot;first_name&quot;:&quot;Franziska&quot;,&quot;last_name&quot;:&quot;Hasler&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Beerli&quot;},{&quot;first_name&quot;:&quot;Pius&quot;,&quot;last_name&quot;:&quot;Loetscher&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Dawson&quot;},{&quot;first_name&quot;:&quot;Grazyna&quot;,&quot;last_name&quot;:&quot;Wieczorek&quot;},{&quot;first_name&quot;:&quot;Shin&quot;,&quot;last_name&quot;:&quot;Numao&quot;},{&quot;first_name&quot;:&quot;Amanda&quot;,&quot;last_name&quot;:&quot;Littlewood-Evans&quot;},{&quot;first_name&quot;:&quot;Till&quot;,&quot;last_name&quot;:&quot;A. Röhn&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1889-1903&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01955&quot;},&quot;abstract&quot;:&quot;The cytosolic metalloenzyme leukotriene A4 hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). Preclinical studies have validated this enzyme as an attractive drug target in chronic inflammatory diseases. Despite several attempts, no LTA4H inhibitor has reached the market, yet. Herein, we disclose the discovery and preclinical profile of LYS006, a highly potent and selective LTA4H inhibitor. A focused fragment screen identified hits that could be cocrystallized with LTA4H and inspired a fragment merging. Further optimization led to chiral amino acids and ultimately to LYS006, a picomolar LTA4H inhibitor with exquisite whole blood potency and long-lasting pharmacodynamic effects. Due to its high selectivity and its ability to fully suppress LTB4 generation at low exposures in vivo, LYS006 has the potential for a best-in-class LTA4H inhibitor and is currently investigated in phase II clinical trials in inflammatory acne, hidradenitis suppurativa&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01955&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01955" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01955&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01955" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01955&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01955" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01955&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01955&amp;href=/doi/10.1021/acs.jmedchem.0c01955" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01955" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01955" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01955%26sid%3Dliteratum%253Aachs%26pmid%3D33592148%26genre%3Darticle%26aulast%3DMarkert%26date%3D2021%26atitle%3DDiscovery%2Bof%2BLYS006%252C%2Ba%2BPotent%2Band%2BHighly%2BSelective%2BInhibitor%2Bof%2BLeukotriene%2BA4%2BHydrolase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D1889%26epage%3D1903%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The cytosolic metalloenzyme leukotriene A<sub>4</sub> hydrolase (LTA4H) is the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B<sub>4</sub> (LTB<sub>4</sub>). Preclinical studies have validated this enzyme as an attractive drug target in chronic inflammatory diseases. Despite several attempts, no LTA4H inhibitor has reached the market, yet. Herein, we disclose the discovery and preclinical profile of LYS006, a highly potent and selective LTA4H inhibitor. A focused fragment screen identified hits that could be cocrystallized with LTA4H and inspired a fragment merging. Further optimization led to chiral amino acids and ultimately to LYS006, a picomolar LTA4H inhibitor with exquisite whole blood potency and long-lasting pharmacodynamic effects. Due to its high selectivity and its ability to fully suppress LTB<sub>4</sub> generation at low exposures <i>in vivo</i>, LYS006 has the potential for a best-in-class LTA4H inhibitor and is currently investigated in phase II clinical trials in inflammatory acne, hidradenitis suppurativa, ulcerative colitis, and NASH.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Leukotriene A4 hydrolase (LTA4H) is a monomeric 69 kDa, cytosolic metalloenzyme with an active site, that contains a Zn<sup>2+</sup> ion, located between two domains. This active site has distinct but overlapping substrate binding pockets and exhibits two enzymatic activities, an aminopeptidase and an epoxide hydrolase function.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">The first pocket of the catalytic site, the aminopeptidase pocket is hydrophilic and open to the solvent. It can cleave tripeptides, and it has been implicated in the degradation of certain opioid peptides as well as tripeptide proline-glycine-proline (PGP). The physiological relevance of this capacity of LTA4H to degrade peptides, however, remains unknown.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2−5)</a></div><div class="NLM_p">The second pocket, the hydrolase pocket of the enzyme, forms a long, L-shaped hydrophobic channel. Substrate leukotriene A<sub>4</sub> (LTA<sub>4</sub>) binds to this pocket. The hydrolase function catalyzes the Zn<sup>2+</sup> assisted vinylogous ring-opening of the epoxide LTA<sub>4</sub> to form pro-inflammatory leukotriene B<sub>4</sub> (LTB<sub>4</sub>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> LTA4H is the final and rate limiting enzyme in the biosynthesis of this pro-inflammatory lipid mediator.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><div class="NLM_p">Whereas LTA4H is expressed in the majority of mammalian cells and tissues, the upstream enzymatic machinery consisting of cytosolic phospholipase (cPLA2), 5-lipoxygenase (5-LO), and 5-lipoxygenase activating protein (FLAP), responsible for the generation of LTA<sub>4</sub>, is present in only a few cell types, particularly leukocytes. Hence, LTB<sub>4</sub> is mainly produced by myeloid cells, especially neutrophils, macrophages, dendritic cells, and monocytes, but also mast cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> It is an important inflammatory mediator capable of initiating and amplifying innate and adaptive immune responses and has a particularly strong effect on the recruitment and activation of neutrophils.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> It has been implicated in many acute and chronic human inflammatory diseases and its inhibition proved beneficial in numerous preclinical models of inflammation with a strong neutrophil component.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div><div class="NLM_p">LTA4H is a particularly interesting target as its inhibition allows for the selective repression of LTB<sub>4</sub> generation without affecting the biosynthesis of lipids that depend on the upstream enzymes 5-LO and FLAP.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These include the different families of anti-inflammatory and resolution promoting lipid mediators such as D- and E-series of resolvins, maresins, and protectins, all of which are 5-LO dependent.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Moreover, inhibition of LTA4H can even lead to elevated levels of anti-inflammatory and anti-fibrotic lipoxin A<sub>4</sub> (LXA<sub>4</sub>) due to pathway shunting.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> LXA<sub>4</sub> is formed by 12- and 15-lipoxygenases from the common precursor LTA<sub>4</sub> that becomes more abundant upon LTA4H inhibition. Hence, inhibition of LTA4H not only reduces pro-inflammatory LTB<sub>4</sub> but can also induce a lipid mediator class-switch from pro-inflammatory to pro-resolving lipids and thereby possibly contribute to the resolution of chronic inflammation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Numerous pharmaceutical companies have initiated programs to discover LTA4H inhibitors and described several clinical stage compounds (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of LTA4H inhibitors that have reached phase II clinical trials but are no longer reported to be in active development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Boehringer Ingelheim’s BI 691751 (structure not disclosed) for the treatment of atherosclerosis was discontinued after phase I. Trial data suggest that BI 691751 may have caused an increase in both heart rate and length of the QT interval at higher doses.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> DeCODE discovered LTA4H inhibitor DG-051.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The compound exhibited mediocre potency in inhibiting LTB<sub>4</sub> biosynthesis in human cells, and further development of DG-051 was discontinued after a phase II PK/PD study.</div><div class="NLM_p">In contrast, compound JNJ-40929837 by Janssen was promoted into a phase II efficacy trial in asthma. Despite target engagement, early and late asthmatic response measured by forced expiratory volume (FEV1) was not reduced.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This is possibly owing to the fact that the role of LTB<sub>4</sub> in human allergic asthma is considered minor.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Cysteinyl leukotrienes (CysLTs), on the other hand, which are not inhibited by LTA4H inhibitors and may even be elevated due to pathway shunting as indicated by the trial data, are key to the pathophysiology of asthma.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> CysLTs cause bronchoconstriction and impact the FEV1 response.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, JNJ-40929837 caused testicular toxicity in rats due to accumulation of a metabolite<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and was not further investigated in indications beyond asthma and eventually discontinued.</div><div class="NLM_p">Celtaxsys CTX-4430 (Acebilustat) is the most advanced LTA4H inhibitor in clinical development.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> It reduced sputum LTB<sub>4</sub> levels and, importantly, led to a clinical reduction of sputum neutrophil counts in cystic fibrosis (CF) patients. This translated to a 19–35% reduction in inflammatory exacerbations, but similarly to the previous observation by Janssen in asthma it did not change FEV1 in a 48 week phase 2b study in 133 patients.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22−24)</a> While Celtaxsys announced preparations toward a phase III study in CF based on these results, no further development of Acebilustat has been reported to date.</div><div class="NLM_p last">Herein, we describe the discovery and preclinical profile of LYS006, a potent and highly selective LTA4H inhibitor. LYS006 not only exhibits an exquisite selectivity profile but also is characterized by picomolar enzyme inhibition, low IC<sub>90</sub> values in human whole blood assays, and sustained PD effects <i>in vivo</i>, ensuring nearly complete target engagement at very low blood and particularly plasma exposures. Furthermore, we could demonstrate that LYS006 elevates LXA<sub>4</sub> biosynthesis in PBMCs via pathway shunting and efficiently suppresses neutrophil activation in skin inflammation and KRN arthritis models under prophylactic and therapeutic conditions.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Finding</h3><div class="NLM_p">The RCSB Protein Data Bank<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> holds several cocrystal structures of small ligands bound to LTA4H. This encouraged us to start our hit finding with a focused screen on ∼1800 compounds of the Novartis fragment library including ∼350 fragment-like molecules with <i>in silico</i> predicted potential for LTA4H binding.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Differential scanning fluorimetry (DSF), which measures the change in temperature at which a purified protein unfolds in the presence of a putative binder, was used as a way of testing for compound binding. A solvatochromic dye with affinity for exposed hydrophobic parts of the protein indicates the progress of unfolding.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a></div><div class="NLM_p">In total, 14 fragments induced significant positive shifts in melting temperature (<i>T</i><sub>m</sub>) and were subsequently studied by X-ray crystallography. From these, diaryl ether <b>1</b> and amine <b>2</b> particularly attracted our attention (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Fragment hits <b>1</b> (7AV2) and <b>2</b> (7AV1) bound to LTA4H (left) and hydrogen bonding network for fragment <b>2</b> (right). For clarity, only key interactions are depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Identification of highly potent starting point <b>3</b> by merging of fragment hits <b>1</b> and <b>2</b>. Under DSF screening conditions, <b>1</b> and <b>2</b> increased the melting temperature (<i>T</i><sub>m</sub>) of LTA4H by 0.5 °C (at 500 μM). Hybrid <b>3</b> stabilized by 6.8 °C (at 100 μM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both fragments bind to the hydrophobic hydrolase substrate pocket of the second lobe of LTA4H. Binding of diaryl ether <b>1</b> is characterized by π–π interactions of both aromatic rings to Phe314. Additionally, fragment <b>2</b> shows such a π–π interaction to Phe314 and a π-stacking of its tetrazole to Tyr267. The amine function of <b>2</b> forms three H-bonds in an almost perfect sp<sup>3</sup> geometry. The first bond of the protonated amine goes to negatively charged Glu271, the second to Gln136, and a third one is a water mediated hydrogen bonding to Tyr383.</div><div class="NLM_p">Most notably, however, superposition of both fragments bound to LTA4H revealed an almost perfect overlay of the central phenyl ring inspiring testing of hybrid amines, such as <b>3</b> and <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. DSF Confirmation Data on Selected Compounds<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">biochem IC<sub>50</sub></th><th class="colsep0 rowsep0" align="center" char=".">concn [μM]</th><th class="colsep0 rowsep0" align="center" char="±">Δ<i>T</i><sub>m</sub> [°C]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 4.5 μM</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">1000</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 8.8 μM</td><td class="colsep0 rowsep0" align="char" char=".">125</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">250</td><td class="colsep0 rowsep0" align="char" char="±">0.3 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">500</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">1000</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 0.004 μM</td><td class="colsep0 rowsep0" align="char" char=".">12.5</td><td class="colsep0 rowsep0" align="char" char="±">4.2 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 0.09</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Each experiment was executed in quadruplicate.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Head Group Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0013.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">LTA4H enzyme inhibition assay using Arg-AMC as substrate with IC<sub>50</sub> shown as the mean ± SD, in the case of <i>n</i> ≥ 2.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Human whole blood ionophore stimulated LTB<sub>4</sub> release assay with IC<sub>50</sub> shown as the mean ± SD, in the case of <i>n</i> ≥ 2.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Metabolic stability in rat liver microsomes supplemented with NADPH.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Binding assay using radiolabeled <sup>3</sup>H-dofetilide and HEK293 cell membranes expressing human recombinant HERG K<sup>+</sup> channels.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Reversible Inhibition of CYP3A4 (midazolam), CYP2C9 (diclofenac) and CYP2D6 (bufuralol) in human liver microsomes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></div><div></div></div><div class="NLM_p">Both hits <b>1</b> and <b>2</b>, as well as hybrid <b>3</b> showed a concentration dependent shift in LTA4H <i>T</i><sub>m</sub>, supporting the notion that DSF is well suited to identify binders to the substrate binding site of LTA4H (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p last">Whereas fragments <b>1</b> and <b>2</b> showed measurable, but weak inhibition in our biochemical peptidase assay (IC<sub>50</sub> of 4.5 μM/8.8 μM), hybrids <b>3</b> and <b>4</b> inhibited LTA4H with remarkable IC<sub>50</sub> values of 0.004 μM biochemically, and 0.121 and 0.129 μM in a human whole blood assay, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Early Optimization: Head Group SAR</h3><div class="NLM_p">Amine <b>3</b> and its chloro-analogue <b>4</b> constituted an excellent starting point for optimization. However, the combination of a basic amine with a lipophilic tail raised concerns with regard to metabolic instability, hERG and cytochrome P450 (CYP) inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Varying the chain length (<b>5</b>) or capping the amine by acetylation (<b>6</b>) led to significant losses in potency. Substitution of the aliphatic chain (<b>7</b>, <b>8</b>) was tolerated to some degree, but it did not solve the inherent liabilities of this starting point.</div><div class="NLM_p">We speculated that more profound modifications were needed and explored a diverse set of linkers and functional groups attached to the tetrazole, while keeping the diaryl ether unchanged. The key molecule identified from this effort was butyric acid derivative <b>9</b>, as it offered a structural alternative to the amine headgroup. Compound <b>9</b> achieved high biochemical activity combined with good microsomal stability, without inhibiting CYPs or the hERG channel. Compound <b>10</b> carrying a shorter propionic acid achieved less biochemical potency. Activity in blood, however, was not detectable for either of the two, which we attributed to very high plasma protein binding of >99% (human plasma, RED).</div><div class="NLM_p last">Once this second motif <b>9</b> was identified, we probed the combination of the two functional groups in different arrangements. The α-amino acids <b>11</b> and <b>12</b> showed good microsomal stability and no hERG inhibition. Even more interesting was β-amino acid <b>13</b>, which as well solved the liabilities of amine <b>4</b>, while preserving or even improving biochemical and cellular activity in human blood. Zwitterionic lead compound <b>13</b> carries a stereocenter and both enantiomers performed equally well in our biochemical and whole blood assays. In an attempt to differentiate the two, we extended our profiling to a panel of >100 potential off-targets and observed very high specificity. Only a moderate binding to a single off-target, the dopamine transporter (DAT) was found. However, differentiation was still not possible, as both enantiomers (<i>S</i>)-<b>13</b> and (<i>R</i>)-<b>13</b> act as antagonists of DAT with similar IC<sub>50</sub> values of 10 and 15 μM, respectively, as determined in a radioligand binding assay.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> As even moderate antagonism of this transporter might complicate the development program at later stages, requiring drug abuse and behavioral studies, we set out to identify compounds without this moderate flag.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Late Optimization: Tail SAR</h3><div class="NLM_p">In addition to DAT inhibition, we considered the low solubility (27 μM in a HT-solubility assay<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a>) as a possible development risk and therefore focused further compound optimization on these two parameters. The terminal chlorophenyl was rapidly confirmed as a promising site for efficient fine-tuning of properties (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The very close fluoro-analogue <b>14</b> addressed DAT inhibition and led to some increase in solubility. Likewise, additional flexibility introduced by aliphatic ethers <b>15</b>–<b>18</b> modulated both parameters. Sparring of DAT was most consistently observed for ethers <b>19</b>–<b>23</b> carrying additional heteroaromatic rings. The strongest increases in solubility were achieved by reducing the degree of planarity (<b>17</b>), or the use of small heteroaromatic ethers (<b>21</b>–<b>23</b>). Fluoro-chloropyridine <b>22</b> ultimately provided the best option for maintaining high potency in enzyme and human whole blood assays, while increasing compound solubility and selectivity versus DAT. However, (<i>S</i>)- and (<i>R</i>)-enantiomers could still not be differentiated based on <i>in vitro</i> behavior.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Tail Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0014.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">LTA4H enzyme inhibition assay in screening mode, using Arg-AMC as substrate with IC<sub>50</sub> shown as the mean ± SD, in case of <i>n</i> ≥ 2. Lowest determined biochemical potency is 3 nM in this setting.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Human whole blood ionophore-stimulated LTB<sub>4</sub> release assay with 15 min compound preincubation. IC<sub>50</sub> shown as the mean ± SD, in case of <i>n</i> ≥ 2.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">DAT radioligand binding assay on human recombinant DAT with IC<sub>50</sub> shown as the mean of 1–6 assessments.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Equilibrated solubility in aqueous buffer at pH 6.8.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Inhibition of LTB<sub>4</sub> release from <i>ex vivo</i> ionophore-stimulated mouse blood 14 h after p.o. dose of compound compared to vehicle control given as the mean percent inhibition ± SEM (<i>n</i> ≥ 3).</p></div></div><div></div></div><div class="NLM_p">Cocrystal structures offered an explanation for the subordinate role of the stereoconfiguration on <i>in vitro</i> potency. <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> shows an overlay of the two cocrystal structures obtained for lead compound (<i>R</i>)-<b>13</b> and the (<i>S</i>)-configured candidate (<i>S</i>)-<b>22</b>. Their carboxylic acids both reach to the catalytic zinc, an important additional interaction introduced by the zwitterionic motif. Notably, despite opposite stereoconfigurations, both ligands locate their primary amines in almost identical positions for the key H-bonding to Glu271, providing a rationale for their similar biochemical behaviors. The tail of <b>(</b><i>S</i><b>)-22</b> superimposes almost perfectly with the original lead structure, illustrating that the nature of the tail optimization was a fine-tuning of properties while preserving an already favorable binding mode. Electron densities and details of interactions between compounds (<i>R</i>)-<b>13</b> and (<i>S</i>)-<b>22</b> and protein are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_001.pdf" class="ext-link">Supplementary Figures S1 and S2</a>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Optimized candidate (<i>S</i>)-<b>22</b> (7AUZ) and lead compound (<i>R</i>)-<b>13</b> (7AV0) bound to LTA4H (overlay). Despite opposite stereoconfigurations, the amine and acid groups occupy almost identical positions, rationalizing similar biochemical behavior of the optical antipodes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Selection of Clinical Candidate (<i>S</i>)-22/LYS006 Based on Mouse PK/PD Data</h3><div class="NLM_p last">As LTA4H is highly expressed in blood cells, particularly in neutrophils and monocytes, <i>in vivo</i> target engagement can be easily assessed via determination of LTB<sub>4</sub> production in <i>ex vivo</i> stimulated blood (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Mouse PK/PD studies at defined time-points after oral dosing confirmed that several of our advanced candidates achieved excellent LTB<sub>4</sub> reduction <i>in vivo</i>. We ranked compounds according to their <i>in vivo</i> potency and in particular according to the longevity of the PD effect by determining LTB<sub>4</sub> release 14 h post oral dosing. Using these conditions, we observed that for all three enantiomeric pairs tested, the (<i>S</i>)-enantiomer showed superior performance in PK/PD experiments [<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>: (<i>S/R</i>)-<b>18</b>, (<i>S</i><b>/</b><i>R</i>)-<b>20</b>, (<i>S</i><b>/</b><i>R</i>)-<b>22</b>], apparently due to faster clearance of the (<i>R</i>)-enantiomers. Based on this assessment, (<i>S</i>)-<b>22</b> was given preference over (<i>R</i>)-<b>22</b>. It showed the best overall profile and was selected for in depth profiling and became clinical development candidate LYS006.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Physicochemical Properties and <i>In Vitro</i> Profile of LYS006</h3><div class="NLM_p">LYS006 is a zwitterion (p<i>K</i><sub>a1</sub> = 7.5; p<i>K</i><sub>a2</sub> = 3.3), showing pH dependent solubility with maxima at low (<2) and high pH (>9) and a minimum between pH 5.4–6. Aqueous solubility of crystalline material was confirmed as 207 μM at 25 °C. Passive permeability of LYS006 is low to moderate (log <i>P</i><sub>e</sub> pH 6.8 = −6).</div><div class="NLM_p">Exact determination of the biochemical potency of LYS006 required a reduction in enzyme concentration compared to screening conditions and delivered a remarkable biochemical IC<sub>50</sub> of 0.12 ± 0.01 nM (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Cellular potency was determined in calcium ionophore stimulated human PBMCs. The potency of LYS006 showed a time dependency, meaning that increased incubation times resulted in lower IC<sub>50</sub> and IC<sub>90</sub> values and steeper dose response curves (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a phenomenon we did not observe for LTA4H inhibitors from other chemical series. Incubation for 4 h revealed an IC<sub>50</sub> of 3.7 nM. LYS006 shows an unbound plasma fraction of 7.9% in human plasma with comparable plasma protein binding across all tested species. In human whole blood, we measured an IC<sub>50</sub> of 53 nM and again noticed a time dependency (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Similar observations have recently been reported for poorly permeable FLAP inhibitors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Whole blood IC<sub>50</sub> values determined in other species such as mouse, dog and rabbit were very similar to those determined with human blood (data not shown). Head to head comparison of LYS006 with previously published clinical stage LTA4H inhibitors revealed similar whole blood potency as JNJ-40929837 but clearly superior potency to DG051 and acebilustat (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Human PBMCs (upper panel) and human whole blood (lower panel) were preincubated for different times with increasing concentrations of LYS006. Compound preincubation times ranged from 15 to 240 min. Cells were then stimulated with ionophore and LTB<sub>4</sub> release determined. Dose–response curves with mean LTB<sub>4</sub> levels ± SD are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Potency of LYS006 versus Clinical Stage LTA4H Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">potency [nM]</th><th class="colsep0 rowsep0" align="center" char="±">LYS006</th><th class="colsep0 rowsep0" align="center" char="±">DG051</th><th class="colsep0 rowsep0" align="center" char="±">JNJ-40929837</th><th class="colsep0 rowsep0" align="center" char="±">Acebilustat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">biochemical IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="±">0.12 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">54 ± 17</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human PBMC IC<sub>50</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">74 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 8.5</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 9.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human PBMC IC<sub>90</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">27 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">1069 ± 759</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 76</td><td class="colsep0 rowsep0" align="char" char="±">181 ± 91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood IC<sub>50</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">53 ± 23</td><td class="colsep0 rowsep0" align="char" char="±">510 ± 133</td><td class="colsep0 rowsep0" align="char" char="±">48 ± 5.5</td><td class="colsep0 rowsep0" align="char" char="±">142 ± 37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood IC<sub>90</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char="±">148 ± 67</td><td class="colsep0 rowsep0" align="char" char="±">5054 ± 2731</td><td class="colsep0 rowsep0" align="char" char="±">104 ± 9.5</td><td class="colsep0 rowsep0" align="char" char="±">728 ± 225</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">LTA4H enzyme inhibition assay using Arg-AMC as substrate with <1 nM enzyme concentration. IC<sub>50</sub> are mean values ± SD (<i>n</i> ≥ 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Human PBMC ionophore stimulated LTB<sub>4</sub> release assay with 4 h compound preincubation. IC<sub>50</sub> and IC<sub>90</sub> shown as the mean ± SD (<i>n</i> ≥ 3).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Human whole blood ionophore stimulated LTB<sub>4</sub> release assay with 4 h compound preincubation. IC<sub>50</sub> and IC<sub>90</sub> shown as the mean ± SD (<i>n</i> ≥ 3).</p></div></div></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Selectivity of LYS006</h3><div class="NLM_p">LYS006 shows an exquisite selectivity profile when tested at concentrations of ≥10 μM in binding or functional mode on a panel of >150 GPCRs, transporters, ion channels, nuclear receptors, and enzymes <i>in vitro</i>. Likewise, <i>in vitro</i> investigations did not indicate any inhibitory potential on hERG channel currents with IC<sub>50</sub> > 30 μM for binding and Qpatch, and >100 μM in a manual patch clamp assay. On Nav 1.5, an IC<sub>50</sub> > 50 μM was also established. LYS006 does not inhibit any CYP450 family member up to tested concentrations of 20 μM, has no phototoxic potential and is negative in genotoxic and mutagenicity assays (Ames and <i>in vitro</i> and <i>in vivo</i> micronucleus test). As LTA4H is a Zn<sup>2+</sup>-containing metallopeptidase, we included cross-reactivity testing versus a selection of other Zn<sup>2+</sup> containing metalloproteases testing matrix metalloproteases 1, 2, 8, 9, 12, 13, 14 and TACE. LYS006 did not inhibit any of these up to concentrations of 30 μM.</div><div class="NLM_p">Another feature of LTA4H is that it carries an aminopeptidase as well as a hydrolase function. Similarly to all previous clinically tested LTA4H inhibitors, LYS006 inhibits both functions, the hydrolytic opening of LTA<sub>4</sub> leading to LTB<sub>4</sub>, and the degradation of tripeptides with similar IC<sub>50</sub> (data not shown).</div><div class="NLM_p">Furthermore, we tested selectivity of LYS006 on eicosanoid metabolizing enzymes and determined the concentration of a panel of 45 lipid mediators released from stimulated human PBMCs after treatment with rising concentrations of LYS006. Whereas formation of LTB<sub>4</sub> was inhibited at concentrations in agreement with the previously determined IC<sub>50</sub> of LYS006 on human PBMCs, and showed >95% inhibition at 1 μM, no other lipid mediator was significantly suppressed by more than 10%, demonstrating the excellent selectivity of LYS006 for LTA4H (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). As expected, formation of the pro-resolution lipid LXA<sub>4</sub> was elevated upon treatment with LYS006 due to pathway shunting and conversion of elevated LTA<sub>4</sub> into LXA<sub>4</sub>. A moderate increase of cysteinyl leukotrienes such as LTC<sub>4</sub> could also be observed due to conversion of LTA<sub>4</sub> into LTC<sub>4</sub> by LTC<sub>4</sub>-synthase, as expected.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Lipidomics profile of LYS006-treated, stimulated human PBMCs. PBMCs were pretreated for 15 min with 1 μM LYS006 or vehicle control prior to stimulation with calcium ionophore for 2 h. Lipids were quantified by LCMS/MS. Concentrations are shown in ng/mL as the mean ± SD. Depicted is a selection of lipid mediators from different eicosanoid metabolism pathways of a total of 45 tested lipids. Statistical analysis Welch’s <i>t</i> test. *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001. Abbreviations: AA, arachidonic acid; 12-HETE, 12-hydroxyeicosatetraenoic acid; 15-HETE, 15-hydroxyeicosotetraenoic acid; PGE2, prostaglandin E2; PGD2, prostaglandin D2; TXB2 = thromboxane B2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preclinical PK Profile of LYS006</h3><div class="NLM_p">The pharmacokinetic profile of LYS006 is characterized by target-mediated drug disposition (TMDD), where the distribution changes with the degree of target saturation. LTA4H is expressed in nearly all mammalian cells and expression in blood is high in neutrophils, monocytes but also erythrocytes.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> One consequence is a concentration-dependent blood-to-plasma distribution (<i>in vitro</i> and <i>in vivo</i>) in all species. For concentrations close to complete target (LTA4H) saturation and above (>250 nM), blood-to-plasma ratios decline to <1, whereas LYS006 was predominantly distributed into blood cells at concentrations below 250 nM reaching ratios of 7:1 in human blood. Data are shown for 30 min incubation time (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). At longer preincubation times, blood/plasma ratios became even larger (data not shown). No concentration-dependency was observed in blood of LTA4H knockout mice (constant distribution <i>C</i><sub>b</sub>/<i>C</i><sub>p</sub> of 0.7), confirming that binding of LYS006 to the target enzyme was mediating the concentration-dependent blood distribution (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vitro</i> blood/plasma distribution ratios of LYS006. Rising concentrations of [<sup>3</sup>H]LYS006 were incubated for 30 min at 37 °C with blood from different species. Total radioactivity in blood and plasma was determined in triplicate. Values are given as the ratio of [<sup>3</sup>H]LYS006 concentration in blood divided by plasma concentration of [<sup>3</sup>H]LYS006.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After i.v. dosing, clearance of LYS006 was low for mice, rats, and dogs (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In all species, we observed nonlinear pharmacokinetics with a concentration-dependent volume of distribution and long terminal half-lives; both volume of distribution and half-life increase with lower systemic concentrations of LYS006 when compound is mainly distributed into blood cells.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> and <i>In Vivo</i> Pharmacokinetic Parameters Of LYS006 in Mouse, Rat, and Dog</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>in vitro</i></th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL int (μL min<sup>–1</sup> mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">10.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatic extraction (%)</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">9.4</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><i>in vivo</i></th><th class="colsep0 rowsep0" align="center">female C57BL6</th><th class="colsep0 rowsep0" align="center">male Wistar</th><th class="colsep0 rowsep0" align="center">male Beagle, fasted</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose</td><td class="colsep0 rowsep0" align="left">3.0 mg/kg i.v.</td><td class="colsep0 rowsep0" align="left">1.0 mg/kg i.v.</td><td class="colsep0 rowsep0" align="left">0.1 mg/kg i.v.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 mg/kg p.o.</td><td class="colsep0 rowsep0" align="left">3.0 mg/kg p.o.</td><td class="colsep0 rowsep0" align="left">0.3 mg/kg p.o.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL(mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">4.12 ± 0.86</td><td class="colsep0 rowsep0" align="left">0.662 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">0.945 ± 0.110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V<sub>ss</sub>(L/kg)</td><td class="colsep0 rowsep0" align="left">2.15 ± 0.78</td><td class="colsep0 rowsep0" align="left">3.29 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">3.81 ± 0.460</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub>(h)</td><td class="colsep0 rowsep0" align="left">16.7 ± 5.3</td><td class="colsep0 rowsep0" align="left">169 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">48.8 ± 4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub>d.n. (nM)</td><td class="colsep0 rowsep0" align="left">689 ± 271</td><td class="colsep0 rowsep0" align="left">1240 ± 232</td><td class="colsep0 rowsep0" align="left">306 ± 60.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub>(h)</td><td class="colsep0 rowsep0" align="left">0.25 ± 0</td><td class="colsep0 rowsep0" align="left">4.0 ± 0</td><td class="colsep0 rowsep0" align="left">5.0 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Oral BA (%F)</td><td class="colsep0 rowsep0" align="left">18.2 ± 1.3</td><td class="colsep0 rowsep0" align="left">56.8 ± 9.0</td><td class="colsep0 rowsep0" align="left">38.7 ± 3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC p.o. d.n.(nM·h)</td><td class="colsep0 rowsep0" align="left">1940 ± 139</td><td class="colsep0 rowsep0" align="left">38500 ± 6070</td><td class="colsep0 rowsep0" align="left">17600 ± 1550</td></tr></tbody></table></div></div><div class="NLM_p last">After oral administration, LYS006 is rapidly absorbed and reaches <i>C</i><sub>max</sub> after 0.25–5 h depending on the species. Bioavailability based on blood concentrations was moderate across species and best in rat (57%). These parameters, however, may be affected by the nonlinear PK properties. Despite long terminal half-lives no relevant accumulation was observed in high dose PK and toxicological studies (data not shown).</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Preclinical Pharmacodynamic Studies with LYS006</h3><div class="NLM_p">We studied the detailed PK/PD relationship of LYS006 in mice determining the release of LTB<sub>4</sub> in <i>ex vivo</i> stimulated blood as a proximal readout for target engagement. Mice were given increasing doses of LYS006 or control compound Acebilustat in a b.i.d. regimen for 3 days (altogether 5 p.o. administrations per dose). Blood exposure, plasma exposure and LTB<sub>4</sub> release were determined at steady state. At an early time point of 2 h after the last compound administration, doses as low as 0.625 mg/kg still led to >90% suppression of LTB<sub>4</sub> release at exposures in agreement with the blood IC<sub>90</sub> determined in human and mouse whole blood assays. Acebilustat showed similar levels of inhibition but at higher blood and plasma exposures. At 14 h after the last dosing, LYS006 maintained strong inhibition of LTB<sub>4</sub> release despite very low plasma exposures. Under these conditions, the compound exhibited a very high blood/plasma ratio, which was even more pronounced than that observed in the <i>in vitro</i> blood/plasma distribution assay described before. IC<sub>90</sub> was achieved at plasma exposures of only 8 nM and blood exposure of 130 nM, again in good agreement with the IC<sub>90</sub> values determined in human whole blood. Acebilustat did not reach IC<sub>90</sub> despite considerably higher blood and plasma exposures, again in good agreement with previously determined blood IC<sub>90</sub> values (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Steady-state PK/PD relationship of LYS006 (blue) and Acebilustat (green). Female C57BL/6 mice (<i>n</i> = 4 per group) were dosed p.o. five times in a b.i.d. regimen. Compound exposures in blood and plasma, and LTB<sub>4</sub> inhibition in <i>ex vivo</i> stimulated blood were determined 2 h (upper panel) and 14 h after the last dose (lower panel). Shown are average exposures in blood (black numbers above graphs) and plasma (green numbers above graph), and the means of LTB<sub>4</sub> inhibition ± SEM (PD). One way ANOVA followed by Dunnett’s multiple comparison correction was applied with **<i>p</i> < 0.01 and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Preclinical Efficacy in Neutrophilic Skin Inflammation Models</h3><div class="NLM_p">Next, we set out to study how LTB<sub>4</sub> inhibition translates into suppression of LTB<sub>4</sub> dependent neutrophil influx and activation. Therefore, we chose the arachidonic acid skin inflammation model and investigated the correlation between LTB<sub>4</sub> inhibition in <i>ex vivo</i> stimulated blood and neutrophil counts in arachidonic acid stimulated skin (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). LYS006 dose dependently inhibited <i>ex vivo</i> LTB<sub>4</sub> formation. At doses >1 mg/kg, LTB4 production was inhibited by at least 90%. The degree of LTB<sub>4</sub> inhibition in <i>ex vivo</i> stimulated blood correlated well with the level of MPO reduction in skin homogenates, indicating that the peripheral PD readout may be a good predictor for the anti-inflammatory effect of LTA4H inhibition in skin. The level of LYS006 in blood required to achieve >90% inhibition of LTB<sub>4</sub> in blood and >90% reduction of MPO levels in the skin was approximately 130 nM, in agreement with the values determined in the PK/PD model and in <i>in vitro</i> whole blood assays.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Suppression of neutrophilic inflammation in arachidonic acid induced skin inflammation model. Female 129S2/SvPasCrl mice were dosed p.o. five times in a b.i.d. regimen. At 3 h after the last dose, inflammation in the skin was induced by topical arachidonic acid challenge for another 3 h. <i>Ex vivo</i> stimulated LTB<sub>4</sub> levels in blood (upper panel) and tissue MPO levels (lower panel) were determined. Shown are the means ± SEM, <i>n</i> = 5 per group. One way ANOVA followed by Dunnett’s multiple comparison correction was applied with *<i>p</i> < 0.05 and **<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Preclinical Efficacy in Prophylactic and Therapeutic Setting in the KRN Arthritis Model</h3><div class="NLM_p">To extend our preclinical pharmacology studies with LYS006, we investigated the efficacy of the drug in the mouse KRN passive serum-induced inflammatory arthritis model in a prophylactic and a therapeutic setting. It has been demonstrated that LTB<sub>4</sub> is a critical mediator for the onset and maintenance of inflammation in this neutrophil and macrophage-driven disease model.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Here, the model served as a mechanistic experiment to study the pharmacology of LYS006 and the relevance of LTA4H inhibition in resolving established neutrophilic inflammatory conditions.</div><div class="NLM_p">For the prophylactic setting, female mice were dosed orally in a b.i.d. regimen (10, 14 h intervals) beginning on day minus 1, with doses of 3, 10, or 30 mg/kg until day 6. On day 0, arthritis was induced by i.v. injection of KRN serum. Efficacy was evaluated via a scoring system, assessing swelling of all four paws in LYS006 treated versus vehicle treated animals (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy of LYS006 administered prophylactically in the mouse KRN passive serum-induced arthritis model. Upper panel: Paw swelling scores of C57BL/6 mice (<i>n</i> = 6 per group) during arthritis are shown as means ± SEM. Treatment with LYS006 was started in a b.i.d. regimen 1 day before disease induction (day 0). Statistical analysis (ANOVA, followed by Dunnett’s test) indicates *<i>p</i> < 0.05 and **<i>p</i> < 0.01. Lower panel: LTB<sub>4</sub> generation in <i>ex vivo</i> stimulated whole blood taken 2 h (gray bars) and 14 h (blue bars) after the final dose at day 6. Shown are the mean LTB<sub>4</sub> levels ± SEM. Numbers above bars indicate compound exposures in blood at indicated dose and time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The model showed efficient and dose-dependent reduction of composite paw swelling scores, leading to half-maximal reduction in the 3 mg/kg group and maximal efficacy at 10 and 30 mg/kg. The target proximal PD marker LTB<sub>4</sub> was assessed in blood 2 and 14 h after the final dose and demonstrated partial target engagement with the 3 mg/kg dose (∼60% LTB<sub>4</sub> reduction 14 h after dosing) and ≥90% reduction of LTB<sub>4</sub> throughout the entire dosing interval with the 10 and 30 mg/kg doses. These results clearly indicate that a high target engagement of at least 90% is required for the entire dosing interval to achieve maximal efficacy. A drop in target engagement at trough directly translated into only partial reduction of overall disease severity.</div><div class="NLM_p">Given the good efficacy of LYS006 in preventing joint inflammation in the prophylactic setting of the KRN arthritis model, a subsequent experiment was set up to assess its ability to resolve already established neutrophilic joint inflammation (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). LYS006, dosed p.o. at 10 mg/kg b.i.d starting at day 4 immediately stopped the progression of paw swelling and from day 7 onward even reduced the severity. In addition, we observed significantly reduced histological parameters of inflammation and tissue destruction, as well as clearance of neutrophils from the inflamed tissue. In contrast, the vehicle group showed further increase in disease severity. The ability of LYS006 to revert established inflammation in this model underlines the importance of LTB<sub>4</sub> in the perpetuation of the inflammatory response. Efficient inhibition of LTA4H may therefore possess the ability to resolve established chronic inflammation, particularly in inflammatory diseases with a strong neutrophilic component.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Efficacy of LYS006 in a therapeutic KRN model: LYS006 reduces clinical scores, histological parameters, and numbers of neutrophils in tissue. Upper left panel: Paw swelling scores of C57BL/6 mice (<i>n</i> = 6) during arthritis are shown as means ± SEM. Treatment with LYS006 was started in a b.i.d. regimen with a 10 mg/kg dose on day 4 after disease induction. Statistical analysis (ANOVA, followed by Dunnett’s test) indicates *<i>p</i> < 0.05 and **<i>p</i> < 0.01. Upper right panel: Histology scores combined for the hind paws of all animals were assessed for cellularity, joint damage, proteoglycan loss, and neutrophil numbers in the joint. Data are presented as the means ± SEM. Statistical analysis: Unpaired <i>t</i> test with *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001. Lower panel: Photomicrographs of hind paw sections stained with H&E (left column), Safranin O (cartilage stained red, middle column), and Ly-6B2 antibody (neutrophils stained brown, right column) illustrate joint inflammation and damage and preservation after LYS006 treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46678" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46678" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of LYS006 [(<i>S</i>)-<b>22</b>] is summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Diaryl ether <b>24</b> was obtained from fluoropyridine <b>25</b> and phenol <b>26</b> via S<sub>N</sub>Ar reaction and further converted into tetrazole <b>27</b> using a tin-catalyzed cycloaddition with TMS-azide. The subsequent alkylation installed the headgroup and occurred with high regioselectivity at the distal nitrogen of the tetrazole. Enantiopure (<i>S</i>)-<b>28</b>, derived from natural <span class="smallcaps smallerCapital">l</span>-aspartic acid, serves as the source of chirality and can be coupled directly using Mitsunobu conditions. On scale, we preferred activation to electrophilic sulfamidate (<i>S</i>)-<b>29</b>, which significantly simplified purification of protected (<i>S</i>)-<b>30</b>. Final deprotection under acidic conditions afforded zwitterionic LYS006 as the HCl salt.</div><figure id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of LYS006 [(<i>S</i>)-<b>22</b>]<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 16 h, 93%; (b) Bu<sub>2</sub>SnO (10%), TMSN<sub>3</sub>, toluene, 90 °C, 18 h, 77%; (c) <b>(</b><i>S</i><b>)-29</b>, DMF, DIPEA, rt, 17 h, 77%; (d) HCl in dioxane, 45 °C, 26 h, 78%; (e) (i) SOCl<sub>2</sub>, imidazole, 2-MeTHF, −78 °C to rt, 2 h; (ii) NaIO<sub>4</sub>, cat. RuCl<sub>3</sub>·H<sub>2</sub>O, MeCN-water, 0 °C, 2 h, 79% (two steps).</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Using a focused fragment-based DSF screen, followed by cocrystallization and structure-guided fragment merging, we identified a potent hit, which we succeeded in developing further into our very potent and selective LTA4H inhibitor LYS006. The key step in the hit to lead optimization was the elaboration of a primary amine headgroup into a zwitterionic β-amino acid. This significantly improved human whole blood potency and microsomal stability while eliminating inhibition of cytochrome P450s or the hERG channel. Lead optimization was instructed by early employment of an <i>ex vivo</i> LTB<sub>4</sub> stimulation assay for selection of compounds with long lasting target engagement/PD effect <i>in vivo</i>. This, together with the optimization of physicochemical properties ultimately favored LYS006 over related analogues. LYS006 exhibits exquisite selectivity in comprehensive off-target profiling. Furthermore, it does not inhibit eicosanoid metabolizing enzymes other than LTA4H and elevates the biosynthesis of pro-resolving LXA<sub>4</sub> upon LTB<sub>4</sub> inhibition. It shows excellent <i>in vitro</i> potency in biochemical and cellular assays. Due to its high blood/plasma ratio at low exposures, LYS006 achieves complete target inhibition <i>in vivo</i> with plasma exposures in the single digit nanomolar range, translating into nearly complete suppression of inflammation in both, a neutrophil skin inflammation and the KRN passive serum induced arthritis model. In summary, in view of its excellent selectivity and <i>in vitro/in vivo</i> potency profile, LYS006 has potential for a best-in-class LTA4H inhibitor.</div><div class="NLM_p last">LYS006 displayed a good preclinical tolerability and safety profile in two species tested, and was therefore progressed into clinical studies where its good safety and tolerability were confirmed in single and multiple ascending dose phase I clinical trials. The compound is currently being tested in several inflammatory diseases in phase II clinical trials, including inflammatory acne, hidradenitis suppurativa, ulcerative colitis, and nonalcoholic steatohepatitis. Further details on clinical properties of LYS006 and results of interventional trials in disease will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General</h3><div class="NLM_p last">All chemicals were used directly as received from commercial suppliers. Reference compounds DG-051, JNJ-40929837, and Acebilustat were synthesized according to published procedures.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> NMR spectra were recorded on Bruker 400 or 600 MHz spectrometers. Chemical shifts are expressed in δ ppm referenced to the residual solvent peak (DMSO-<i>d</i><sub>6</sub>, δ = 2.50 ppm; CDCl<sub>3</sub>, δ = 7.27 ppm; CD<sub>3</sub>OD, δ = 3.31 ppm). Abbreviations used in describing peak signals are br = broad signal, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. All final compounds were purified to ≥95% by reverse phase high performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), normal or reverse phase column chromatography. Purities were assessed by reverse phase UPLC with a gradient of 5–60% isopropanol in water (with either acid or base modifier) and monitored by UV absorption at 210–450 nm. Optical purity was determined by HPLC (Agilent 1100 COOK) on chiral stationary phase. Low-resolution mass spectra were recorded on a liquid chromatography–mass spectrometer in electrospray positive (ESI+) and negative (ESI−) modes. HR-MS analyses were performed by using electrospray ionization in positive ion mode after separation by liquid chromatography (UltiMate 3000 from Dionex). The elemental compositions were derived from the mass spectra acquired at a high resolution of about 70000 on a QExactive Plus mass spectrometer (Thermo Scientific). The high mass accuracy below 1 ppm was obtained by using a lock mass.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of LYS006 [(<i>S</i>)-22]. 4-((5-Chloro-3-fluoropyridin-2-yl)oxy)benzonitrile (<b>24</b>)</h3><div class="NLM_p last">A colorless suspension of 5-chloro-2,3-difluoropyridine (<b>25</b>, 25.0 g, 167 mmol), 4-hydroxybenzonitrile (<b>26</b>, 19.0 g, 160 mmol), and K<sub>2</sub>CO<sub>3</sub> (26.5 g, 191 mmol) in DMF (100 mL) was heated to 50 °C for 16 h. The reaction mixture was partitioned between heptane/EtOAc (2:1, 480 mL) and water (200 mL). The organic phase was washed with aq. NaHCO<sub>3</sub> (8%, 200 mL) and brine (200 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford nitrile <b>24</b> (37.7 g, 93%) in 98% purity. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.31 (d, <i>J</i> = 9.8 Hz, 1H), 8.13 (s, 1H), 7.94 (d, <i>J</i> = 8.2 Hz, 2H), 7.44 (d, <i>J</i> = 8.2 Hz, 2H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −133.65 (d, <i>J</i> = 11 Hz, 1F). MS (ESI ± ): <i>m</i>/<i>z</i> = +249.0/-247.1.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 2-(4-(Tetrazol-5-yl)phenoxy)-5-chloro-3-fluoropyridine (<b>27</b>)</h3><div class="NLM_p">This reaction was executed in nine vials in parallel: To a solution of nitrile <b>24</b> (2.24 g, 9.0 mmol) in dry toluene (9 mL) were added dibutylstannanone (224 mg, 0.90 mmol) and azidotrimethylsilane (2.4 mL, 18 mmol). The vials were sealed and heated to 90 °C for 18 h. After cooling to rt, all volatiles were removed <i>in vacuo</i>. and the combined crudes were triturated with MeOH (100 mL) and concentrated again. The material was suspended in MeOH (100 mL) and filtered. The solids were washed with heptane (100 mL) and pentane (50 mL) and dried <i>in vacuo</i> to afford tetrazole <b>27</b> as a colorless powder (18.5 g, 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 16.87 (s, 1H), 8.29 (dd, <i>J</i> = 9.9, 2.2 Hz, 1H), 8.15–8.06 (m, 3H), 7.50–7.42 (m, 2H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −133.98 (d, <i>J</i> = 7.5 Hz, 1F). MS (ESI ± ): <i>m</i>/<i>z</i> = +292.1/-290.1.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>tert</i>-Butyl (<i>S</i>)-4-(2-(<i>tert</i>-Butoxy)-2-oxoethyl)-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide [(<i>S</i>)-<b>29</b>] Step 1</h4><div class="NLM_p last">A solution of imidazole (29.7 g, 436 mmol) in 2-MeTHF (300 mL) was cooled to −78 °C and treated dropwise with SOCl<sub>2</sub> (7.95 mL, 109 mmol). After 10 min, (<i>S</i>)-<i>tert</i>-butyl 3-((<i>tert</i>-butoxycarbonyl)amino)-4-hydroxybutanoate (<b>28</b>, 10.0 g, 36.3 mmol) in 2-MeTHF (50 mL) was added dropwise. Cooling was removed and the reaction mixture was stirred at rt for 2 h, before it was filtered over a pad of Celite. All volatiles were removed <i>in vacuo</i>, and the residue was partitioned between DCM (100 mL) and water (100 mL). The aqueous phase was extracted with DCM (2 × 50 mL), and the combined organic layers were washed with aq. HCl (10%, 20 mL) and brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford a pale yellow liquid (10.7 g) that was used directly in the next step. MS (ESI ± ): <i>m</i>/<i>z</i> = +322.2/-320.3.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Step 2</h4><div class="NLM_p last">The residue was dissolved in MeCN (150 mL), cooled to 0 °C, and treated with portions of solid RuCl<sub>3</sub> monohydrate (328 mg, 1.45 mmol) and NaIO<sub>4</sub> (11.7 g, 54.5 mmol), followed by dropwise addition of water (75 mL). After stirring at 0 °C for 2 h, the reaction mixture was partitioned between EtOAc (100 mL) and water (20 mL). The aqueous phase was extracted with EtOAc (2 × 50 mL), and the combined organic layers were washed with sat. NaHCO<sub>3</sub> (50 mL) and brine (50 mL). The gray organic phase was filtered successively over plugs of Celite, Na<sub>2</sub>SO<sub>4</sub>, and silica until clear and colorless. Removal of all volatiles <i>in vacuo</i> afforded the title compound <b>29</b> (10.2 g, 79%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.78 (ddd, <i>J</i> = 9.6, 5.9, 1.3 Hz, 1H), 4.64–4.56 (m, 1H), 4.53 (dd, <i>J</i> = 9.6, 2.2 Hz, 1H), 3.02 (dd, <i>J</i> = 17.0, 3.4 Hz, 1H), 2.77 (dd, <i>J</i> = 16.9, 10.9 Hz, 1H), 1.58 (s, 9H), 1.48 (s, 9H).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl (<i>S</i>)-3-((<i>tert</i>-Butoxycarbonyl)amino)-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2<i>H</i>-tetrazol-2-yl)butanoate [(<i>S</i>)-<b>30</b>]</h3><div class="NLM_p last">A clear yellow solution of tetrazole <b>27</b> (73.0 g, 213 mmol) and sulfamidate <b>29</b> (75.0 g, 223 mmol) in DMF (620 mL) was treated with DIPEA (111 mL, 638 mmol) and stirred at rt for 17 h. The reaction mixture was partitioned between EtOAc (1 L) and 10% citric acid (300 mL). The aqueous phase was extracted with EtOAc (500 mL), and the combined organic layers were washed with brine (700 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The crude material was purified by preparative MPLC (7 kg SiO<sub>2</sub>, 25–40 μm, heptane to EtOAc) to afford <b>(</b><i>S</i><b>)-30</b> as a colorless powder (91.2 g, 77%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (dd, <i>J</i> = 9.9, 2.2 Hz, 1H), 8.14–8.07 (m, 3H), 7.43–7.38 (m, 2H), 7.03 (d, <i>J</i> = 9.0 Hz, 1H), 4.85 (dd, <i>J</i> = 13.6, 4.3 Hz, 1H), 4.64 (dd, <i>J</i> = 13.6, 8.5 Hz, 1H), 4.36–4.27 (m, 1H), 2.63 (dd, <i>J</i> = 15.7, 5.5 Hz, 1H), 2.44 (dd, <i>J</i> = 15.7, 9.1 Hz, 1H), 1.40 (s, 9H), 1.25 (s, 9H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −134.02 (d, <i>J</i> = 7.5 Hz, 1F). MS (ESI+/−): <i>m</i>/<i>z</i> = +549.3/–547.4.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-3-Amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2<i>H</i>-tetrazol-2-yl)butanoic acid hydrochloride [(<i>S</i>)-<b>22</b>, LYS006]</h3><div class="NLM_p last">Solid (<i>S</i>)-<b>30</b> (108 g, 197 mmol) was suspended in 4 M HCl in dioxane (0.95 L) and stirred at 45 °C, until no more starting material was detectable by UPLC-MS (26 h). All volatiles were removed <i>in vacuo</i>. The crude material was suspended in MeCN, stirred for 20 min at 45 °C, cooled to 10 °C, filtered, and washed with additional MeCN (2 × 250 mL). The colorless solid was dissolved in water/MeCN (5:2, 700 mL) and lyophilized to afford 68 g (78%) of (<i>S</i>)-<b>22</b> as a colorless solid. <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD): δ 8.25–8.19 (m, 2H), 7.96 (d, <i>J</i> = 2.2 Hz, 1H), 7.90 (dd, <i>J</i> = 9.4, 2.2 Hz, 1H), 7.36–7.31 (m, 2H), 5.16 (d, <i>J</i> = 5.7 Hz, 2H), 4.30–4.26 (m, 1H), 2.95 (dd, <i>J</i> = 18.0, 5.9 Hz, 1H), 2.80 (dd, <i>J</i> = 17.9, 6.9 Hz, 1H). <sup>13</sup>C NMR (151 MHz, CD<sub>3</sub>OD): δ 170.82, 164.79, 155.29, 150.09 (d, <i>J</i> = 11.8 Hz, 1C), 147.22 (d, <i>J</i> = 265 Hz, 1C), 139.86 (d, <i>J</i> = 5.9 Hz, 1C), 127.85 (2C), 126.00, 125.31 (d, <i>J</i> = 19.1 Hz, 1C), 123.50, 120.85 (2C), 52.93, 47.03, 33.17. <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD): δ −135.63 (d, <i>J</i> = 9.4 Hz, 1F). 99.7% <i>ee</i> (Agilent 1100 COOK, Chiracel IC, heptane/EtOH/MeOH 80/10/10 + 0.1% HNEt<sub>2</sub> + 0.1% TFA, 1.0 mL/min, 249 nm). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>ClFN<sub>6</sub>O<sub>3</sub>[M + H]<sup>+</sup>, 393.08727; found, 393.08728.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Differential Scanning Fluorimetry (DSF) Screening Assay</h3><div class="NLM_p last">A DSF assay was run in 384-well microtiter well plates on a CFX384 real-time PCR instrument (Bio-Rad, Hercules, CA). Heat induced unfolding of LTA4H was monitored by measuring the fluorescence increase of the solvatochromic dye SYPRO Orange (ThermoFisher Scientific, Waltham, MA) under the following assay conditions: 500 μM fragment concentration, 50 mM HEPES pH 7.4, 50 mM NaCl, 1 or 2% DMSO, 1.1 μM LTA4H, 1:1000 dilution of commercial SYPRO Orange stock (5000×), temperature gradient 25–90 °C, heating rate 1 °C/min, increment 0.5 °C, FRET channel (excitation 450–490 nM, emission 560–580 nm). Screening plates were incubated for 30 min at room temperature prior to measurement. Each screening plate contained 16 control wells (LTA4H with 1% DMSO) to monitor assay quality. Melting temperatures (<i>T</i><sub>m</sub>) were extracted by plotting fluorescence against temperature. The inflection point of the first derivative of the melting curve represents <i>T</i><sub>m</sub>. Melting temperature shifts (Δ<i>T</i><sub>m</sub>) were calculated as difference to DMSO control. A Δ<i>T</i><sub>m</sub> > 3-fold the standard deviation of <i>T</i><sub>m(LTA4H/DMSO)</sub> was classified as significant. Standard deviations for <i>T</i><sub>m(LTA4H/DMSO)</sub> were in the range of 0.1 °C for all experiments. Screening hits identified to stabilize LTA4H were confirmed by DSF using a 4-point concentration series of 125, 250, 500, and 1000 μM fragments.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> hERG Binding Assay</h3><div class="NLM_p last">HEK293 cells stably transfected with the HERG-1 gene (Swiss-Prot: Q12809) were obtained under a license from the Wisconsin Alumni Research Foundation. Membranes prepared from these cells were used in the binding assay using the radioligand [<sup>3</sup>H]dofetilide with specific activity of 46.5 Ci/mmol. The assay contains in a 96-well Millipore GF/C filter plate 119 μL of buffer, 1 μL of compound, 40 μL of 12.5 nM [<sup>3</sup>H]dofetilide, and 40 μL of crude membrane suspension (15 μg protein). After 90 min at room temperature, incubations were terminated by rapid filtration and three washes with ice-cold buffer. Filters were partially dried at 40 °C for 15 min, then 40 μL of scintillant was added, and the plate was sealed. Plates were read in a Wallac MicroBeta Trilux β counter.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Enzymatic Screening Assay</h3><div class="NLM_p last">In screening mode all compounds were tested in 8-point serial dilutions in 384-well plates in duplicate with compound concentrations starting at 50 000 nM. LTA4H (9 nM) was preincubated with compound for 15 min at room temperature in assay buffer (50 mM Tris buffer, pH 7.5, 150 mM NaCl, 10 mM CaCl<sub>2</sub>, Sigma, Switzerland) prior to addition of substrate (600 μM Arg-AMC (Bachem, Switzerland). Upon addition of the substrate, the plate was immediately placed in a fluorescence reader (SpectraMax Paradigm, Molecular Devices) and the fluorescence was measured every 10 min for 300 min at 25 °C using as filter settings λ<sub>excitation</sub> = 380 nm and λ<sub>emission</sub> = 460 nm. For accurate determination of IC<sub>50</sub> values of key compounds, 12-point serial dilutions of compound were tested in an assay format with reduced enzyme concentration (0.5 nM) and otherwise identical assay conditions as described above.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Human PBMC Eicosanoid Release Assay</h3><div class="NLM_p last">Fresh blood was collected in heparinized vacutainers by venipuncture from healthy volunteers in accordance with the guidelines of the Novartis Blood Donor Center, Basel. Informed consent of all blood donors was obtained and experimental protocols approved by the Novartis Blood Donor Center. Mononuclear cells from human peripheral blood were isolated by density gradient centrifugation from 1:1 diluted blood with RPMI 1640 and layered onto Ficoll-Paque. Mononuclear cells were carefully collected from the interphase. Erythrocytes were lysed with red blood cell lysis buffer (Miltenyi). Cells were counted using Trypan Blue staining on a Countess automated cell counter to determine number of viable cells. A volume of 200 μL of PBMC (2 × 10<sup>6</sup> cells/mL) was transferred to 96-well cell culture plates. All compounds were tested in 11-point dose–response curves, and the final compound concentration range was from 5000 to 4.9 nM in a 1:2 dose titration. Cells and compounds were incubated for indicated preincubation times at 37 °C in a humidified incubator. Cells were then stimulated with 1 μg/mL calcium ionophore A23187 (Sigma) or an equal volume of DMSO (control), mixed and incubated for an additional 2 h at 37 °C in a humidified incubator. Cell supernatants were taken for LTB<sub>4</sub> determination by competitive immunoassays EIA (Assay designs). Concentrations of LTB<sub>4</sub> in cell supernatants were quantified according to the manufacturer̀s manual. OD was determined at 405 nm on a SpectraMax Paradigm (Molecular Devices, USA).</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Human Whole Blood Eicosanoid Release Assay</h3><div class="NLM_p last">Compounds were tested in 11-point dose response curves and the final compound concentration range was from 5000 to 4.9 nM in a 1:2 dose titration. Fresh blood was collected in heparinized vacutainers by venipuncture from healthy volunteers of the Basel Tissue Donor program. Blood was diluted 1:2 with RPMI 1640 and incubated for the indicated times with compounds at 37 °C in a humidified incubator. Then, the blood was stimulated with 10 μg/mL calcium ionophore A23187 (Sigma) or equal volume DMSO (control), mixed well and incubated for an additional 15 min at 37 °C in a humidified incubator. Plasma supernatants were taken for eicosanoid determination by competitive immunoassays EIA (Assay designs). Concentrations of LTB<sub>4</sub> in plasma supernatants were quantified according to the manufacturer̀s manual. OD was determined at 405 nm on a SpectraMax Paradigm (Molecular Devices, USA)</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Lipidomics Profiling of LYS006 Treated Human PBMCs by LCMS/MS</h3><div class="NLM_p last">Human PBMCs were isolated as described above. A volume of 1100 μL of PBMCs (4 × 10<sup>6</sup> cells/mL) was transferred to 24-well flat bottom cell culture plates. For LYS006 testing, a 1:10 serial dilution was prepared with concentrations ranging from 10 000 to 10 nM. Cells were incubated with LYS006 for 15 min at 37 °C in a humidified incubator. Cells were then stimulated with 1 μg/mL calcium ionophore A23187 (Sigma) or an equal volume of DMSO (control), mixed, and incubated for an additional 2 h at 37 °C in a humidified incubator. Incubation was terminated by centrifugation at 300<i>g</i> for 10 min at 22 °C, and supernatants (1000 μL) transferred into 2 mL Eppendorf tubes. A volume of 800 μL of methanol containing deuterium-labeled internal standards (ISTDs) at the final concentration of 5 nM was added to each sample and immediately frozen on dry ice. Samples were stored at −80 °C until LCMS analysis. For lipid extraction, samples were acidified with formic acid (FA) at the final concentration of 1% and centrifuged at 16 000<i>g</i> for 10 min at 4 °C. Samples were loaded and diluted (800 μL water) in a previously methanol equilibrated SPE SOLA HRP plate (Thermo Scientific). After loading, the SPE plate was washed with 2 mL of water and lipids were eluted with 0.5 mL of acetonitrile. The eluted fraction was evaporated under nitrogen flow at room temperature for approximately 1 h. Samples were then reconstituted in methanol/water (50%/50%; v/v). The injection volume was 10 μL. The LCMS/MS method used for data acquisition has been recently described in detail<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and employed in this study with a few modifications. Briefly, the analytical platform consisted of a Waters H Class UPLC system coupled to a Waters XevoTQS triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) source. Separation of lipids was achieved using reverse-phase column (ACQUITY UPLC BEH C18 1.7 μm, 2.1 × 50 mm) heated at 40 °C. The flow rate was set to 0.180 mL/min, and the mobile phase consisted of water/formic acid (99.9/0.1; v/v) (A) and methanol/acetonitrile/formic acid (B) (50/50/0.05; v/v/v). The eluent gradient was set from 45%–65% of B during 0–16 min, from 65%–100% during 16–19 min and 100% of B from 19 to 24 min. From 24 to 35 min the column was re-equilibrated with initial conditions. Ionization was performed using an ESI source operated in the negative ion mode. Fragmentation was tuned for each compound individually using Intellistart (Waters). The source parameters were set to source temperature, 150 °C; cone gas flow, 150 L/h; nebulizer gas flow, 7 bar; desolvation temperature, 350 °C; desolvation gas flow, 600 L/h; capillary voltage, 2.5 kV; collision gas flow, 0.25 mL/min. During data acquisition, the MS program was divided in different functions in which defined MRM transitions were monitored according to the elution of lipid mediators. Quantification and data analysis of lipids was carried out essentially as described previously.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>In Vitro</i> Blood/Plasma Distribution Assay</h3><div class="NLM_p last">Blood was collected from female mice (C57/BL6), female LTA4H KO mice (C57/BL6), male rats (Hanover Wistar), male dogs (beagle), and male Caucasian volunteers, spiked with raising concentrations of [<sup>3</sup>H]LYS006, and incubated for 0.5 h at 37 °C. Plasma fractions were obtained after cell separation by centrifugation (10 min, 1500<i>g</i>, 37 °C), and blood samples were taken before centrifugation. Total radioactivity was determined by liquid scintillation counting in triplicates (Packard Tricarb LSC). Concentration of [<sup>3</sup>H]LYS006 was calculated based on the determination of total radioactivity using the specific radioactivity. Concentrations of radiolabeled LYS006 in blood distribution experiments were determined in weighed samples. Data were converted from Bq/g to ng/mL assuming a density of 1.00 g/mL for all samples and using the specific radioactivity of the test compound.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Animal Studies</h3><div class="NLM_p last">All animal studies were conducted in accordance with the Swiss Animal Welfare Regulations and specifically according to animal licenses BS-2053, BS-2798, BS-2181, BS-2793, BS-2639, and BS-2640 issued by the Basel-Stadt Cantonal Veterinary Office.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> PK Studies</h3><div class="NLM_p last">For intravenous administration compounds were formulated at indicated doses and dissolved in PEG200:NMP (70:30 v/v), followed by application via the vena femoralis of female C57/BL6 mice. For intravenous administration to male Wistar rats compounds were prepared in NMP:PEG200:NaCl (0.9%) (5:30:65 v/v/v). For oral gavage compounds were formulated in propylenglycol: VitE TPGS (20:10 v/v). The clear solution was diluted (30:70 v/v) with 100 mM Na-citrate buffer pH 3. At selected time points (0.25, 0.5, 1, 2, 4, 8, 24 h post dose for both routes), 20 μL whole blood was collected with heparin coated minicaps via the vena saphena by puncture. The blood was stored at −80 °C in EDTA tubes until PK analysis by LCMS/MS. For intravenous application in dogs, compounds were dissolved in PEG200:NMP (90:10 v/v) and applied via the vena cephalica. For oral gavage the compound was administered in 0.5% Tween80, 0.5% methyl cellulose in 99% water. Blood was collected predose and at selected time points for i.v. at 0.083, 0.25, 0.5, 1, 2, 4, 7, 24, 48, and 120 h and for p.o. at 0.25, 0.5, 1, 2, 4, 7, 24, 48, and 120 h post dose, respectively.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> PD Profiling</h3><div class="NLM_p last">All experiments were performed with adult female C57/BL6 mice (Charles River, France). Animals were dosed p.o. with the indicated doses of compounds for the indicated times. For PD analysis, heparinized animal blood was collected and diluted 1:2 with RPMI medium. Blood was then stimulated and released LTB<sub>4</sub> quantified as described in the section “<a class="ref internalNav" href="#sec5_10" aria-label="Human Whole Blood Eicosanoid Release Assay">Human Whole Blood Eicosanoid Release Assay</a>”.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Murine Model of Arachidonic Acid Induced Skin Inflammation</h3><div class="NLM_p last">The experiment was performed with adult female 129S2/SvPasCrl mice. Compounds were applied p.o. in a b.i.d regimen for 3 days (in total 5 doses) to achieve steady state drug exposures. Three hours after the final compound application, mice were topically treated on left ears with 10 μL of acetone and on right ears with 10 μL of arachidonic acid (CalBiochem) solution (100 mg/mL). At 3 h post sensitization and 6 h post drug administration, mice were terminated and blood was collected in heparinized tubes for PD analysis and EDTA coated tubes for PK analysis as described above. Ear punches (6 mm) were collected from both ears, weighted and frozen at −80 °C for subsequent determination of tissue MPO levels. To this end, ear punches were cut in 1 mm<sup>2</sup> squares and immediately transferred into homogenization tubes prefilled with 250 μL of lysis buffer (200 mM NaCl, 6.4 mM EDTA, 10 mM Tris-HCl pH 7.5, 11.5% v/v glycerin, + protease inhibitor cocktail). Samples were homogenized with “Precellys 24” 3 × 15 s at 5500 rpm, and homogenates were centrifuged for 30 min at 4 °C at 13 000 rpm. Supernatants were frozen at −80 °C until MPO quantification with ELISA (Hycult biotech), according to the manufacturer’s manual.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> KRN Passive Serum Induced Arthritis Model in Mouse</h3><div class="NLM_p last">Female 8 week old C57BL/6 mice (Janiver, France) were used for these studies. To induce arthritis in these mice, 200 μL of serum from KRN mice (pool, received from Genomics Institute of the Novartis Research Foundation (GNF), San Diego, CA, USA) was injected i.v. to recipient mice. Swelling of hind paws was scored three times a week. Scoring was done on a composite scale of 0–24 per mouse, evaluating each paw by visual inspection in the metatarsal region with a score of 0–3 and in the ankle with a score of 0–3, thus obtaining a maximal score of 6 per paw. The following scoring system used was: 0 = no detectable signs of inflammation; 1 = lightly swollen region; 2 = more obviously swollen region; 3 = ankyloses or severely swollen region. The paw scores were summed to obtain a score for each individual animal. Prophylactic treatment of twice daily dosing started on day −1 and continued until day 6 with either vehicle or compound treatment at indicated doses. KRN serum was applied i.v. on day 0. On day 6, animals were sacrificed. Hind paws were taken for histology and blood for PK/PD analysis as described above. For therapeutic treatment, 200 μL of KRN serum was administered via i.v. injection on day 0. On day 4, mice were distributed to different groups so that each group had equal swelling prior to compound treatment. Therapeutic treatment started on day 4 and continued until day 12 with b.i.d. dosing. On day 12, animals were sacrificed, blood was collected for PK/PD analysis, and hind paws were collected for histology.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Histopathology</h3><div class="NLM_p last">Hind paw samples were fixed in 10% buffered formalin for 48 h, decalcified over 6 days in Immunocal (Decal Chemical Corp,), changed every second day, processed, and embedded in paraffin. Sections of 3 μm thickness were stained with hematoxylin and eosin (HE) and Safranin O (SafO). Histopathological changes were blindly scored on a scale of 0 (normal) to 3 (severe changes). The following parameters were assessed: inflammatory cell infiltrate, joint damage, and proteoglycan loss. Immunohistochemical staining for neutrophil-granulocytes was performed on a Ventana Discovery XT stainer (Roche Diagnostics) with monoclonal rat anti-Ly-6B2 (clone 7/4, AbD Serotec), followed by goat anti-rat IgG (Jackson Immunoresearch) and DapMap detection system (Roche Diagnostics).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01955" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07720" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07720" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01955?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01955</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis of compounds <b>2</b>–<b>23</b>; structural biology data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_001.pdf">jm0c01955_si_001.pdf (2.0 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_002.csv">jm0c01955_si_002.csv (3.37 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes: <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV2">7AV2</a>; <b>2</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV1">7AV1</a>; (<i><b>R</b></i>)-<b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV0">7AV0</a>; (<i><b>S</b></i>)-<b>22</b> = LYS006, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AUZ">7AUZ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c01955" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34578" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34578" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Markert</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1857-9885" title="Orcid link">http://orcid.org/0000-0003-1857-9885</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1c7f746e756f68757d7232717d6e77796e685c72736a7d6e68756f327f7371"><span class="__cf_email__" data-cfemail="84e7ecf6edf7f0ede5eaaae9e5f6efe1f6f0c4eaebf2e5f6f0edf7aae7ebe9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gebhard Thoma</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Honnappa Srinivas</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology and Therapeutics, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Birgit Bollbuck</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rainer M. Lüönd</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wolfgang Miltz</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rudolf Wälchli</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Romain Wolf</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jürgen Hinrichs</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Bergsdorf</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology and Therapeutics, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kamal Azzaoui</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology and Therapeutics, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlos A. Penno</span> - <span class="hlFld-Affiliation affiliation">Analytical Sciences
& Imaging, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Klein</span> - <span class="hlFld-Affiliation affiliation">PK Sciences, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathalie Wack</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Jäger</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Franziska Hasler</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Beerli</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pius Loetscher</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Dawson</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4615-4091" title="Orcid link">http://orcid.org/0000-0003-4615-4091</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Grazyna Wieczorek</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shin Numao</span> - <span class="hlFld-Affiliation affiliation">Chemical Biology and Therapeutics, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6204-7117" title="Orcid link">http://orcid.org/0000-0002-6204-7117</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amanda Littlewood-Evans</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Till A. Röhn</span> - <span class="hlFld-Affiliation affiliation">Autoimmunity, Transplantation and Inflammation, , , , , Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All work described was funded by Novartis Institutes for BioMedical Research Inc. All authors are or were employees of Novartis and may hold company stocks or stock options with Novartis Pharma AG.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank J. G. Ternois, L. Wohlgensinger, P. Nganga, J. Wiest, N. Eckert, F. Gruber, O. Decoret, C. Rolando, E. Bucceri, E. Aebischer, T. Hurni, E. Hugenschmidt, H. Lehmann, T. Ruppen, and E. Schueller for their synthesis support, F. Freuler, L. Leder, and E. Koch for cloning and protein expression of LTA4H, O. Esser for his technical support of the DSF screen, P. Ramseier, M. Vogelsanger, S. Sarret, and R. Keller for their support of the <i>in vivo</i> studies, N. Caesar for histological tissue processing, and C. Laguerre and B. Urban for LCMS/MS analysis of lipid mediators. We are grateful to the X10SA beamline team at the Swiss Light Source (PSI Villigen, Switzerland) for outstanding support at the beamline and Expose GmbH (Switzerland) for diffraction data collection.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">b.i.d., (lat.) bis in die</td><td class="NLM_def"><p class="first last">twice a day</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human Ether-à-go-go-Related Gene</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intraveneous</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomes</p></td></tr><tr><td class="NLM_term">2-MeTHF</td><td class="NLM_def"><p class="first last">2-methyl tetrahydrofuran</p></td></tr><tr><td class="NLM_term">MPO:</td><td class="NLM_def"><p class="first last">Myeloperoxidase</p></td></tr><tr><td class="NLM_term">NASH:</td><td class="NLM_def"><p class="first last">Nonalcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RED</td><td class="NLM_def"><p class="first last">rapid equilibrium dialysis</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">TACE</td><td class="NLM_def"><p class="first last">tumor necrosis factor-α converting enzyme</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 39 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis</span>. <i>Clin. Rev. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1007/BF02737600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1007%2FBF02737600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10436862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=111-131&author=J.+Z.+Haeggstrom&title=Leukotriene+A4+hydrolase+and+the+committed+step+in+leukotriene+B4+biosynthesis&doi=10.1007%2FBF02737600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis</span></div><div class="casAuthors">Haeggstrom, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Reviews in Allergy & Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">111-131</span>CODEN:
                <span class="NLM_cas:coden">CRAIF2</span>;
        ISSN:<span class="NLM_cas:issn">1080-0549</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review, with 87 refs., on LTA4 hydrolase and its role in the final step in the biosynthesis of LTB4.  The authors discussed the tissue and cellular distribution of LTA4 hydrolase, various amino acids residues involved in its different enzymic activities, structural determinants for suicide inactivation of LTA4 hydrolase, model of the active site of LTA4 hydrolase, variant forms of LTA4 hydrolase; development of LTA4 hydrolase inhibitors, and receptors for LTB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1zSpEq9I9LbVg90H21EOLACvtfcHk0lhlkFfBk9EExw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKhu7Y%253D&md5=e1be809666043ae8f775ea6e793344f4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2FBF02737600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02737600%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520A4%2520hydrolase%2520and%2520the%2520committed%2520step%2520in%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DClin.%2520Rev.%2520Allergy%2520Immunol.%26date%3D1999%26volume%3D17%26spage%3D111%26epage%3D131%26doi%3D10.1007%2FBF02737600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, F. A.</span></span> <span> </span><span class="NLM_article-title">Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase</span>. <i>Prostaglandins</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/0090-6980(92)90018-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2F0090-6980%2892%2990018-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1410529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK38XmsVOmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1992&pages=251-257&author=K.+J.+Griffinauthor=J.+Gierseauthor=G.+Kriviauthor=F.+A.+Fitzpatrick&title=Opioid+peptides+are+substrates+for+the+bifunctional+enzyme+LTA4+hydrolase%2Faminopeptidase&doi=10.1016%2F0090-6980%2892%2990018-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase</span></div><div class="casAuthors">Griffin, K. J.; Gierse, J.; Krivi, G.; Fitzpatrick, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-7</span>CODEN:
                <span class="NLM_cas:coden">PRGLBA</span>;
        ISSN:<span class="NLM_cas:issn">0090-6980</span>.
    </div><div class="casAbstract">It was the aim of the described research to detd. if any naturally occurring peptides could act as substrates or inhibitors of the bifunctional, Zn2+ metalloenzyme LT (leukotriene) A4 hydrolase/aminopeptidase (E.C. 3.3.2.6).  Several opioid peptides including met5-enkephalin, leu5-enkephalin, dynorphin1-6, dynorphin1-7, and dynorphin1-8 competitively inhibited the hydrolysis of L-proline-p-nitroanilide by leukotriene A4 hydrolase/aminopeptidase, consistent with an interaction at its active site.  The enzyme catalyzed the N-terminal hydrolysis of tyrosine from met5-enkephalin with Km = 450 μM and Vmax = 4.9 nmol-h-1-ug-1 and from leu5-enkephalin with Km = 387 μM and Vmax = 6.2 nmol-h-1-ug-1.  Bestatin, captopril and carnosine inhibited the hydrolysis of the enkephalins.  It is noteworthy that the bifunctional catalytic traits of this enzyme include generation of an hyperanalgesic substance, LTB4, and inactivation of analgesic opioid peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetmUg2KNhmrVg90H21EOLACvtfcHk0lhlkFfBk9EExw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVOmuro%253D&md5=a4a40b53b67ea6383e95459aa0a0d816</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0090-6980%2892%2990018-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0090-6980%252892%252990018-O%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DK.%2BJ.%26aulast%3DGierse%26aufirst%3DJ.%26aulast%3DKrivi%26aufirst%3DG.%26aulast%3DFitzpatrick%26aufirst%3DF.%2BA.%26atitle%3DOpioid%2520peptides%2520are%2520substrates%2520for%2520the%2520bifunctional%2520enzyme%2520LTA4%2520hydrolase%252Faminopeptidase%26jtitle%3DProstaglandins%26date%3D1992%26volume%3D44%26spage%3D251%26epage%3D257%26doi%3D10.1016%2F0090-6980%2892%2990018-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kragballe, K.</span></span> <span> </span><span class="NLM_article-title">Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1–7</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.1995.tb02749.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fj.1365-2133.1995.tb02749.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=8555027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK28Xps1Wj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1995&pages=742-749&author=J.+B.+Nissenauthor=L.+Iversenauthor=K.+Kragballe&title=Characterization+of+the+aminopeptidase+activity+of+epidermal+leukotriene+A4+hydrolase+against+the+opioid+dynorphin+fragment+1%E2%80%937&doi=10.1111%2Fj.1365-2133.1995.tb02749.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1-7</span></div><div class="casAuthors">Nissen, J. B.; Iversen, L.; Kragballe, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">742-9</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase is a bifunctional cytosolic enzyme, which both hydrolyzes leukotriene A4 (LTA4) into leukotriene B4 (LTB4) and exerts aminopeptidase activity against opioid peptides.  In the present study the authors have investigated whether the peptides angiotensin I and II, bradykinin, kallidine, histamine, dynorphin fragment 1-7 and substance P can act as substrates for epidermal and neutrophil LTA4 hydrolase.  Among the tested substrates, dynorphin fragment 1-7 was the best substrate for the enzyme.  The aminopeptidase activity of epidermal and neutrophil LTA4 hydrolase against dynorphin fragment 1-7 was further characterized.  The enzyme was purified from human epidermis and human neutrophils by anion exchange chromatog. (Q-Sepharose) and affinity chromatog. on a column with the LTA4 hydrolase inhibitor bestatin coupled to AH-Sepharose.  The incubation of the dynorphin fragment 1-7 with LTA4 hydrolase resulted in the formation of tyrosine.  The presence of the N-terminal amino acid tyrosine is essential for the interaction of opioids with their receptors, and this finding indicates that the LTA4 hydrolase can inactivate dynorphin fragment 1-7.  After the two purifn. steps no other aminopeptidases acting at the N-terminal tyrosine of dynorphin fragment 1-7 was present in the prepn.  This was demonstrated by the abolishment of the degrdn. at the N-terminal end of dynorphin fragment 1-7 when preincubating the enzyme prepn. with LTA4 before the incubation with the dynorphin fragment 1-7.  The abolishment of the aminopeptidase activity shows that activation of the hydrolase part of the enzyme, with conversion of LTA4 into the potent proinflammatory compd. LTB4, results in an inhibition of the aminopeptidase activity of the enzyme.  As a result, the catabolism of dynorphin fragment 1-7 and probably of other opioid peptides is inhibited, resulting in sustained biol. effects of these opioids.  This phenomenon may be important for the maintenance of inflammation in skin conditions, such as psoriasis and atopic dermatitis, in which LTB4 is formed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotevaEksnRBbVg90H21EOLACvtfcHk0lhlkFfBk9EExw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xps1Wj&md5=209651b9980a116fcca59ab16f3915ec</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.1995.tb02749.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.1995.tb02749.x%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DJ.%2BB.%26aulast%3DIversen%26aufirst%3DL.%26aulast%3DKragballe%26aufirst%3DK.%26atitle%3DCharacterization%2520of%2520the%2520aminopeptidase%2520activity%2520of%2520epidermal%2520leukotriene%2520A4%2520hydrolase%2520against%2520the%2520opioid%2520dynorphin%2520fragment%25201%25E2%2580%25937%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D1995%26volume%3D133%26spage%3D742%26epage%3D749%26doi%3D10.1111%2Fj.1365-2133.1995.tb02749.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Numao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laguerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wack, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlisberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houguenade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardaker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penno, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollbuck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miltz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röhn, T. A.</span></span> <span> </span><span class="NLM_article-title">Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13591</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-13490-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fs41598-017-13490-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29051536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BC1M7is1CgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=13591&author=S.+Numaoauthor=F.+Haslerauthor=C.+Laguerreauthor=H.+Srinivasauthor=N.+Wackauthor=P.+Jagerauthor=A.+Schmidauthor=A.+Osmontauthor=P.+Rothlisbergerauthor=J.+Houguenadeauthor=C.+Bergsdorfauthor=J.+Dawsonauthor=N.+Carteauthor=A.+Hofmannauthor=C.+Markertauthor=L.+Hardakerauthor=A.+Billichauthor=R.+M.+Wolfauthor=C.+A.+Pennoauthor=B.+Bollbuckauthor=W.+Miltzauthor=T.+A.+R%C3%B6hn&title=Feasibility+and+physiological+relevance+of+designing+highly+potent+aminopeptidase-sparing+leukotriene+A4+hydrolase+inhibitors&doi=10.1038%2Fs41598-017-13490-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors</span></div><div class="casAuthors">Numao Shin; Srinivas Honnappa; Schmid Andres; Rothlisberger Patrik; Bergsdorf Christian; Hasler Franziska; Wack Nathalie; Jager Petra; Houguenade Jeremy; Dawson Janet; Billich Andreas; Rohn Till A; Laguerre Claire; Osmont Arnaud; Carte Nathalie; Hofmann Andreas; Penno Carlos A; Markert Christian; Wolf Romain M; Bollbuck Birgit; Miltz Wolfgang; Hardaker Liz</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13591</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukotriene A4 Hydrolase (LTA4H) is a bifunctional zinc metalloenzyme that comprises both epoxide hydrolase and aminopeptidase activity, exerted by two overlapping catalytic sites.  The epoxide hydrolase function of the enzyme catalyzes the biosynthesis of the pro-inflammatory lipid mediator leukotriene (LT) B4.  Recent literature suggests that the aminopeptidase function of LTA4H is responsible for degradation of the tripeptide Pro-Gly-Pro (PGP) for which neutrophil chemotactic activity has been postulated.  It has been speculated that the design of epoxide hydrolase selective LTA4H inhibitors that spare the aminopeptidase pocket may therefore lead to more efficacious anti-inflammatory drugs.  In this study, we conducted a high throughput screen (HTS) for LTA4H inhibitors and attempted to rationally design compounds that would spare the PGP degrading function.  While we were able to identify compounds with preference for the epoxide hydrolase function, absolute selectivity was not achievable for highly potent compounds.  In order to assess the relevance of designing such aminopeptidase-sparing LTA4H inhibitors, we studied the role of PGP in inducing inflammation in different settings in wild type and LTA4H deficient (LTA4H KO) animals but could not confirm its chemotactic potential.  Attempting to design highly potent epoxide hydrolase selective LTA4H inhibitors, therefore seems to be neither feasible nor relevant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6ihDczXmk7TC850By6mxpfW6udTcc2ea2HpIEruz-xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7is1CgtQ%253D%253D&md5=38103beaecb2080bd5a6c87fbf38172e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-13490-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-13490-1%26sid%3Dliteratum%253Aachs%26aulast%3DNumao%26aufirst%3DS.%26aulast%3DHasler%26aufirst%3DF.%26aulast%3DLaguerre%26aufirst%3DC.%26aulast%3DSrinivas%26aufirst%3DH.%26aulast%3DWack%26aufirst%3DN.%26aulast%3DJager%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DA.%26aulast%3DOsmont%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DP.%26aulast%3DHouguenade%26aufirst%3DJ.%26aulast%3DBergsdorf%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DCarte%26aufirst%3DN.%26aulast%3DHofmann%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DC.%26aulast%3DHardaker%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DPenno%26aufirst%3DC.%2BA.%26aulast%3DBollbuck%26aufirst%3DB.%26aulast%3DMiltz%26aufirst%3DW.%26aulast%3DR%25C3%25B6hn%26aufirst%3DT.%2BA.%26atitle%3DFeasibility%2520and%2520physiological%2520relevance%2520of%2520designing%2520highly%2520potent%2520aminopeptidase-sparing%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D13591%26doi%3D10.1038%2Fs41598-017-13490-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snelgrove, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardison, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noerager, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinloch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shastry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, J. E.</span></span> <span> </span><span class="NLM_article-title">A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1126/science.1190594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1126%2Fscience.1190594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=20813919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=90-94&author=R.+J.+Snelgroveauthor=P.+L.+Jacksonauthor=M.+T.+Hardisonauthor=B.+D.+Noeragerauthor=A.+Kinlochauthor=A.+Gaggarauthor=S.+Shastryauthor=S.+M.+Roweauthor=Y.+M.+Shimauthor=T.+Hussellauthor=J.+E.+Blalock&title=A+critical+role+for+LTA4H+in+limiting+chronic+pulmonary+neutrophilic+inflammation&doi=10.1126%2Fscience.1190594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation</span></div><div class="casAuthors">Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Noerager, Brett D.; Kinloch, Andrew; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Shim, Yun M.; Hussell, Tracy; Blalock, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6000</span>),
    <span class="NLM_cas:pages">90-94</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase (LTA4H) is a proinflammatory enzyme that generates the inflammatory mediator leukotriene B4 (LTB4).  LTA4H also possesses aminopeptidase activity with unknown substrate and physiol. importance; we identified the neutrophil chemoattractant proline-glycine-proline (PGP) as this physiol. substrate.  PGP is a biomarker for chronic obstructive pulmonary disease (COPD) and is implicated in neutrophil persistence in the lung.  In acute neutrophil-driven inflammation, PGP was degraded by LTA4H, which facilitated the resoln. of inflammation.  In contrast, cigarette smoke, a major risk factor for the development of COPD, selectively inhibited LTA4H aminopeptidase activity, which led to the accumulation of PGP and neutrophils.  These studies imply that therapeutic strategies inhibiting LTA4H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopOXZMg4c8WLVg90H21EOLACvtfcHk0ljMR8vNyzes0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WmtbnF&md5=d56b04312a721afb31fc9d505ab74fb0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1190594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1190594%26sid%3Dliteratum%253Aachs%26aulast%3DSnelgrove%26aufirst%3DR.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%2BL.%26aulast%3DHardison%26aufirst%3DM.%2BT.%26aulast%3DNoerager%26aufirst%3DB.%2BD.%26aulast%3DKinloch%26aufirst%3DA.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DShastry%26aufirst%3DS.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DShim%26aufirst%3DY.%2BM.%26aulast%3DHussell%26aufirst%3DT.%26aulast%3DBlalock%26aufirst%3DJ.%2BE.%26atitle%3DA%2520critical%2520role%2520for%2520LTA4H%2520in%2520limiting%2520chronic%2520pulmonary%2520neutrophilic%2520inflammation%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D90%26epage%3D94%26doi%3D10.1126%2Fscience.1190594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stsiapanava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis of leukotriene B4</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.smim.2017.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29042025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=3-15&author=M.+Wanauthor=X.+Tangauthor=A.+Stsiapanavaauthor=J.+Z.+Haeggstrom&title=Biosynthesis+of+leukotriene+B4&doi=10.1016%2Fj.smim.2017.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis of leukotriene B4</span></div><div class="casAuthors">Wan, Min; Tang, Xiao; Stsiapanava, Alena; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukotriene B4 (LTB4) is a lipid mediator derived from arachidonic acid (AA) by the sequential action of 5-lipoxygenase (5-LOX), 5-lipoxygenase-activating protein (FLAP) and LTA4 hydrolase (LTA4H).  It was initially recognized for its involvement in the recruitment of neutrophils and is one of the most potent chemotactic agents known to date.  A large body of data has indicated that LTB4 plays a significant role in many chronic inflammatory diseases, such as arthritis, chronic obstructive pulmonary disease (COPD), cardiovascular disease, cancer and more recently, metabolic disorder.  In this review, it focus on the biosynthesis of LTB4 and its biol. effects.  In particular, it will describe a basic biochem. understanding integrated with recent developments in the field of structural biol. of the three key enzymes (5-LOX, FLAP and LTA4H) in LTB4 biosynthesis, and also summarize the most outstanding work on in vivo biol. and pathogenic roles of these enzymes and the development of enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotjqcm1CReC7Vg90H21EOLACvtfcHk0ljMR8vNyzes0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfO&md5=77bb630dccc209c51960939751c989a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DStsiapanava%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DBiosynthesis%2520of%2520leukotriene%2520B4%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.smim.2017.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">50639</span>– <span class="NLM_lpage">50642</span>, <span class="refDoi"> DOI: 10.1074/jbc.R400027200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1074%2Fjbc.R400027200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=15339917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BD2crptVCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=50639-50642&author=J.+Z.+Haeggstrom&title=Leukotriene+A4+hydrolase%2Faminopeptidase%2C+the+gatekeeper+of+chemotactic+leukotriene+B4+biosynthesis&doi=10.1074%2Fjbc.R400027200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis</span></div><div class="casAuthors">Haeggstrom Jesper Z</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">50639-42</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiXk-VGR69cTMsgLhIoICsfW6udTcc2ea2HpIEruz-xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crptVCrtA%253D%253D&md5=693071a8de53cf6e14ad82b78caa417e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R400027200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R400027200%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520A4%2520hydrolase%252Faminopeptidase%252C%2520the%2520gatekeeper%2520of%2520chemotactic%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D50639%26epage%3D50642%26doi%3D10.1074%2Fjbc.R400027200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters-Golden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Leukotrienes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1056/NEJMra071371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1056%2FNEJMra071371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17978293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=1841-1854&author=M.+Peters-Goldenauthor=W.+R.+Henderson&title=Leukotrienes&doi=10.1056%2FNEJMra071371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotrienes</span></div><div class="casAuthors">Peters-Golden, Marc; Henderson, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1841-1854</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Leukotrienes comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metab.  The cysteinyl leukotrienes C4, D4, and E4 account for the biol. activity that was previously termed "slow-reacting substance of anaphylaxis", and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT1) in asthma validates the importance of cysteinyl leukotrienes and CysLT1 in this disease.  Here, the authors discuss: synthesis of leukotrienes; leukotriene receptors; blockade of leukotriene synthesis and leukotriene receptors; leukotrienes in disease; and leukotrienes in antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjehKHMPz2p7Vg90H21EOLACvtfcHk0lhG8YyowhlH7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM&md5=4e617e65cf4b1f55f595bc03344fdb55</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMra071371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra071371%26sid%3Dliteratum%253Aachs%26aulast%3DPeters-Golden%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DW.%2BR.%26atitle%3DLeukotrienes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D1841%26epage%3D1854%26doi%3D10.1056%2FNEJMra071371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Gennaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">The leukotrienes: immune-modulating lipid mediators of disease</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-394300-2.00002-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FB978-0-12-394300-2.00002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23063073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2hsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2012&pages=51-92&author=A.+Di%0AGennaroauthor=J.+Z.+Haeggstrom&title=The+leukotrienes%3A+immune-modulating+lipid+mediators+of+disease&doi=10.1016%2FB978-0-12-394300-2.00002-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The leukotrienes: immune-modulating lipid mediators of disease</span></div><div class="casAuthors">Di Gennaro, Antonio; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-92</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The leukotrienes are important lipid mediators with immune modulatory and proinflammatory properties.  Classical bioactions of leukotrienes include chemotaxis, endothelial adherence, and activation of leukocytes, chemokine prodn., as well as contraction of smooth muscles in the microcirculation and respiratory tract.  When formed in excess, these compds. play a pathogenic role in several acute and chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease.  An increasing no. of diseases have been linked to inflammation implicating the leukotrienes as potential mediators.  For example, recent investigations using genetic, morphol., and biochem. approaches have pointed to the involvement of leukotrienes in cardiovascular diseases including atherosclerosis, myocardial infarction, stroke, and abdominal aortic aneurysm.  Moreover, new insights have changed our previous notion of leukotrienes as mediators of inflammatory reactions to mols. that can fine-tune the innate and adaptive immune response.  Here, we review the most recent understanding of the leukotriene cascade with emphasis on recently identified roles in immune reactions and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJiBdkcXX6LVg90H21EOLACvtfcHk0lhG8YyowhlH7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2hsLs%253D&md5=729c0bf2cdb69123f4c0e2cd7abae06f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394300-2.00002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394300-2.00002-8%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGennaro%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DThe%2520leukotrienes%253A%2520immune-modulating%2520lipid%2520mediators%2520of%2520disease%26jtitle%3DAdv.%2520Immunol.%26date%3D2012%26volume%3D116%26spage%3D51%26epage%3D92%26doi%3D10.1016%2FB978-0-12-394300-2.00002-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Gennaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Targeting leukotriene B4 in inflammation</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1517/14728222.2013.843671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1517%2F14728222.2013.843671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=24090264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWqtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=79-93&author=A.+Di%0AGennaroauthor=J.+Z.+Haeggstrom&title=Targeting+leukotriene+B4+in+inflammation&doi=10.1517%2F14728222.2013.843671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting leukotriene B4 in inflammation</span></div><div class="casAuthors">Di Gennaro, Antonio; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-93</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Leukotriene (LT) B4 is a powerful proinflammatory lipid mediator and triggers adherence to the endothelium, activates and recruits leukocytes to the site of injury.  When formed in excess, LTB4 plays a pathogenic role and may sustain chronic inflammation in diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease.  Recent investigations have also indicated that LTB4 is involved in cardiovascular diseases.  Areas covered: As the 5-lipoxygenase pathway involves several discrete, tightly coupled, enzymes, which convert the substrate, 'step by step', into bioactive products, several different strategies have been used to target LTB4 as a means to treat inflammation.  Here, we discuss recent findings regarding the development of selective enzyme inhibitors and antagonists for LTB4 receptors, as well as their application in preclin. and clin. studies.  Expert opinion: Components of the 5-lipoxygenase pathway have received considerable attention as candidate drug targets resulting in one new class of medications against asthma, i.e., the antileukotrienes.  However, efforts to specifically target LTB4 have not yet been fruitful in the clin. setting, in spite of very promising preclin. data.  Recently, crystal structures along with hitherto unknown functions of key enzymes in the leukotriene cascade have emerged, offering new opportunities for drug development and, with time, pharmacol. intervention in LTB4-mediated pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC8FhaNUW8M7Vg90H21EOLACvtfcHk0lhG8YyowhlH7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWqtrbI&md5=7ac4ca614b0a2fbe8126492736883783</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14728222.2013.843671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2013.843671%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGennaro%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DTargeting%2520leukotriene%2520B4%2520in%2520inflammation%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D79%26epage%3D93%26doi%3D10.1517%2F14728222.2013.843671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase</span>. <i>Curr. Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=19876785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Khtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1173-1182&author=A.+M.+Fourie&title=Modulation+of+inflammatory+disease+by+inhibitors+of+leukotriene+A4+hydrolase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase</span></div><div class="casAuthors">Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (BioMed Central)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-3429</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukotriene A4 hydrolase (LTA4H) is a ubiquitously expressed enzyme that catalyzes the final step in the synthesis of leukotriene B4 (LTB4), a potent proinflammatory lipid mediator derived from arachidonic acid.  Although LTB4 was identified 30 years ago, several recent findings have refocused attention on this mediator as a target for inflammatory and autoimmune diseases.  While LTB4 was once thought to be a chemoattractant and activator only of leukocytes mediating acute, innate inflammatory responses, LTB4 receptors have since been discovered on multiple cell types, including T-lymphocytes and antigen-presenting dendritic cells.  Thus, the inhibition of LTB4 synthesis demonstrates potential for targeting chronic, autoimmune-driven inflammation.  In addn. to genetic data in animals and humans linking the LTB4 pathway to cardiovascular disease, variants in the LTA4H gene have been linked with susceptibility to asthma.  Several companies have initiated drug discovery efforts to identify potent, selective LTA4H inhibitors.  Selected mols. have demonstrated oral efficacy in preclin. models of asthma, inflammatory bowel disease and arthritis, suggesting therapeutic potential for multiple indications.  This review focuses on developments with therapeutic relevance for inhibitors of LTA4H as anti-inflammatory drugs, and particularly in the treatment of respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprm0-IV6joSrVg90H21EOLACvtfcHk0ljPDbhXsYmT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Khtbs%253D&md5=0983f70fcf38f28f689f66cb1af7f7c1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DModulation%2520of%2520inflammatory%2520disease%2520by%2520inhibitors%2520of%2520leukotriene%2520A4%2520hydrolase%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D1173%26epage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene biosynthetic enzymes as therapeutic targets</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2680</span>– <span class="NLM_lpage">2690</span>, <span class="refDoi"> DOI: 10.1172/JCI97945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1172%2FJCI97945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30108195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BB3c7otFCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=2680-2690&author=J.+Z.+Haeggstrom&title=Leukotriene+biosynthetic+enzymes+as+therapeutic+targets&doi=10.1172%2FJCI97945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene biosynthetic enzymes as therapeutic targets</span></div><div class="casAuthors">Haeggstrom Jesper Z</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2680-2690</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukotrienes are powerful immune-regulating lipid mediators with established pathogenic roles in inflammatory allergic diseases of the respiratory tract - in particular, asthma and hay fever.  More recent work indicates that these lipids also contribute to low-grade inflammation, a hallmark of cardiovascular, neurodegenerative, and metabolic diseases as well as cancer.  Biosynthesis of leukotrienes involves oxidative metabolism of arachidonic acid and proceeds via a set of soluble and membrane enzymes that are primarily expressed by cells of myeloid origin.  In activated immune cells, these enzymes assemble at the endoplasmic and perinuclear membrane, constituting a biosynthetic complex.  This Review describes recent advances in our understanding of the components of the leukotriene-synthesizing enzyme machinery, emerging opportunities for pharmacological intervention, and the development of new medicines exploiting both antiinflammatory and pro-resolving mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRpINUyhQuIGxpATR2EQURfW6udTcc2eZ-pnTE0ThnqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7otFCltQ%253D%253D&md5=e4fe4a2a01c986c3cc3f87537042ef95</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI97945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI97945%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520biosynthetic%2520enzymes%2520as%2520therapeutic%2520targets%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D2680%26epage%3D2690%26doi%3D10.1172%2FJCI97945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T. E.</span></span> <span> </span><span class="NLM_article-title">Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nri2294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fnri2294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=18437155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=349-361&author=C.+N.+Serhanauthor=N.+Chiangauthor=T.+E.+Van+Dyke&title=Resolving+inflammation%3A+dual+anti-inflammatory+and+pro-resolution+lipid+mediators&doi=10.1038%2Fnri2294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</span></div><div class="casAuthors">Serhan, Charles N.; Chiang, Nan; Van Dyke, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-361</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Active resoln. of acute inflammation is a previously unrecognized interface between innate and adaptive immunity.  Once thought to be a passive process, the resoln. of inflammation is now shown to involve active biochem. programs that enable inflamed tissues to return to homeostasis.  This Review presents new cellular and mol. mechanisms for the resoln. of inflammation, revealing key roles for eicosanoids, such as lipoxins, and recently discovered families of endogenous chem. mediators, termed resolvins and protectins.  These mediators have anti-inflammatory and pro-resoln. properties, thereby protecting organs from collateral damage, stimulating the clearance of inflammatory debris and promoting mucosal antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAVfszaqPwhrVg90H21EOLACvtfcHk0ljPDbhXsYmT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbw%253D&md5=058b12867becddc68602238a6128c6df</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnri2294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2294%26sid%3Dliteratum%253Aachs%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DVan%2BDyke%26aufirst%3DT.%2BE.%26atitle%3DResolving%2520inflammation%253A%2520dual%2520anti-inflammatory%2520and%2520pro-resolution%2520lipid%2520mediators%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D349%26epage%3D361%26doi%3D10.1038%2Fnri2294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoubian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory and pro-resolving lipid mediators</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathmechdis.3.121806.151409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1146%2Fannurev.pathmechdis.3.121806.151409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=18233953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFersLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=279-312&author=C.+N.+Serhanauthor=S.+Yacoubianauthor=R.+Yang&title=Anti-inflammatory+and+pro-resolving+lipid+mediators&doi=10.1146%2Fannurev.pathmechdis.3.121806.151409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory and proresolving lipid mediators</span></div><div class="casAuthors">Serhan, Charles N.; Yacoubian, Stephanie; Yang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">279-312</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The popular view that all lipid mediators are pro-inflammatory arises largely from the finding that nonsteroidal anti-inflammatory drugs block the biosynthesis of prostaglandins.  The resoln. of inflammation was widely held as a passive event until recently, with the characterization of novel biochem. pathways and lipid-derived mediators that are actively turned on in resoln. and that possess potent anti-inflammatory and proresolving actions.  A lipid-mediator informatics approach was employed to systematically identify new families of endogenous local-acting mediators from omega-3 polyunsatd. fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in resolving exudates, which also contain lipoxins and aspirin-triggered lipoxins generated from arachidonic acid.  Given their potent bioactions, these new chem. mediator families were termed resolvins and protectins.  Here, we review the recent advances in our understanding of the biosynthesis and stereospecific actions of these new proresolving mediators, which have also proven to be organ protective and antifibrotic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqro738WYmTdrVg90H21EOLACvtfcHk0ljPDbhXsYmT2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFersLw%253D&md5=8dcc9d14debaffce326d06f4a68de873</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathmechdis.3.121806.151409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathmechdis.3.121806.151409%26sid%3Dliteratum%253Aachs%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DYacoubian%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DAnti-inflammatory%2520and%2520pro-resolving%2520lipid%2520mediators%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2008%26volume%3D3%26spage%3D279%26epage%3D312%26doi%3D10.1146%2Fannurev.pathmechdis.3.121806.151409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundeen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.115436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1124%2Fjpet.106.115436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17371808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1154-1160&author=N.+L.+Raoauthor=P.+J.+Dunfordauthor=X.+Xueauthor=X.+Jiangauthor=K.+A.+Lundeenauthor=F.+Colesauthor=J.+P.+Rileyauthor=K.+N.+Williamsauthor=C.+A.+Griceauthor=J.+P.+Edwardsauthor=L.+Karlssonauthor=A.+M.+Fourie&title=Anti-inflammatory+activity+of+a+potent%2C+selective+leukotriene+A4+hydrolase+inhibitor+in+comparison+with+the+5-lipoxygenase+inhibitor+zileuton&doi=10.1124%2Fjpet.106.115436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton</span></div><div class="casAuthors">Rao, Navin L.; Dunford, Paul J.; Xue, Xiaohua; Jiang, Xiaohui; Lundeen, Katherine A.; Coles, Fawn; Riley, Jason P.; Williams, Kacy N.; Grice, Cheryl A.; Edwards, James P.; Karlsson, Lars; Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1154-1160</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase (LTA4H) catalyzes prodn. of the proinflammatory lipid mediator, leukotriene (LT) B4, which is implicated in a no. of inflammatory diseases.  We have identified a potent and selective inhibitor of both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H (IC50, approx. 10 nM).  In a murine model of arachidonic acid-induced ear inflammation, the LTA4H inhibitor, JNJ-26993135 (1-[4-(benzothiazol-2-yloxy)-benzyl]-piperidine-4-carboxylic acid), dose-dependently inhibited ex vivo LTB4 prodn. in blood, in parallel with dose-dependent inhibition of neutrophil influx (ED50, 1-3 mg/kg) and ear edema.  In murine whole blood and in zymosan-induced peritonitis, JNJ-26993135 selectively inhibited LTB4 prodn., without affecting cysteinyl leukotriene prodn., while maintaining or increasing prodn. of the anti-inflammatory mediator, lipoxin (LX) A4.  The 5-lipoxygenase (5-LO) inhibitor zileuton showed inhibition of LTB4, LTC4, and LXA4 prodn.  Although zileuton inhibited LTB4 prodn. in the peritonitis model more effectively than the LTA4H inhibitor, the influx of neutrophils into the peritoneum after 1 and 2 h was significantly higher in zileuton- vs. JNJ-26993135-treated animals.  This difference may have been mediated by the increased LXA4 levels in the presence of the LTA4H inhibitor.  The selective inhibition of LTB4 prodn. by JNJ-26993135, while increasing levels of the anti-inflammatory mediator, LXA4, may translate to superior therapeutic efficacy vs. 5-LO or 5-LO-activating protein inhibitors in LTB4-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM4FqRH-INZ7Vg90H21EOLACvtfcHk0ljYVm9o2bw3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLo%253D&md5=a74aea05870846dd51c7660c08762521</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115436%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DN.%2BL.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLundeen%26aufirst%3DK.%2BA.%26aulast%3DColes%26aufirst%3DF.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DKarlsson%26aufirst%3DL.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DAnti-inflammatory%2520activity%2520of%2520a%2520potent%252C%2520selective%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%2520in%2520comparison%2520with%2520the%25205-lipoxygenase%2520inhibitor%2520zileuton%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1154%26epage%3D1160%26doi%3D10.1124%2Fjpet.106.115436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caliskan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banoglu, E.</span></span> <span> </span><span class="NLM_article-title">Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.735228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1517%2F17460441.2013.735228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23095029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFShsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=49-63&author=B.+Caliskanauthor=E.+Banoglu&title=Overview+of+recent+drug+discovery+approaches+for+new+generation+leukotriene+A4+hydrolase+inhibitors&doi=10.1517%2F17460441.2013.735228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors</span></div><div class="casAuthors">Caliskan, Burcu; Banoglu, Erden</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: LTA4H is a bifunctional enzyme with hydrolase and aminopeptidase activities.  The hydrolase function of this enzyme specifically catalyzes the rate-limiting step in the conversion of LTA4 to LTB4, one of the most potent chemoattractant and activator of neutrophils.  The wealth of in vitro and in vivo data favors in support of LTA4H as an appealing target for the discovery and development of anti-inflammatory drugs.Areas covered: The authors provide an overview of the recent advances on LTA4H inhibitors since 2000.  The review details the medicinal chem. efforts leading to the generation of novel inhibitor chemotypes with desirable drug-like properties as well as the advantages and disadvantages of LTA4H as a desirable therapeutic target.  Expert opinion: Most of the LTA4H inhibitors block pro-inflammatory LTB4 biosynthesis by concomitant inhibition of both the hydrolase and aminopeptidase activities of LTA4H.  However, the degrdn. of another endogenous chemoattractant substrate (PGP) by aminopeptidase function of LTA4H was shown, introducing a new anti-inflammatory mission for this pro-inflammatory enzyme.  LTA4H inhibitors were also shown to maintain anti-inflammatory lipoxin formation.  Hence, the data on new LTA4H inhibitors should be cautiously interpreted with regard to potential repercussions of preventing PGP degrdn. as well as for the clin. benefits of concomitant lipoxin formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk4naHC_qarbVg90H21EOLACvtfcHk0ljYVm9o2bw3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFShsr7F&md5=93e3c122ba2fe19eea79df358022705a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.735228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.735228%26sid%3Dliteratum%253Aachs%26aulast%3DCaliskan%26aufirst%3DB.%26aulast%3DBanoglu%26aufirst%3DE.%26atitle%3DOverview%2520of%2520recent%2520drug%2520discovery%2520approaches%2520for%2520new%2520generation%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D49%26epage%3D63%26doi%3D10.1517%2F17460441.2013.735228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roinestad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Recent advances in clinical development of leukotriene B4 pathway drugs</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.smim.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29042030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=65-73&author=L.+Bhattauthor=K.+Roinestadauthor=T.+Vanauthor=E.+B.+Springman&title=Recent+advances+in+clinical+development+of+leukotriene+B4+pathway+drugs&doi=10.1016%2Fj.smim.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in clinical development of leukotriene B4 pathway drugs</span></div><div class="casAuthors">Bhatt, L.; Roinestad, K.; Van, T.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The LTB4 pathway is an attractive target for therapeutic drug development.  Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the rate limiting enzyme in the prodn. of LTB4.  An initial wave of effort culminated in the 1990s.  Over the past 15 years, a second wave of more selective drug candidates, including at least 5 BLT antagonists and 6 LTA4H inhibitors, have reached Phase 2 clin. trials.  Despite the extensive efforts to discover and develop LTB4 pathway targeting drugs, only one has reached the market to date.  Recently discovered complexities in the pathway and challenges in matching pathway intervention with therapeutic effect could explain the limited clin. success of LTB4 pathway drugs, even though there is a large body of scientific evidence linking LTB4 to human diseases and demonstrating efficacy of these compds. in a wide array of preclin. models.  Herein, we describe the clin. programs for the most prominent recent examples from each broad class and discuss the clin. outcomes and their implications for future development of LTB4 pathway drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomAJhLJFJTE7Vg90H21EOLACvtfcHk0ljYVm9o2bw3tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN&md5=a45e8c63d30430dbd71821c36b90c4ae</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DRoinestad%26aufirst%3DK.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DRecent%2520advances%2520in%2520clinical%2520development%2520of%2520leukotriene%2520B4%2520pathway%2520drugs%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.smim.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span>For details,
see <a href="https://trials.boehringer-ingelheim.com/public/trial_results_documents/1334/_english_13341c2248492COpdf.pdf" class="extLink">https://trials.boehringer-ingelheim.com/public/trial_results_documents/1334/_english_13341c2248492COpdf.pdf</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Ftrials.boehringer-ingelheim.com%2Fpublic%2Ftrial_results_documents%2F1334%2F_english_13341c2248492COpdf.pdf+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandanayaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyvan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enache, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onua, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldorsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorlaksdottir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinnsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zembower, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andresson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-[(2<i>S</i>)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1021/jm900838g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900838g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2hurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=573-585&author=V.+Sandanayakaauthor=B.+Mamatauthor=R.+K.+Mishraauthor=J.+Wingerauthor=M.+Krohnauthor=L.+M.+Zhouauthor=M.+Keyvanauthor=L.+Enacheauthor=D.+Sullinsauthor=E.+Onuaauthor=J.+Zhangauthor=G.+Halldorsdottirauthor=H.+Sigthorsdottirauthor=A.+Thorlaksdottirauthor=G.+Sigthorssonauthor=M.+Thorsteinnsdottirauthor=D.+R.+Daviesauthor=L.+J.+Stewartauthor=D.+E.+Zembowerauthor=T.+Andressonauthor=A.+S.+Kiselyovauthor=J.+Singhauthor=M.+E.+Gurney&title=Discovery+of+4-%5B%282S%29-2-%7B%5B4-%284-chlorophenoxy%29phenoxy%5Dmethyl%7D-1-pyrrolidinyl%5Dbutanoic+acid+%28DG-051%29+as+a+novel+leukotriene+A4+hydrolase+inhibitor+of+leukotriene+B4+biosynthesis&doi=10.1021%2Fjm900838g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis</span></div><div class="casAuthors">Sandanayaka, Vincent; Mamat, Bjorn; Mishra, Rama K.; Winger, Jennifer; Krohn, Michael; Zhou, Li-Ming; Keyvan, Monica; Enache, Livia; Sullins, David; Onua, Emmanuel; Zhang, Jun; Halldorsdottir, Gudrun; Sigthorsdottir, Heida; Thorlaksdottir, Audur; Sigthorsson, Gudmundur; Thorsteinnsdottir, Margret; Davies, Douglas R.; Stewart, Lance J.; Zembower, David E.; Andresson, Thorkell; Kiselyov, Alex S.; Singh, Jasbir; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both inhouse human genetic and literature data have converged on the identification of leukotriene 4 hydrolase (LTA4H) as a key target for the treatment of cardiovascular disease.  We combined fragment-based crystallog. screening with an iterative medicinal chem. effort to optimize inhibitors of LTA4H.  Ligand efficiency was followed throughout our structure-activity studies.  As applied within the context of LTA4H inhibitor design, the chem. team was able to design a potent compd. 20 (DG-051, I) (Kd = 26 nM) with high aq. soly. (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clin. evaluation for the treatment of myocardial infarction and stroke.  The structural biol.-chem. interaction described in this paper provides a sound alternative to conventional screening techniques.  This is the first example of a gene-to-clinic paradigm enabled by a fragment-based drug discovery effort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoySRkJb-vbd7Vg90H21EOLACvtfcHk0lhAUneTVZHR4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2hurvE&md5=29fc128c8ee8e7f24849da18f923cffe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm900838g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900838g%26sid%3Dliteratum%253Aachs%26aulast%3DSandanayaka%26aufirst%3DV.%26aulast%3DMamat%26aufirst%3DB.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DWinger%26aufirst%3DJ.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DL.%2BM.%26aulast%3DKeyvan%26aufirst%3DM.%26aulast%3DEnache%26aufirst%3DL.%26aulast%3DSullins%26aufirst%3DD.%26aulast%3DOnua%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHalldorsdottir%26aufirst%3DG.%26aulast%3DSigthorsdottir%26aufirst%3DH.%26aulast%3DThorlaksdottir%26aufirst%3DA.%26aulast%3DSigthorsson%26aufirst%3DG.%26aulast%3DThorsteinnsdottir%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DZembower%26aufirst%3DD.%2BE.%26aulast%3DAndresson%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%25204-%255B%25282S%2529-2-%257B%255B4-%25284-chlorophenoxy%2529phenoxy%255Dmethyl%257D-1-pyrrolidinyl%255Dbutanoic%2520acid%2520%2528DG-051%2529%2520as%2520a%2520novel%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%2520of%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D573%26epage%3D585%26doi%3D10.1021%2Fjm900838g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barchuk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkoff, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnathan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R.</span></span> <span> </span><span class="NLM_article-title">Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2014.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.pupt.2014.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=25018015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=15-23&author=W.+Barchukauthor=J.+Lambertauthor=R.+Fuhrauthor=J.+Z.+Jiangauthor=K.+Bertelsenauthor=A.+Fourieauthor=X.+Liuauthor=P.+E.+Silkoffauthor=E.+S.+Barnathanauthor=R.+Thurmond&title=Effects+of+JNJ-40929837%2C+a+leukotriene+A4+hydrolase+inhibitor%2C+in+a+bronchial+allergen+challenge+model+of+asthma&doi=10.1016%2Fj.pupt.2014.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma</span></div><div class="casAuthors">Barchuk, W.; Lambert, J.; Fuhr, R.; Jiang, J. Z.; Bertelsen, K.; Fourie, A.; Liu, X.; Silkoff, P. E.; Barnathan, E. S.; Thurmond, R.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Leukotriene B4 (LTB4) is a chemotactic mediator implicated in the pathogenesis of asthma.  JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 prodn.  We evaluated the effects of JNJ-40929837 in a human bronchial allergen challenge (BAC) model.  In this double-blind, 3-period crossover study, 22 patients with mild, atopic asthma were randomized to one of three treatments per period: 100 mg/day JNJ-40929837 for 6 days followed by 50 mg/day on day 7; 10 mg/day montelukast for 6 days; and matched placebo.  The BAC was performed on day 6 of each treatment period.  Primary outcome was BAC-induced late asthmatic response (LAR) measured by maximal percent redn. in forced expiratory vol. (FEV1) in one second.  Secondary outcomes included early asthmatic response (EAR) by maximal percent redn. in FEV1, EAR and LAR evaluated by area under the FEV1/time curve (AUC0-2, AUC3-10, resp.), change in baseline FEV1 after 5-day treatment, safety, and correlation of JNJ-40929837 to the divalent cation ionophore A23187-stimulated whole blood LTB4 levels and sputum basal LTB4 levels.  No significant differences were obsd. in the primary or secondary FEV1 endpoints with JNJ-40929837 vs. placebo.  Compared with placebo (n = 17, LS mean = 27.7), there was no significant attenuation of the maximal percent redn. in the LAR FEV1 with JNJ-40929837 (n = 16, LS mean = 28.6, P = 0.63) but montelukast (n = 17, LS mean = 22.6, P = 0.01) significantly attenuated the LAR.  JNJ-40929837 substantially inhibited LTB4 prodn. in whole blood, decreased sputum LTB4 levels and was well-tolerated.  The no. of adverse events leading to study withdrawal was the same in JNJ-40929837 and placebo groups.  In conclusion, JNJ-40929837 demonstrated target engagement in blood and sputum.  No significant impact in response to allergen inhalation was obsd. with JNJ-40929837 vs. placebo.This study is registered at ClinicalTrials.gov: NCT01241422.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Pv2-mB8Ag7Vg90H21EOLACvtfcHk0lhAUneTVZHR4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymsLjK&md5=894edcc79d795811670b454e8acda213</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2014.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2014.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarchuk%26aufirst%3DW.%26aulast%3DLambert%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DJ.%2BZ.%26aulast%3DBertelsen%26aufirst%3DK.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSilkoff%26aufirst%3DP.%2BE.%26aulast%3DBarnathan%26aufirst%3DE.%2BS.%26aulast%3DThurmond%26aufirst%3DR.%26atitle%3DEffects%2520of%2520JNJ-40929837%252C%2520a%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%252C%2520in%2520a%2520bronchial%2520allergen%2520challenge%2520model%2520of%2520asthma%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D29%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.pupt.2014.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span> <span> </span><span class="NLM_article-title">Testicular distribution and toxicity of a novel LTA4H inhibitor in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.taap.2014.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=24769091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2014&pages=26-30&author=P.+D.+Wardauthor=D.+La&title=Testicular+distribution+and+toxicity+of+a+novel+LTA4H+inhibitor+in+rats&doi=10.1016%2Fj.taap.2014.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular distribution and toxicity of a novel LTA4H inhibitor in rats</span></div><div class="casAuthors">Ward, P. D.; La, D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-30</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">JNJ 40929837, a novel leukotriene A4 hydrolase inhibitor in drug development, was reported to induce testicular toxicity in rats.  The mechanism of toxicity was considered to be rodent specific and not relevant to humans.  To further investigate this finding in rats, the distribution and toxicokinetics of JNJ 40929837 and its two metabolites, M1 and M2, were investigated.  A quant. whole body autoradiog. study showed preferential distribution and retention of JNJ 40929837-derived radioactivity in the testes consistent with the obsd. site of toxicity.  Subsequent studies with unlabeled JNJ 40929837 showed different metabolite profiles between the plasma and testes.  Following a single oral 50 mg/kg dose of JNJ 40929837, M2 was the primary metabolite in plasma whereas M1 was the primary metabolite in testes.  The exposure of M1 was 386-fold higher in the testes compared to plasma whereas M2 had limited exposure in testes.  Furthermore, the Tmax of M1 was 48 h in testes suggesting a large accumulation potential of this metabolite in testes compared to plasma.  Following six months of repeated daily oral dosing, M1 accumulated approx. five-fold in the testes whereas the parent did not accumulate.  These results indicate that the toxicokinetic profiles of JNJ 40929837 and its two metabolites in testes are markedly different compared to plasma and support the importance of understanding the toxicokinetic profiles of compds. and their metabolites in organs/tissues where toxicity is obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lpMCIw4BcrVg90H21EOLACvtfcHk0lh2QnXYqagB9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2hsbs%253D&md5=1b9aefd05547e7a0e9d9a270c04bee4c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BD.%26aulast%3DLa%26aufirst%3DD.%26atitle%3DTesticular%2520distribution%2520and%2520toxicity%2520of%2520a%2520novel%2520LTA4H%2520inhibitor%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D278%26spage%3D26%26epage%3D30%26doi%3D10.1016%2Fj.taap.2014.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mershon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span> <span> </span><span class="NLM_article-title">EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - study design and patient demographics</span>. <i>Contemp. Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.cct.2018.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.cct.2018.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30056216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ivFOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=86-94&author=J.+S.+Elbornauthor=S.+Ahujaauthor=E.+Springmanauthor=J.+Mershonauthor=R.+Grosswaldauthor=S.+M.+Rowe&title=EMPIRE-CF%3A+a+phase+II+randomized+placebo-controlled+trial+of+once-daily%2C+oral+acebilustat+in+adult+patients+with+cystic+fibrosis+-+study+design+and+patient+demographics&doi=10.1016%2Fj.cct.2018.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics</span></div><div class="casAuthors">Elborn J Stuart; Ahuja Sanjeev; Springman Eric; Mershon John; Grosswald Ralph; Rowe Steven M</div><div class="citationInfo"><span class="NLM_cas:title">Contemporary clinical trials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammation causes irreparable damage in the cystic fibrosis (CF) lung.  Despite high standards of care and the advent of new therapies, inflammation continues to cause significant loss of lung function and morbidity.  Acebilustat is a once-daily, oral molecule with anti-inflammatory activity through the inhibition of LTA4 hydrolase and modulation of LTB4.  It has potential to reduce lung function decline and pulmonary exacerbations in patients with CF and is currently being tested in a Phase II multicenter, randomized, double-blind, placebo-controlled, parallel-group study (EMPIRE-CF).  Strict inclusion criteria based on modeling of the Cystic Fibrosis Foundation Patient Registry data were selected to enrich the trial with patients most likely to benefit from chronic anti-inflammatory therapy that reduces lung function decline. 200 patients between 18 and 30 years of age, with an FEV1 percent predicted (pp) ≥50%, and ≥1 exacerbation in the past year have been enrolled.  Patients are randomized 1:1:1 to placebo, acebilustat 50 mg or 100 mg for 48 weeks, taken concomitantly with their current standard of care, and stratified based on concomitant CFTR modulator use, baseline FEV1pp (50% to 75% and >75%), and number of exacerbations in the past year (1 or >1).  The primary endpoints are absolute change from baseline in FEV1pp and safety outcomes.  Secondary endpoints include rate of pulmonary exacerbations and time to first pulmonary exacerbation.  Biomarkers of inflammation will also be assessed.  EMPIRE-CF is expected to identify the optimal patient population, dose, duration and endpoints for future acebilustat trials, and widen understanding of the drug's efficacy in patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsW06namU1-SjiVMCqkKxVfW6udTcc2eZlbbrAZK25Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ivFOgtg%253D%253D&md5=9d3cd61558f5fd31f0d8f7fe72dcbb59</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cct.2018.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cct.2018.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%26aulast%3DMershon%26aufirst%3DJ.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26atitle%3DEMPIRE-CF%253A%2520a%2520phase%2520II%2520randomized%2520placebo-controlled%2520trial%2520of%2520once-daily%252C%2520oral%2520acebilustat%2520in%2520adult%2520patients%2520with%2520cystic%2520fibrosis%2520-%2520study%2520design%2520and%2520patient%2520demographics%26jtitle%3DContemp.%2520Clin.%2520Trials%26date%3D2018%26volume%3D72%26spage%3D86%26epage%3D94%26doi%3D10.1016%2Fj.cct.2018.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Phase I studies of acebilustat: pharmacokinetics, pharmacodynamics, food effect, and CYP3A induction</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1111/cts.12426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fcts.12426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=27792868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=20-27&author=J.+S.+Elbornauthor=L.+Bhattauthor=R.+Grosswaldauthor=S.+Ahujaauthor=E.+B.+Springman&title=Phase+I+studies+of+acebilustat%3A+pharmacokinetics%2C+pharmacodynamics%2C+food+effect%2C+and+CYP3A+induction&doi=10.1111%2Fcts.12426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction</span></div><div class="casAuthors">Elborn, J. S.; Bhatt, L.; Grosswald, R.; Ahuja, S.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases.  It is an inhibitor of leukotriene A4 hydrolase; therefore, prodn. of leukotriene B4 (LTB4) in biol. fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment.  Here we compare the pharmacokinetics (PK) and PD between CF patients and healthy volunteers, and investigate the food effect and CYP3A4 induction in healthy volunteers.  No significant differences between study populations were obsd. for peak plasma level (Cmax) or exposure (AUC).  In healthy volunteers, a shift in time to Cmax (Tmax) was obsd. after a high-fat meal, but there was no change in AUC.  LTB4 prodn. was reduced in the blood of both populations and in sputum from CF patients.  Acebilustat did not induce CYP3A4.  These results support continued clin. study of once-daily oral acebilustat in CF at doses of 50 and 100 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWsgOa7asJLVg90H21EOLACvtfcHk0lh2QnXYqagB9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12ksw%253D%253D&md5=53db82198031280fc06ead4a6fa8f55c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fcts.12426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12426%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520I%2520studies%2520of%2520acebilustat%253A%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520food%2520effect%252C%2520and%2520CYP3A%2520induction%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D20%26epage%3D27%26doi%3D10.1111%2Fcts.12426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/cts.12428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fcts.12428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=27806191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=28-34&author=J.+S.+Elbornauthor=A.+Horsleyauthor=G.+MacGregorauthor=D.+Biltonauthor=R.+Grosswaldauthor=S.+Ahujaauthor=E.+B.+Springman&title=Phase+I+studies+of+acebilustat%3A+biomarker+response+and+safety+in+patients+with+cystic+fibrosis&doi=10.1111%2Fcts.12428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis</span></div><div class="casAuthors">Elborn, J. S.; Horsley, A.; MacGregor, G.; Bilton, D.; Grosswald, R.; Ahuja, S.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There is a significant unmet need for safe and effective anti-inflammatory treatment for cystic fibrosis.  The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis.  Seventeen patients with mild to moderate cystic fibrosis were enrolled and randomized into groups receiving placebo or doses of 50 mg or 100 mg acebilustat administered orally, once daily for 15 days.  Sputum neutrophil counts were reduced by 65% over baseline values in patients treated with 100 mg acebilustat.  A modestly significant 58% redn. vs. placebo in sputum elastase was obsd. with acebilustat treatment.  Favorable trends were obsd. for redn. of serum C-reactive protein and sputum neutrophil DNA in acebilustat-treated patients.  No changes in pulmonary function were obsd.  Acebilustat was safe and well tolerated.  The results of this study support further clin. development of acebilustat for treatment of cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSdSxMFr8ErVg90H21EOLACvtfcHk0lhpSzTEYBz5Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12ltA%253D%253D&md5=8eee0575c0951be7c91cf87fc0904034</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fcts.12428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12428%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DHorsley%26aufirst%3DA.%26aulast%3DMacGregor%26aufirst%3DG.%26aulast%3DBilton%26aufirst%3DD.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520I%2520studies%2520of%2520acebilustat%253A%2520biomarker%2520response%2520and%2520safety%2520in%2520patients%2520with%2520cystic%2520fibrosis%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D28%26epage%3D34%26doi%3D10.1111%2Fcts.12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span>For details,
see <a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Fwww.rcsb.org%2F+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span>For details,
see <a href="https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/" class="extLink">https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Fwww.3ds.com%2Fproducts-services%2Fbiovia%2Fproducts%2Fdata-science%2Fpipeline-pilot%2F+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niesen, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span> <span> </span><span class="NLM_article-title">The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fnprot.2007.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17853878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2212-2221&author=F.+H.+Niesenauthor=H.+Berglundauthor=M.+Vedadi&title=The+use+of+differential+scanning+fluorimetry+to+detect+ligand+interactions+that+promote+protein+stability&doi=10.1038%2Fnprot.2007.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</span></div><div class="casAuthors">Niesen, Frank H.; Berglund, Helena; Vedadi, Masoud</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2212-2221</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Differential scanning fluorometry (DSF) is a rapid and inexpensive screening method to identify low-mol.-wt. ligands that bind and stabilize purified proteins.  The temp. at which a protein unfolds is measured by an increase in the fluorescence of a dye with affinity for hydrophobic parts of the protein, which are exposed as the protein unfolds.  A simple fitting procedure allows quick calcn. of the transition midpoint; the difference in the temp. of this midpoint in the presence and absence of ligand is related to the binding affinity of the small mol., which can be a low-mol.-wt. compd., a peptide or a nucleic acid.  DSF is best performed using a conventional real-time PCR instrument.  Ligand solns. from a storage plate are added to a soln. of protein and dye, distributed into the wells of the PCR plate and fluorescence intensity measured as the temp. is raised gradually.  Results can be obtained in a single day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomViqp6Tq7krVg90H21EOLACvtfcHk0lhpSzTEYBz5Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb7N&md5=8a74dbb348ab81179614ab4ae5797d94</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.321%26sid%3Dliteratum%253Aachs%26aulast%3DNiesen%26aufirst%3DF.%2BH.%26aulast%3DBerglund%26aufirst%3DH.%26aulast%3DVedadi%26aufirst%3DM.%26atitle%3DThe%2520use%2520of%2520differential%2520scanning%2520fluorimetry%2520to%2520detect%2520ligand%2520interactions%2520that%2520promote%2520protein%2520stability%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2212%26epage%3D2221%26doi%3D10.1038%2Fnprot.2007.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergsdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. K.</span></span> <span> </span><span class="NLM_article-title">A guide to run affinity screens using differential scanning fluorimetry and surface plasmon resonance assays</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>610</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2018.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fbs.mie.2018.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30390797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKrsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=610&publication_year=2018&pages=135-165&author=C.+Bergsdorfauthor=S.+K.+Wright&title=A+guide+to+run+affinity+screens+using+differential+scanning+fluorimetry+and+surface+plasmon+resonance+assays&doi=10.1016%2Fbs.mie.2018.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to run affinity screens using differential scanning fluorimetry and surface plasmon resonance assays</span></div><div class="casAuthors">Bergsdorf, Christian; Wright, S. Kirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">610</span>
        (<span class="NLM_cas:issue">Modern Approaches in Drug Discovery</span>),
    <span class="NLM_cas:pages">135-165</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The implementation of high-throughput biochem. and cellular assays has enabled the screening of large compd. libraries which has become an important and often times the main source of new chem. matter that serve as starting point for medicinal chem. efforts.  In addn., biophys. methods measuring the phys. interaction (affinity) between a low mol. wt. ligand and a target protein became an integral part of hit validation/optimization to rule out false positives due to assay artifacts.  Recent advances in throughput, robustness, and sensitivity of biophys. affinity screening methods have broadened their application in hit identification and validation such that they can now complement classical functional readouts.  As a result, new target classes can be accessed that have not been amenable to functional assays.  In this chapter, two affinity screening methods, differential scanning fluorimetry and surface plasmon resonance, which are broadly utilized in both academia and pharmaceutical industry are discussed in respect to their use in hit identification and validation.  These methods exemplify how assays which differ in complexity, throughput, and information content can support the hit identification/validation process.  This chapter focuses on the practical aspects and caveats of these techniques in order to enable the reader to establish their own affinity-based screens in both formats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyuSs53WKzPrVg90H21EOLACvtfcHk0lhpSzTEYBz5Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKrsrzF&md5=3595b2a989df03ad6fb9e6b5eab98f80</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2018.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2018.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DBergsdorf%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DS.%2BK.%26atitle%3DA%2520guide%2520to%2520run%2520affinity%2520screens%2520using%2520differential%2520scanning%2520fluorimetry%2520and%2520surface%2520plasmon%2520resonance%2520assays%26jtitle%3DMethods%2520Enzymol.%26date%3D2018%26volume%3D610%26spage%3D135%26epage%3D165%26doi%3D10.1016%2Fbs.mie.2018.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pristupa, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niznik, H. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=8302271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFemu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1994&pages=125-135&author=Z.+B.+Pristupaauthor=J.+M.+Wilsonauthor=B.+J.+Hoffmanauthor=S.+J.+Kishauthor=H.+B.+Niznik&title=Pharmacological+heterogeneity+of+the+cloned+and+native+human+dopamine+transporter%3A+disassociation+of+%5B3H%5DWIN+35%2C428+and+%5B3H%5DGBR+12%2C935+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding</span></div><div class="casAuthors">Pristupa, Zdenek B.; Wilson, Julie M.; Hoffman, Beth J.; Kish, Stephen J.; Niznik, Hyman B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-35</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Controversy exists as to whether the functional state of the dopamine (DA) transporter is identical to sites mediating the specific binding of selective DA transporter radioligands.  Therefore, the authors compared the pharmacol. profile of numerous dopamine transport substrates and inhibitors on [3H]DA uptake with the binding of [3H]WIN 35,428 and [3H]GBR 12,935 to COS-7 cells transiently expressing the cloned human DA transporter.  [3H]DA uptake and [3H]WIN 35,428 binding was specific, saturable, and to a single class of binding sites with an estd. Km/Vmax of ∼2 μM and 6 pmol/min/105 cells for DA uptake and Kd/Bmax values of ∼10 nM and 113 fmol/105 cells for [3H]WIN 35,428.  [3H]DA uptake was inhibited in a concn.-dependent and uniphasic manner by dopaminergic agents with an appropriate rank order of potency for the DA transporter.  Although most uptake blockers inhibited [3H]WIN 35,428 binding in a uniphasic manner, WIN 35,428, Lu 19,005, D-amphetamine, and DA clearly displayed the presence of both high and low affinity components.  Comparison of the Ki values for the inhibition of [3H]DA uptake with [3H]WIN 35,428 binding reveals that, for uptake blockers and D-amphetamine, it is the high affinity component that shares pharmacol. identity with effects on DA uptake (r = 0.9985), whereas for DA it is the low affinity site.  In striking contrast, however, [3H]GBR 12,935 binding to COS-7 cells could not be made to exhibit a pharmacol. profile indicative of the DA transporter and suggests that the site regulating functional [3H]DA uptake may not be identical with sites labeled by [3H]GBR 12,935 in these cells.  Moreover, these sites appear unrelated to those previously described in native membranes as "piperazine acceptor" or P 450 proteins.  Comparison of Ki values and rank order of potency for the inhibition of [3H]WIN 35,428 or [3H]GBR 12,935 binding to human caudate membranes reveals pharmacol. homol., but not identity, with that of the cloned DA uptake process.  Taken together, these data suggest that 1) [3H]WIN 35,428 recognizes two sites of the DA transporter, of which only one appears to represent the functional state of the protein, and 2) [3H]WIN 35,428 and [3H]GBR 12,935 do not appear to bind the same functional form/state of the DA transporter.  Whether the nonidentity of binding sites is a manifestation of some post-translational regulatory event (e.g., phosphorylation/accessory binding protein) or caused by the existence of multiple mol. forms of the DA transporter is currently unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU2Vc8HuOAsLVg90H21EOLACvtfcHk0lgUmTLjx4AROg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFemu7c%253D&md5=a6ce271aad17d6f7f282bd716bbd1ddf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPristupa%26aufirst%3DZ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BM.%26aulast%3DHoffman%26aufirst%3DB.%2BJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DNiznik%26aufirst%3DH.%2BB.%26atitle%3DPharmacological%2520heterogeneity%2520of%2520the%2520cloned%2520and%2520native%2520human%2520dopamine%2520transporter%253A%2520disassociation%2520of%2520%255B3H%255DWIN%252035%252C428%2520and%2520%255B3H%255DGBR%252012%252C935%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1994%26volume%3D45%26spage%3D125%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlayson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">January, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. S.</span></span> <span> </span><span class="NLM_article-title">[3H]Dofetilide binding to herg transfected membranes: a potential high throughput preclinical screen</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01362-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FS0014-2999%2801%2901362-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=11698075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFWhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2001&pages=147-148&author=K.+Finlaysonauthor=L.+Turnbullauthor=C.+T.+Januaryauthor=J.+Sharkeyauthor=J.+S.+Kelly&title=%5B3H%5DDofetilide+binding+to+herg+transfected+membranes%3A+a+potential+high+throughput+preclinical+screen&doi=10.1016%2FS0014-2999%2801%2901362-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen</span></div><div class="casAuthors">Finlayson, Keith; Turnbull, Lorna; January, Craig T.; Sharkey, John; Kelly, John S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-148</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The pharmacol. characteristics of [3H]dofetilide binding were examd. in membranes prepd. from human embryonic kidney (HEK293) cells stably expressing human ether-a-go-go related gene (HERG) K+ channels.  The class III antiarrhythmic compds. dofetilide, clofilium, 4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide (E-4031), N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzene-sulfonamide (WAY-123,398) and d-sotalol all inhibited [3H]dofetilide binding.  In addn., the structurally unrelated compds. pimozide, terfenadine and haloperidol, all of which prolong the QT interval in man, also inhibited binding.  These data indicate that a [3H]dofetilide binding assay using HERG membranes may help identify compds. that prolong the QT interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09GxPknr35bVg90H21EOLACvtfcHk0lgUmTLjx4AROg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFWhs74%253D&md5=9849fe1d07c00f00be2ba076ecc7d93b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901362-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901362-0%26sid%3Dliteratum%253Aachs%26aulast%3DFinlayson%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DL.%26aulast%3DJanuary%26aufirst%3DC.%2BT.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%2BS.%26atitle%3D%255B3H%255DDofetilide%2520binding%2520to%2520herg%2520transfected%2520membranes%253A%2520a%2520potential%2520high%2520throughput%2520preclinical%2520screen%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D430%26spage%3D147%26epage%3D148%26doi%3D10.1016%2FS0014-2999%2801%2901362-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1124%2Fdmd.110.037911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=21383203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs&doi=10.1124%2Fdmd.110.037911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span></div><div class="casAuthors">Zimmerlin, Alfred; Trunzer, Markus; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although reversible CYP3A inhibition testing is well established for predicting the drug-drug interaction potential of clin. candidates, time-dependent inhibition (TDI) has become the focus of drug designers only recently.  Failure of several late-stage clin. candidates has been attributed to TDI, and this mechanism is also suspected to play a role in liver toxicities often obsd. in preclin. species.  Measurement of enzyme inactivation rates (kinact and KI) is tech. challenging, and a great deal of variability can be found in the literature.  In this article, we have evaluated the TDI potential for 400 registered drugs using a high-throughput assay format based on detn. of the inactivation rate (kobs) at a single concn. of test compd. (10 μM).  The advantages of this new assay format are highlighted by comparison with data generated using the IC50 shift assay, a current std. approach for preliminary assessment of TDI.  With use of an empirically defined pos./neg. kobs bin of 0.02 min-1, only 4% of registered drugs were found to be pos.  This proportion increased to more than 20% when inhouse lead optimization mols. were considered, emphasizing the importance of identifying this property in selection of promising drug candidates.  Finally, it is suggested that the data and technol. described here may be a good basis for building structure-activity relationships and in silico modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobYvW4ft03jbVg90H21EOLACvtfcHk0lgUmTLjx4AROg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D&md5=d21b39e85ab9410b7addfc820c1a4e18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037911%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1039%26epage%3D1046%26doi%3D10.1124%2Fdmd.110.037911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">3052</span>– <span class="NLM_lpage">3071</span>, <span class="refDoi"> DOI: 10.1002/jps.20913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1002%2Fjps.20913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17722003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12jtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=3052-3071&author=L.+Zhouauthor=L.+Yangauthor=S.+Tiltonauthor=J.+Wang&title=Development+of+a+high+throughput+equilibrium+solubility+assay+using+miniaturized+shake-flask+method+in+early+drug+discovery&doi=10.1002%2Fjps.20913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery</span></div><div class="casAuthors">Zhou, Liping; Yang, Linhong; Tilton, Suzanne; Wang, Jianling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3052-3071</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Increasingly, pharmaceutical and biotech companies have begun to realize the importance of obtaining soly. information in early drug discovery as it is one of the crit. parameters for lead selection and optimization.  This report introduces a high-throughput equil. soly. (HT-Eq sol) assay using a novel miniaturized shake-flask approach and streamlined HPLC anal.  The new HT-Eq sol assay, validated and optimized via a test set of 85 marketed drugs and Novartis internal compds., shows an excellent correlation to the conventional shake-flask thermodn. soly. data generated inhouse and the equil. soly. results reported in literature.  It therefore offers a fast, reliable and cost-effective screening tool for soly. assessment in early drug discovery, allowing for prioritization of drug candidates using aq. soly. in conjunction with other profiling information and efficacy data.  Our work demonstrates that presence of a small amt. of DMSO (0.5-5%) will result in significant overestimation of equil. soly. (up to 6 folds).  In addn., monitoring of drug dissoln. process using the current approach as well as the interplay between equil. soly. data and those from kinetic soly. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLEKUmI4vDMLVg90H21EOLACvtfcHk0ljL6JfmeSfqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12jtrrO&md5=e04d5b859372d08551b4a6af19e23fb5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjps.20913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20913%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTilton%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520high%2520throughput%2520equilibrium%2520solubility%2520assay%2520using%2520miniaturized%2520shake-flask%2520method%2520in%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D3052%26epage%3D3071%26doi%3D10.1002%2Fjps.20913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemurell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amilon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstedt, E. L.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of an inhibitor of 5-lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4312</span>– <span class="NLM_lpage">4324</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b02004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b02004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4312-4324&author=D.+Pettersenauthor=J.+Broddefalkauthor=H.+Emtenasauthor=M.+A.+Hayesauthor=M.+Lemurellauthor=M.+Swansonauthor=J.+Ulanderauthor=C.+Whatlingauthor=C.+Amilonauthor=H.+Ericssonauthor=A.+Westin+Erikssonauthor=K.+Granbergauthor=A.+T.+Plowrightauthor=I.+Shamovskyauthor=A.+Dellsenauthor=M.+Sundqvistauthor=M.+Nagardauthor=E.+L.+Lindstedt&title=Discovery+and+early+clinical+development+of+an+inhibitor+of+5-lipoxygenase+activating+protein+%28AZD5718%29+for+treatment+of+coronary+artery+disease&doi=10.1021%2Facs.jmedchem.8b02004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease</span></div><div class="casAuthors">Pettersen, Daniel; Broddefalk, Johan; Emtenaes, Hans; Hayes, Martin A.; Lemurell, Malin; Swanson, Marianne; Ulander, Johan; Whatling, Carl; Amilon, Carl; Ericsson, Hans; Westin Eriksson, Annika; Granberg, Kenneth; Plowright, Alleyn T.; Shamovsky, Igor; Dellsen, Anita; Sundqvist, Monica; Naagaard, Mats; Lindstedt, Eva-Lotte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4312-4324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the prodn. of proinflammatory and vasoactive leukotrienes.  As such, they are hypothesized to have therapeutic benefit for the treatment of diseases that involve chronic inflammation including coronary artery disease.  Herein, we disclose the medicinal chem. discovery and the early clin. development of the FLAP inhibitor AZD5718 (12).  Multiparameter optimization included securing adequate potency in human whole blood, navigation away from Ames mutagenic amine fragments while balancing metabolic stability and PK properties allowing for clin. relevant exposures after oral dosing.  The superior safety profile of AZD5718 compared to earlier front-runner compds. allowed us to perform a phase 1 clin. study in which AZD5718 demonstrated a dose dependent and greater than 90% suppression of leukotriene prodn. over 24 h.  Currently, AZD5718 is evaluated in a phase 2a study for treatment of coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn10AbsxceKbVg90H21EOLACvtfcHk0ljL6JfmeSfqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvF2gu7k%253D&md5=2f4eb866bc093f89ab36d97369eec718</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b02004%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DEmtenas%26aufirst%3DH.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DLemurell%26aufirst%3DM.%26aulast%3DSwanson%26aufirst%3DM.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DWhatling%26aufirst%3DC.%26aulast%3DAmilon%26aufirst%3DC.%26aulast%3DEricsson%26aufirst%3DH.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DGranberg%26aufirst%3DK.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DDellsen%26aufirst%3DA.%26aulast%3DSundqvist%26aufirst%3DM.%26aulast%3DNagard%26aufirst%3DM.%26aulast%3DLindstedt%26aufirst%3DE.%2BL.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%2520an%2520inhibitor%2520of%25205-lipoxygenase%2520activating%2520protein%2520%2528AZD5718%2529%2520for%2520treatment%2520of%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4312%26epage%3D4324%26doi%3D10.1021%2Facs.jmedchem.8b02004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, F.</span></span> <span> </span><span class="NLM_article-title">Enzymatic hydration of leukotriene A4. purification and characterization of a novel epoxide hydrolase from human erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">12832</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)38953-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FS0021-9258%2817%2938953-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=2995393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaL2MXmtV2msLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=12832-7&author=J.+McGeeauthor=F.+Fitzpatrick&title=Enzymatic+hydration+of+leukotriene+A4.+purification+and+characterization+of+a+novel+epoxide+hydrolase+from+human+erythrocytes&doi=10.1016%2FS0021-9258%2817%2938953-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymic hydration of leukotriene A4.  Purification and characterization of a novel epoxide hydrolase from human erythrocytes</span></div><div class="casAuthors">McGee, James; Fitzpatrick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12832-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Human erythrocytes contained a sol. cytosolic epoxide hydrolase for stereospecific enzymic hydration of leukotriene A4 into leukotriene B4.  The enzyme was purified 1100-fold, to apparent electrophoretic homogeneity, by conventional DEAE-Sephacel fractionation followed by high-performance anion-exchange and chromatofocusing procedures.  Its characteristics include a mol. wt. of 54,000, a pI of 4.9, an apparent Km of 7-36 μM for hydration of leukotriene A4, and a pH optimum of 7-8.  The enzyme was partially inactivated on initial exposure to leukotriene A4.  There was slow but detectable enzymic hydration (rates on the order of pmol/min/mg) of certain arachidonic acid epoxides including (±)-14,15-oxido-5,8,11-eicosatrienoic acid and (±)-11,12-oxido-5,8,14-eicosatrienoic acid, but not of others, including 5,6-oxido-8,11,14-eicosatrienoic acid.  Human erythrocyte epoxide hydrolase did not hydrate either styrene oxide or trans-stilbene oxide.  In terms of its phys. properties and substrate preference for leukotriene A4, the erythrocyte enzyme differs from previously described epoxide hydrolases.  Human erythrocytes represent a novel source for an extrahepatic, cytosolic epoxide hydrolase with a potential physiol. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqGTP2_pyk7Vg90H21EOLACvtfcHk0ljL6JfmeSfqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtV2msLk%253D&md5=ce741ac81c849f240c3aeb4de1c95ba0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2938953-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252938953-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DJ.%26aulast%3DFitzpatrick%26aufirst%3DF.%26atitle%3DEnzymatic%2520hydration%2520of%2520leukotriene%2520A4.%2520purification%2520and%2520characterization%2520of%2520a%2520novel%2520epoxide%2520hydrolase%2520from%2520human%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D12832%26epage%3D7%26doi%3D10.1016%2FS0021-9258%2817%2938953-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigrovic, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audoly, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austen, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span> <span> </span><span class="NLM_article-title">Neutrophil-derived leukotriene B4 is required for inflammatory arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1084/jem.20052371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1084%2Fjem.20052371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=16567388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjsl2isrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2006&pages=837-842&author=M.+Chenauthor=B.+K.+Lamauthor=Y.+Kanaokaauthor=P.+A.+Nigrovicauthor=L.+P.+Audolyauthor=K.+F.+Austenauthor=D.+M.+Lee&title=Neutrophil-derived+leukotriene+B4+is+required+for+inflammatory+arthritis&doi=10.1084%2Fjem.20052371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil-derived leukotriene B4 is required for inflammatory arthritis</span></div><div class="casAuthors">Chen, Mei; Lam, Bing K.; Kanaoka, Yoshihide; Nigrovic, Peter A.; Audoly, Laurent P.; Austen, K. Frank; Lee, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">837-842</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Neutrophils serve as a vanguard of the acute innate immune response to invading pathogens.  Neutrophils are also abundant at sites of autoimmune inflammation, such as the rheumatoid joint, although their pathophysiol. role is incompletely defined and relevant effector functions remain obscure.  Using genetic and pharmacol. approaches in the K/BxN serum transfer model of arthritis, we find that autoantibody-driven erosive synovitis is critically reliant on the generation of leukotrienes, and more specifically on leukotriene B4 (LTB4), for disease induction as well as perpetuation.  Pursuing the cellular source for this mediator, we find via reconstitution expts. that mast cells are a dispensable source of leukotrienes, whereas arthritis susceptibility can be restored to leukotriene-deficient mice by i.v. administration of wild-type neutrophils.  These expts. demonstrate a nonredundant role for LTB4 in inflammatory arthritis and define a neutrophil mediator involved in orchestrating the synovial eruption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQxyyQ20JRbVg90H21EOLACvtfcHk0lj4DjWpjhtLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjsl2isrs%253D&md5=d2b74595b60d56bb7d8d3850da3a98ed</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1084%2Fjem.20052371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20052371%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DB.%2BK.%26aulast%3DKanaoka%26aufirst%3DY.%26aulast%3DNigrovic%26aufirst%3DP.%2BA.%26aulast%3DAudoly%26aufirst%3DL.%2BP.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DLee%26aufirst%3DD.%2BM.%26atitle%3DNeutrophil-derived%2520leukotriene%2520B4%2520is%2520required%2520for%2520inflammatory%2520arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2006%26volume%3D203%26spage%3D837%26epage%3D842%26doi%3D10.1084%2Fjem.20052371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zembower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4694</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/jm900259h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900259h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4694-4715&author=D.+R.+Daviesauthor=B.+Mamatauthor=O.+T.+Magnussonauthor=J.+Christensenauthor=M.+H.+Haraldssonauthor=R.+Mishraauthor=B.+Peaseauthor=E.+Hansenauthor=J.+Singhauthor=D.+Zembowerauthor=H.+Kimauthor=A.+S.+Kiselyovauthor=A.+B.+Burginauthor=M.+E.+Gurneyauthor=L.+J.+Stewart&title=Discovery+of+leukotriene+A4+hydrolase+inhibitors+using+metabolomics+biased+fragment+crystallography&doi=10.1021%2Fjm900259h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography</span></div><div class="casAuthors">Davies, Douglas R.; Mamat, Bjorn; Magnusson, Olafur T.; Christensen, Jeff; Haraldsson, Magnus H.; Mishra, Rama; Pease, Brian; Hansen, Erik; Singh, Jasbir; Zembower, David; Kim, Hidong; Kiselyov, Alex S.; Burgin, Alex B.; Gurney, Mark E.; Stewart, Lance J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4694-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a novel fragment library termed fragments of life (FOL) for structure-based drug discovery.  The FOL library includes natural small mols. of life, derivs. thereof, and biaryl protein architecture mimetics.  The choice of fragments facilitates the interrogation of protein active sites, allosteric binding sites, and protein-protein interaction surfaces for fragment binding.  We screened the FOL library against leukotriene A4 hydrolase (LTA4H) by X-ray crystallog.  A diverse set of fragments including derivs. of resveratrol, nicotinamide, and indole were identified as efficient ligands for LTA4H.  These fragments were elaborated in a small no. of synthetic cycles into potent inhibitors of LTA4H representing multiple novel chemotypes for modulating leukotriene biosynthesis.  Anal. of the fragment-bound structures also showed that the fragments comprehensively recapitulated key chem. features and binding modes of several reported LTA4H inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKrUSDopfiLVg90H21EOLACvtfcHk0lj4DjWpjhtLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCntbo%253D&md5=017d54b1dc012e3dcdf7194c04ef8cff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm900259h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900259h%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DMamat%26aufirst%3DB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DM.%2BH.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DPease%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZembower%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%2520using%2520metabolomics%2520biased%2520fragment%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4694%26epage%3D4715%26doi%3D10.1021%2Fjm900259h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanis, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blevitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry-Bayle, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Dutra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santillán, A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiener, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. L.</span></span> <span> </span><span class="NLM_article-title">Azabenzthiazole inhibitors of leukotriene A4 hydrolase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7504</span>– <span class="NLM_lpage">7511</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.bmcl.2012.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23127888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aru7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7504-7511&author=V.+M.+Tanisauthor=G.+M.+Bacaniauthor=J.+M.+Blevittauthor=C.+C.+Chrovianauthor=S.+Crawfordauthor=A.+De+Leonauthor=A.+M.+Fourieauthor=L.+Gomezauthor=C.+A.+Griceauthor=K.+Hermanauthor=A.+M.+Kearneyauthor=A.+M.+Landry-Bayleauthor=A.+Lee-Dutraauthor=J.+Nelsonauthor=J.+P.+Rileyauthor=A.+Santill%C3%A1nauthor=J.+J.+Wienerauthor=X.+Xueauthor=A.+L.+Young&title=Azabenzthiazole+inhibitors+of+leukotriene+A4+hydrolase&doi=10.1016%2Fj.bmcl.2012.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Azabenzthiazole inhibitors of leukotriene A4 hydrolase</span></div><div class="casAuthors">Tanis, Virginia M.; Bacani, Genesis M.; Blevitt, Jonathan M.; Chrovian, Christa C.; Crawford, Shelby; De Leon, Aimee; Fourie, Anne M.; Gomez, Laurent; Grice, Cheryl A.; Herman, Krystal; Kearney, Aaron M.; Landry-Bayle, Adrienne M.; Lee-Dutra, Alice; Nelson, Jay; Riley, Jason P.; Santillan, Alejandro; Wiener, John J. M.; Xue, Xiaohua; Young, Arlene L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7504-7511</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, benzthiazole contg. LTA4H inhibitors were discovered that were potent (1-3), but were assocd. with the potential for a hERG liability.  Utilizing medicinal chem. first principles (e.g., introducing rigidity, lowering c Log D) a new benzthiazole series was designed, congeners of 1-3, which led to compds. 7a, 7c, 12a-d which exhibited LTA4H IC50 = 3-6 nM and hERG Dofetilide Binding IC50 = 8.9-> >10 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7wPhfnUv2bVg90H21EOLACvtfcHk0lj4DjWpjhtLSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aru7zJ&md5=c621215851acb4598d945faac3e12be0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DTanis%26aufirst%3DV.%2BM.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DBlevitt%26aufirst%3DJ.%2BM.%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DCrawford%26aufirst%3DS.%26aulast%3DDe%2BLeon%26aufirst%3DA.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DHerman%26aufirst%3DK.%26aulast%3DKearney%26aufirst%3DA.%2BM.%26aulast%3DLandry-Bayle%26aufirst%3DA.%2BM.%26aulast%3DLee-Dutra%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DSantill%25C3%25A1n%26aufirst%3DA.%26aulast%3DWiener%26aufirst%3DJ.%2BJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYoung%26aufirst%3DA.%2BL.%26atitle%3DAzabenzthiazole%2520inhibitors%2520of%2520leukotriene%2520A4%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7504%26epage%3D7511%26doi%3D10.1016%2Fj.bmcl.2012.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span> </span><span class="NLM_article-title">Diamine derivatives as inhibitors of leukotriene A4
hydrolase</span>. US <span class="NLM_patent">2007/155726</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Diamine+derivatives+as+inhibitors+of+leukotriene+A4%0Ahydrolase.+US+2007%2F155726%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DDiamine%2520derivatives%2520as%2520inhibitors%2520of%2520leukotriene%2520A4%250Ahydrolase%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penno, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laguerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettstein-Ling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raulf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röhn, T. A.</span></span> <span> </span><span class="NLM_article-title">Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">2421</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.1016/j.jid.2020.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.jid.2020.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=32387270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOjtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2020&pages=2421-2432&author=C.+A.+Pennoauthor=P.+Jagerauthor=C.+Laguerreauthor=F.+Haslerauthor=A.+Hofmannauthor=S.+K.+Gassauthor=B.+Wettstein-Lingauthor=D.+J.+Schaeferauthor=A.+Avrameasauthor=F.+Raulfauthor=G.+Wieczorekauthor=J.+C.+U.+Lehmannauthor=C.+Loescheauthor=L.+Rothauthor=T.+A.+R%C3%B6hn&title=Lipidomics+profiling+of+hidradenitis+suppurativa+skin+lesions+reveals+lipoxygenase+pathway+dysregulation+and+accumulation+of+proinflammatory+leukotriene+B4&doi=10.1016%2Fj.jid.2020.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4</span></div><div class="casAuthors">Penno, Carlos A.; Jager, Petra; Laguerre, Claire; Hasler, Franziska; Hofmann, Andreas; Gass, Stephanie K.; Wettstein-Ling, Barbara; Schaefer, Dirk J.; Avrameas, Alexandre; Raulf, Friedrich; Wieczorek, Grazyna; Lehmann, Joachim C. U.; Loesche, Christian; Roth, Lukas; Rohn, Till A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2421-2432.e10</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory dermatosis characterized by abscesses, deep-seated nodules, sinus tracts, and fibrosis in skin lesions around hair follicles of the axillary, inguinal, and anogenital regions.  Whereas the exact pathogenesis remains poorly defined, clear evidence suggests that HS is a multifactorial inflammatory disease characterized by innate and adaptive immune components.  Bioactive lipids are important regulators of cutaneous homeostasis, inflammation, and resoln. of inflammation.  Alterations in the lipid mediator profile can lead to malfunction and cutaneous inflammation.  We used targeted lipidomics to analyze selected omega-3 and omega-6 polyunsatd. fatty acids in skin of patients with HS and of healthy patients.  Lesional HS skin displayed enrichment of 5-lipoxygenase (LO)-derived metabolites, esp. leukotriene B4.  In addn., 15-LO-derived metabolites were underrepresented in HS lesions.  Changes in the lipid mediator profile were accompanied by transcriptomic dysregulation of the 5-LO and 15-LO pathways.  Hyperactivation of the 5-LO pathway in lesional macrophages identified these cells as potential sources of leukotriene B4, which may cause neutrophil influx and activation.  Furthermore, leukotriene B4-induced mediators and pathways were elevated in HS lesions, suggesting a contribution of this proinflammatory lipid meditator to the pathophysiol. of HS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Nh26aY3EnrVg90H21EOLACvtfcHk0lhOMYpeT9pe1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOjtrfM&md5=97fa46a26120c196c6b85ca8aab0b77d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jid.2020.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jid.2020.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPenno%26aufirst%3DC.%2BA.%26aulast%3DJager%26aufirst%3DP.%26aulast%3DLaguerre%26aufirst%3DC.%26aulast%3DHasler%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DA.%26aulast%3DGass%26aufirst%3DS.%2BK.%26aulast%3DWettstein-Ling%26aufirst%3DB.%26aulast%3DSchaefer%26aufirst%3DD.%2BJ.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DRaulf%26aufirst%3DF.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DLehmann%26aufirst%3DJ.%2BC.%2BU.%26aulast%3DLoesche%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DL.%26aulast%3DR%25C3%25B6hn%26aufirst%3DT.%2BA.%26atitle%3DLipidomics%2520profiling%2520of%2520hidradenitis%2520suppurativa%2520skin%2520lesions%2520reveals%2520lipoxygenase%2520pathway%2520dysregulation%2520and%2520accumulation%2520of%2520proinflammatory%2520leukotriene%2520B4%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2020%26volume%3D140%26spage%3D2421%26epage%3D2432%26doi%3D10.1016%2Fj.jid.2020.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pim  Aarts</span>, <span class="hlFld-ContribAuthor ">Koen  Dudink</span>, <span class="hlFld-ContribAuthor ">Allard R. J. V.  Vossen</span>, <span class="hlFld-ContribAuthor ">Kelsey R.  van Straalen</span>, <span class="hlFld-ContribAuthor ">Christine B.  Ardon</span>, <span class="hlFld-ContribAuthor ">Errol P.  Prens</span>, <span class="hlFld-ContribAuthor ">Hessel H.  van der Zee</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>6 </em><a href="https://doi.org/10.1007/s40265-021-01566-2" title="DOI URL">https://doi.org/10.1007/s40265-021-01566-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-021-01566-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-021-01566-2%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DClinical%252BImplementation%252Bof%252BBiologics%252Band%252BSmall%252BMolecules%252Bin%252Bthe%252BTreatment%252Bof%252BHidradenitis%252BSuppurativa%26aulast%3DAarts%26aufirst%3DPim%26date%3D2021%26date%3D2021%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Till A  Röhn</span>, <span class="hlFld-ContribAuthor ">Shin  Numao</span>, <span class="hlFld-ContribAuthor ">Heike  Otto</span>, <span class="hlFld-ContribAuthor ">Christian  Loesche</span>, <span class="hlFld-ContribAuthor ">Gebhard  Thoma</span>. </span><span class="cited-content_cbyCitation_article-title">Drug discovery strategies for novel leukotriene A4 hydrolase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>10 </em>, 1-13. <a href="https://doi.org/10.1080/17460441.2021.1948998" title="DOI URL">https://doi.org/10.1080/17460441.2021.1948998</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1948998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1948998%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DDrug%252Bdiscovery%252Bstrategies%252Bfor%252Bnovel%252Bleukotriene%252BA4%252Bhydrolase%252Binhibitors%26aulast%3DR%25C3%25B6hn%26aufirst%3DTill%2BA%26date%3D2021%26date%3D2021%26volume%3D10%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.  Qin</span>, <span class="hlFld-ContribAuthor ">H.  Wang</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2021,</strong> <em>32 </em>
                                    (5)
                                     , 411-431. <a href="https://doi.org/10.1080/1062936X.2021.1910862" title="DOI URL">https://doi.org/10.1080/1062936X.2021.1910862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2021.1910862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2021.1910862%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DClassification%252Band%252BQSAR%252Bmodels%252Bof%252Bleukotriene%252BA4%252Bhydrolase%252B%252528LTA4H%252529%252Binhibitors%252Bby%252Bmachine%252Blearning%252Bmethods%26aulast%3DQin%26aufirst%3DR.%26date%3D2021%26date%3D2021%26volume%3D32%26issue%3D5%26spage%3D411%26epage%3D431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Discovery of LYS006, an Inhibitor of Leukotriene A4 Hydrolase for the Treatment of Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0573. <a href="https://doi.org/10.1055/s-0040-1719803" title="DOI URL">https://doi.org/10.1055/s-0040-1719803</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719803%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DDiscovery%252Bof%252BLYS006%25252C%252Ban%252BInhibitor%252Bof%252BLeukotriene%252BA4%252BHydrolase%252Bfor%252Bthe%252BTreatment%252Bof%252BInflammatory%252BDiseases%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D05%26spage%3D0573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shin  Numao</span>, <span class="hlFld-ContribAuthor ">Gianluca  Etienne</span>, <span class="hlFld-ContribAuthor ">Goran  Malojcic</span>, <span class="hlFld-ContribAuthor ">Enrico  Schmidt</span>, <span class="hlFld-ContribAuthor ">Christoph E.  Dumelin</span>. </span><span class="cited-content_cbyCitation_article-title">Compound Screening. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00078-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00078-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00078-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00078-5%26sid%3Dliteratum%253Aachs%26atitle%3DCompound%252BScreening%26aulast%3DNumao%26aufirst%3DShin%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of LTA4H inhibitors that have reached phase II clinical trials but are no longer reported to be in active development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Fragment hits <b>1</b> (7AV2) and <b>2</b> (7AV1) bound to LTA4H (left) and hydrogen bonding network for fragment <b>2</b> (right). For clarity, only key interactions are depicted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Identification of highly potent starting point <b>3</b> by merging of fragment hits <b>1</b> and <b>2</b>. Under DSF screening conditions, <b>1</b> and <b>2</b> increased the melting temperature (<i>T</i><sub>m</sub>) of LTA4H by 0.5 °C (at 500 μM). Hybrid <b>3</b> stabilized by 6.8 °C (at 100 μM, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Optimized candidate (<i>S</i>)-<b>22</b> (7AUZ) and lead compound (<i>R</i>)-<b>13</b> (7AV0) bound to LTA4H (overlay). Despite opposite stereoconfigurations, the amine and acid groups occupy almost identical positions, rationalizing similar biochemical behavior of the optical antipodes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Human PBMCs (upper panel) and human whole blood (lower panel) were preincubated for different times with increasing concentrations of LYS006. Compound preincubation times ranged from 15 to 240 min. Cells were then stimulated with ionophore and LTB<sub>4</sub> release determined. Dose–response curves with mean LTB<sub>4</sub> levels ± SD are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Lipidomics profile of LYS006-treated, stimulated human PBMCs. PBMCs were pretreated for 15 min with 1 μM LYS006 or vehicle control prior to stimulation with calcium ionophore for 2 h. Lipids were quantified by LCMS/MS. Concentrations are shown in ng/mL as the mean ± SD. Depicted is a selection of lipid mediators from different eicosanoid metabolism pathways of a total of 45 tested lipids. Statistical analysis Welch’s <i>t</i> test. *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001. Abbreviations: AA, arachidonic acid; 12-HETE, 12-hydroxyeicosatetraenoic acid; 15-HETE, 15-hydroxyeicosotetraenoic acid; PGE2, prostaglandin E2; PGD2, prostaglandin D2; TXB2 = thromboxane B2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <i>In vitro</i> blood/plasma distribution ratios of LYS006. Rising concentrations of [<sup>3</sup>H]LYS006 were incubated for 30 min at 37 °C with blood from different species. Total radioactivity in blood and plasma was determined in triplicate. Values are given as the ratio of [<sup>3</sup>H]LYS006 concentration in blood divided by plasma concentration of [<sup>3</sup>H]LYS006.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Steady-state PK/PD relationship of LYS006 (blue) and Acebilustat (green). Female C57BL/6 mice (<i>n</i> = 4 per group) were dosed p.o. five times in a b.i.d. regimen. Compound exposures in blood and plasma, and LTB<sub>4</sub> inhibition in <i>ex vivo</i> stimulated blood were determined 2 h (upper panel) and 14 h after the last dose (lower panel). Shown are average exposures in blood (black numbers above graphs) and plasma (green numbers above graph), and the means of LTB<sub>4</sub> inhibition ± SEM (PD). One way ANOVA followed by Dunnett’s multiple comparison correction was applied with **<i>p</i> < 0.01 and ***<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Suppression of neutrophilic inflammation in arachidonic acid induced skin inflammation model. Female 129S2/SvPasCrl mice were dosed p.o. five times in a b.i.d. regimen. At 3 h after the last dose, inflammation in the skin was induced by topical arachidonic acid challenge for another 3 h. <i>Ex vivo</i> stimulated LTB<sub>4</sub> levels in blood (upper panel) and tissue MPO levels (lower panel) were determined. Shown are the means ± SEM, <i>n</i> = 5 per group. One way ANOVA followed by Dunnett’s multiple comparison correction was applied with *<i>p</i> < 0.05 and **<i>p</i> < 0.001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Efficacy of LYS006 administered prophylactically in the mouse KRN passive serum-induced arthritis model. Upper panel: Paw swelling scores of C57BL/6 mice (<i>n</i> = 6 per group) during arthritis are shown as means ± SEM. Treatment with LYS006 was started in a b.i.d. regimen 1 day before disease induction (day 0). Statistical analysis (ANOVA, followed by Dunnett’s test) indicates *<i>p</i> < 0.05 and **<i>p</i> < 0.01. Lower panel: LTB<sub>4</sub> generation in <i>ex vivo</i> stimulated whole blood taken 2 h (gray bars) and 14 h (blue bars) after the final dose at day 6. Shown are the mean LTB<sub>4</sub> levels ± SEM. Numbers above bars indicate compound exposures in blood at indicated dose and time point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Efficacy of LYS006 in a therapeutic KRN model: LYS006 reduces clinical scores, histological parameters, and numbers of neutrophils in tissue. Upper left panel: Paw swelling scores of C57BL/6 mice (<i>n</i> = 6) during arthritis are shown as means ± SEM. Treatment with LYS006 was started in a b.i.d. regimen with a 10 mg/kg dose on day 4 after disease induction. Statistical analysis (ANOVA, followed by Dunnett’s test) indicates *<i>p</i> < 0.05 and **<i>p</i> < 0.01. Upper right panel: Histology scores combined for the hind paws of all animals were assessed for cellularity, joint damage, proteoglycan loss, and neutrophil numbers in the joint. Data are presented as the means ± SEM. Statistical analysis: Unpaired <i>t</i> test with *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001. Lower panel: Photomicrographs of hind paw sections stained with H&E (left column), Safranin O (cartilage stained red, middle column), and Ly-6B2 antibody (neutrophils stained brown, right column) illustrate joint inflammation and damage and preservation after LYS006 treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/medium/jm0c01955_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of LYS006 [(<i>S</i>)-<b>22</b>]<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01955/20210218/images/large/jm0c01955_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01955&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, DMF, 50 °C, 16 h, 93%; (b) Bu<sub>2</sub>SnO (10%), TMSN<sub>3</sub>, toluene, 90 °C, 18 h, 77%; (c) <b>(</b><i>S</i><b>)-29</b>, DMF, DIPEA, rt, 17 h, 77%; (d) HCl in dioxane, 45 °C, 26 h, 78%; (e) (i) SOCl<sub>2</sub>, imidazole, 2-MeTHF, −78 °C to rt, 2 h; (ii) NaIO<sub>4</sub>, cat. RuCl<sub>3</sub>·H<sub>2</sub>O, MeCN-water, 0 °C, 2 h, 79% (two steps).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i47">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 39 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis</span>. <i>Clin. Rev. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1007/BF02737600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1007%2FBF02737600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10436862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisVKhu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=111-131&author=J.+Z.+Haeggstrom&title=Leukotriene+A4+hydrolase+and+the+committed+step+in+leukotriene+B4+biosynthesis&doi=10.1007%2FBF02737600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene A4 hydrolase and the committed step in leukotriene B4 biosynthesis</span></div><div class="casAuthors">Haeggstrom, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Reviews in Allergy & Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">111-131</span>CODEN:
                <span class="NLM_cas:coden">CRAIF2</span>;
        ISSN:<span class="NLM_cas:issn">1080-0549</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review, with 87 refs., on LTA4 hydrolase and its role in the final step in the biosynthesis of LTB4.  The authors discussed the tissue and cellular distribution of LTA4 hydrolase, various amino acids residues involved in its different enzymic activities, structural determinants for suicide inactivation of LTA4 hydrolase, model of the active site of LTA4 hydrolase, variant forms of LTA4 hydrolase; development of LTA4 hydrolase inhibitors, and receptors for LTB4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1zSpEq9I9LbVg90H21EOLACvtfcHk0liIc3yGFoQVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisVKhu7Y%253D&md5=e1be809666043ae8f775ea6e793344f4</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2FBF02737600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02737600%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520A4%2520hydrolase%2520and%2520the%2520committed%2520step%2520in%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DClin.%2520Rev.%2520Allergy%2520Immunol.%26date%3D1999%26volume%3D17%26spage%3D111%26epage%3D131%26doi%3D10.1007%2FBF02737600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gierse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, F. A.</span></span> <span> </span><span class="NLM_article-title">Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase</span>. <i>Prostaglandins</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/0090-6980(92)90018-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2F0090-6980%2892%2990018-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1410529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK38XmsVOmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1992&pages=251-257&author=K.+J.+Griffinauthor=J.+Gierseauthor=G.+Kriviauthor=F.+A.+Fitzpatrick&title=Opioid+peptides+are+substrates+for+the+bifunctional+enzyme+LTA4+hydrolase%2Faminopeptidase&doi=10.1016%2F0090-6980%2892%2990018-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase</span></div><div class="casAuthors">Griffin, K. J.; Gierse, J.; Krivi, G.; Fitzpatrick, F. A.</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-7</span>CODEN:
                <span class="NLM_cas:coden">PRGLBA</span>;
        ISSN:<span class="NLM_cas:issn">0090-6980</span>.
    </div><div class="casAbstract">It was the aim of the described research to detd. if any naturally occurring peptides could act as substrates or inhibitors of the bifunctional, Zn2+ metalloenzyme LT (leukotriene) A4 hydrolase/aminopeptidase (E.C. 3.3.2.6).  Several opioid peptides including met5-enkephalin, leu5-enkephalin, dynorphin1-6, dynorphin1-7, and dynorphin1-8 competitively inhibited the hydrolysis of L-proline-p-nitroanilide by leukotriene A4 hydrolase/aminopeptidase, consistent with an interaction at its active site.  The enzyme catalyzed the N-terminal hydrolysis of tyrosine from met5-enkephalin with Km = 450 μM and Vmax = 4.9 nmol-h-1-ug-1 and from leu5-enkephalin with Km = 387 μM and Vmax = 6.2 nmol-h-1-ug-1.  Bestatin, captopril and carnosine inhibited the hydrolysis of the enkephalins.  It is noteworthy that the bifunctional catalytic traits of this enzyme include generation of an hyperanalgesic substance, LTB4, and inactivation of analgesic opioid peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetmUg2KNhmrVg90H21EOLACvtfcHk0liIc3yGFoQVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmsVOmuro%253D&md5=a4a40b53b67ea6383e95459aa0a0d816</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0090-6980%2892%2990018-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0090-6980%252892%252990018-O%26sid%3Dliteratum%253Aachs%26aulast%3DGriffin%26aufirst%3DK.%2BJ.%26aulast%3DGierse%26aufirst%3DJ.%26aulast%3DKrivi%26aufirst%3DG.%26aulast%3DFitzpatrick%26aufirst%3DF.%2BA.%26atitle%3DOpioid%2520peptides%2520are%2520substrates%2520for%2520the%2520bifunctional%2520enzyme%2520LTA4%2520hydrolase%252Faminopeptidase%26jtitle%3DProstaglandins%26date%3D1992%26volume%3D44%26spage%3D251%26epage%3D257%26doi%3D10.1016%2F0090-6980%2892%2990018-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nissen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kragballe, K.</span></span> <span> </span><span class="NLM_article-title">Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1–7</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">749</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2133.1995.tb02749.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fj.1365-2133.1995.tb02749.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=8555027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK28Xps1Wj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=1995&pages=742-749&author=J.+B.+Nissenauthor=L.+Iversenauthor=K.+Kragballe&title=Characterization+of+the+aminopeptidase+activity+of+epidermal+leukotriene+A4+hydrolase+against+the+opioid+dynorphin+fragment+1%E2%80%937&doi=10.1111%2Fj.1365-2133.1995.tb02749.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid dynorphin fragment 1-7</span></div><div class="casAuthors">Nissen, J. B.; Iversen, L.; Kragballe, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">742-9</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase is a bifunctional cytosolic enzyme, which both hydrolyzes leukotriene A4 (LTA4) into leukotriene B4 (LTB4) and exerts aminopeptidase activity against opioid peptides.  In the present study the authors have investigated whether the peptides angiotensin I and II, bradykinin, kallidine, histamine, dynorphin fragment 1-7 and substance P can act as substrates for epidermal and neutrophil LTA4 hydrolase.  Among the tested substrates, dynorphin fragment 1-7 was the best substrate for the enzyme.  The aminopeptidase activity of epidermal and neutrophil LTA4 hydrolase against dynorphin fragment 1-7 was further characterized.  The enzyme was purified from human epidermis and human neutrophils by anion exchange chromatog. (Q-Sepharose) and affinity chromatog. on a column with the LTA4 hydrolase inhibitor bestatin coupled to AH-Sepharose.  The incubation of the dynorphin fragment 1-7 with LTA4 hydrolase resulted in the formation of tyrosine.  The presence of the N-terminal amino acid tyrosine is essential for the interaction of opioids with their receptors, and this finding indicates that the LTA4 hydrolase can inactivate dynorphin fragment 1-7.  After the two purifn. steps no other aminopeptidases acting at the N-terminal tyrosine of dynorphin fragment 1-7 was present in the prepn.  This was demonstrated by the abolishment of the degrdn. at the N-terminal end of dynorphin fragment 1-7 when preincubating the enzyme prepn. with LTA4 before the incubation with the dynorphin fragment 1-7.  The abolishment of the aminopeptidase activity shows that activation of the hydrolase part of the enzyme, with conversion of LTA4 into the potent proinflammatory compd. LTB4, results in an inhibition of the aminopeptidase activity of the enzyme.  As a result, the catabolism of dynorphin fragment 1-7 and probably of other opioid peptides is inhibited, resulting in sustained biol. effects of these opioids.  This phenomenon may be important for the maintenance of inflammation in skin conditions, such as psoriasis and atopic dermatitis, in which LTB4 is formed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotevaEksnRBbVg90H21EOLACvtfcHk0liIc3yGFoQVig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xps1Wj&md5=209651b9980a116fcca59ab16f3915ec</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2133.1995.tb02749.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2133.1995.tb02749.x%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DJ.%2BB.%26aulast%3DIversen%26aufirst%3DL.%26aulast%3DKragballe%26aufirst%3DK.%26atitle%3DCharacterization%2520of%2520the%2520aminopeptidase%2520activity%2520of%2520epidermal%2520leukotriene%2520A4%2520hydrolase%2520against%2520the%2520opioid%2520dynorphin%2520fragment%25201%25E2%2580%25937%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D1995%26volume%3D133%26spage%3D742%26epage%3D749%26doi%3D10.1111%2Fj.1365-2133.1995.tb02749.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Numao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laguerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wack, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osmont, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlisberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houguenade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergsdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardaker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penno, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollbuck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miltz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röhn, T. A.</span></span> <span> </span><span class="NLM_article-title">Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13591</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-13490-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fs41598-017-13490-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29051536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BC1M7is1CgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=13591&author=S.+Numaoauthor=F.+Haslerauthor=C.+Laguerreauthor=H.+Srinivasauthor=N.+Wackauthor=P.+Jagerauthor=A.+Schmidauthor=A.+Osmontauthor=P.+Rothlisbergerauthor=J.+Houguenadeauthor=C.+Bergsdorfauthor=J.+Dawsonauthor=N.+Carteauthor=A.+Hofmannauthor=C.+Markertauthor=L.+Hardakerauthor=A.+Billichauthor=R.+M.+Wolfauthor=C.+A.+Pennoauthor=B.+Bollbuckauthor=W.+Miltzauthor=T.+A.+R%C3%B6hn&title=Feasibility+and+physiological+relevance+of+designing+highly+potent+aminopeptidase-sparing+leukotriene+A4+hydrolase+inhibitors&doi=10.1038%2Fs41598-017-13490-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors</span></div><div class="casAuthors">Numao Shin; Srinivas Honnappa; Schmid Andres; Rothlisberger Patrik; Bergsdorf Christian; Hasler Franziska; Wack Nathalie; Jager Petra; Houguenade Jeremy; Dawson Janet; Billich Andreas; Rohn Till A; Laguerre Claire; Osmont Arnaud; Carte Nathalie; Hofmann Andreas; Penno Carlos A; Markert Christian; Wolf Romain M; Bollbuck Birgit; Miltz Wolfgang; Hardaker Liz</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13591</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukotriene A4 Hydrolase (LTA4H) is a bifunctional zinc metalloenzyme that comprises both epoxide hydrolase and aminopeptidase activity, exerted by two overlapping catalytic sites.  The epoxide hydrolase function of the enzyme catalyzes the biosynthesis of the pro-inflammatory lipid mediator leukotriene (LT) B4.  Recent literature suggests that the aminopeptidase function of LTA4H is responsible for degradation of the tripeptide Pro-Gly-Pro (PGP) for which neutrophil chemotactic activity has been postulated.  It has been speculated that the design of epoxide hydrolase selective LTA4H inhibitors that spare the aminopeptidase pocket may therefore lead to more efficacious anti-inflammatory drugs.  In this study, we conducted a high throughput screen (HTS) for LTA4H inhibitors and attempted to rationally design compounds that would spare the PGP degrading function.  While we were able to identify compounds with preference for the epoxide hydrolase function, absolute selectivity was not achievable for highly potent compounds.  In order to assess the relevance of designing such aminopeptidase-sparing LTA4H inhibitors, we studied the role of PGP in inducing inflammation in different settings in wild type and LTA4H deficient (LTA4H KO) animals but could not confirm its chemotactic potential.  Attempting to design highly potent epoxide hydrolase selective LTA4H inhibitors, therefore seems to be neither feasible nor relevant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6ihDczXmk7TC850By6mxpfW6udTcc2eYHw2CKap3Kzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7is1CgtQ%253D%253D&md5=38103beaecb2080bd5a6c87fbf38172e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-13490-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-13490-1%26sid%3Dliteratum%253Aachs%26aulast%3DNumao%26aufirst%3DS.%26aulast%3DHasler%26aufirst%3DF.%26aulast%3DLaguerre%26aufirst%3DC.%26aulast%3DSrinivas%26aufirst%3DH.%26aulast%3DWack%26aufirst%3DN.%26aulast%3DJager%26aufirst%3DP.%26aulast%3DSchmid%26aufirst%3DA.%26aulast%3DOsmont%26aufirst%3DA.%26aulast%3DRothlisberger%26aufirst%3DP.%26aulast%3DHouguenade%26aufirst%3DJ.%26aulast%3DBergsdorf%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DCarte%26aufirst%3DN.%26aulast%3DHofmann%26aufirst%3DA.%26aulast%3DMarkert%26aufirst%3DC.%26aulast%3DHardaker%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DWolf%26aufirst%3DR.%2BM.%26aulast%3DPenno%26aufirst%3DC.%2BA.%26aulast%3DBollbuck%26aufirst%3DB.%26aulast%3DMiltz%26aufirst%3DW.%26aulast%3DR%25C3%25B6hn%26aufirst%3DT.%2BA.%26atitle%3DFeasibility%2520and%2520physiological%2520relevance%2520of%2520designing%2520highly%2520potent%2520aminopeptidase-sparing%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D13591%26doi%3D10.1038%2Fs41598-017-13490-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snelgrove, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardison, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noerager, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinloch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shastry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, J. E.</span></span> <span> </span><span class="NLM_article-title">A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1126/science.1190594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1126%2Fscience.1190594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=20813919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2010&pages=90-94&author=R.+J.+Snelgroveauthor=P.+L.+Jacksonauthor=M.+T.+Hardisonauthor=B.+D.+Noeragerauthor=A.+Kinlochauthor=A.+Gaggarauthor=S.+Shastryauthor=S.+M.+Roweauthor=Y.+M.+Shimauthor=T.+Hussellauthor=J.+E.+Blalock&title=A+critical+role+for+LTA4H+in+limiting+chronic+pulmonary+neutrophilic+inflammation&doi=10.1126%2Fscience.1190594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation</span></div><div class="casAuthors">Snelgrove, Robert J.; Jackson, Patricia L.; Hardison, Matthew T.; Noerager, Brett D.; Kinloch, Andrew; Gaggar, Amit; Shastry, Suresh; Rowe, Steven M.; Shim, Yun M.; Hussell, Tracy; Blalock, J. Edwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">6000</span>),
    <span class="NLM_cas:pages">90-94</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase (LTA4H) is a proinflammatory enzyme that generates the inflammatory mediator leukotriene B4 (LTB4).  LTA4H also possesses aminopeptidase activity with unknown substrate and physiol. importance; we identified the neutrophil chemoattractant proline-glycine-proline (PGP) as this physiol. substrate.  PGP is a biomarker for chronic obstructive pulmonary disease (COPD) and is implicated in neutrophil persistence in the lung.  In acute neutrophil-driven inflammation, PGP was degraded by LTA4H, which facilitated the resoln. of inflammation.  In contrast, cigarette smoke, a major risk factor for the development of COPD, selectively inhibited LTA4H aminopeptidase activity, which led to the accumulation of PGP and neutrophils.  These studies imply that therapeutic strategies inhibiting LTA4H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopOXZMg4c8WLVg90H21EOLACvtfcHk0lgB-e6I_BaZGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WmtbnF&md5=d56b04312a721afb31fc9d505ab74fb0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscience.1190594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1190594%26sid%3Dliteratum%253Aachs%26aulast%3DSnelgrove%26aufirst%3DR.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%2BL.%26aulast%3DHardison%26aufirst%3DM.%2BT.%26aulast%3DNoerager%26aufirst%3DB.%2BD.%26aulast%3DKinloch%26aufirst%3DA.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DShastry%26aufirst%3DS.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DShim%26aufirst%3DY.%2BM.%26aulast%3DHussell%26aufirst%3DT.%26aulast%3DBlalock%26aufirst%3DJ.%2BE.%26atitle%3DA%2520critical%2520role%2520for%2520LTA4H%2520in%2520limiting%2520chronic%2520pulmonary%2520neutrophilic%2520inflammation%26jtitle%3DScience%26date%3D2010%26volume%3D330%26spage%3D90%26epage%3D94%26doi%3D10.1126%2Fscience.1190594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stsiapanava, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis of leukotriene B4</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.smim.2017.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29042025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=3-15&author=M.+Wanauthor=X.+Tangauthor=A.+Stsiapanavaauthor=J.+Z.+Haeggstrom&title=Biosynthesis+of+leukotriene+B4&doi=10.1016%2Fj.smim.2017.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis of leukotriene B4</span></div><div class="casAuthors">Wan, Min; Tang, Xiao; Stsiapanava, Alena; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukotriene B4 (LTB4) is a lipid mediator derived from arachidonic acid (AA) by the sequential action of 5-lipoxygenase (5-LOX), 5-lipoxygenase-activating protein (FLAP) and LTA4 hydrolase (LTA4H).  It was initially recognized for its involvement in the recruitment of neutrophils and is one of the most potent chemotactic agents known to date.  A large body of data has indicated that LTB4 plays a significant role in many chronic inflammatory diseases, such as arthritis, chronic obstructive pulmonary disease (COPD), cardiovascular disease, cancer and more recently, metabolic disorder.  In this review, it focus on the biosynthesis of LTB4 and its biol. effects.  In particular, it will describe a basic biochem. understanding integrated with recent developments in the field of structural biol. of the three key enzymes (5-LOX, FLAP and LTA4H) in LTB4 biosynthesis, and also summarize the most outstanding work on in vivo biol. and pathogenic roles of these enzymes and the development of enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotjqcm1CReC7Vg90H21EOLACvtfcHk0lgB-e6I_BaZGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfO&md5=77bb630dccc209c51960939751c989a6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DStsiapanava%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DBiosynthesis%2520of%2520leukotriene%2520B4%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.smim.2017.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">50639</span>– <span class="NLM_lpage">50642</span>, <span class="refDoi"> DOI: 10.1074/jbc.R400027200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1074%2Fjbc.R400027200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=15339917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BD2crptVCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=50639-50642&author=J.+Z.+Haeggstrom&title=Leukotriene+A4+hydrolase%2Faminopeptidase%2C+the+gatekeeper+of+chemotactic+leukotriene+B4+biosynthesis&doi=10.1074%2Fjbc.R400027200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis</span></div><div class="casAuthors">Haeggstrom Jesper Z</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">50639-42</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiXk-VGR69cTMsgLhIoICsfW6udTcc2eYTp-rzjTCE87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crptVCrtA%253D%253D&md5=693071a8de53cf6e14ad82b78caa417e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R400027200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R400027200%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520A4%2520hydrolase%252Faminopeptidase%252C%2520the%2520gatekeeper%2520of%2520chemotactic%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D50639%26epage%3D50642%26doi%3D10.1074%2Fjbc.R400027200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters-Golden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, W. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Leukotrienes</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>357</i></span>,  <span class="NLM_fpage">1841</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1056/NEJMra071371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1056%2FNEJMra071371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17978293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=1841-1854&author=M.+Peters-Goldenauthor=W.+R.+Henderson&title=Leukotrienes&doi=10.1056%2FNEJMra071371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotrienes</span></div><div class="casAuthors">Peters-Golden, Marc; Henderson, William R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1841-1854</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Leukotrienes comprise a family of products of the 5-lipoxygenase pathway of arachidonic acid metab.  The cysteinyl leukotrienes C4, D4, and E4 account for the biol. activity that was previously termed "slow-reacting substance of anaphylaxis", and the efficacy of antagonists to type 1 cysteinyl leukotriene receptor (CysLT1) in asthma validates the importance of cysteinyl leukotrienes and CysLT1 in this disease.  Here, the authors discuss: synthesis of leukotrienes; leukotriene receptors; blockade of leukotriene synthesis and leukotriene receptors; leukotrienes in disease; and leukotrienes in antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjehKHMPz2p7Vg90H21EOLACvtfcHk0liAFxtrjJpxoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitL%252FM&md5=4e617e65cf4b1f55f595bc03344fdb55</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMra071371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra071371%26sid%3Dliteratum%253Aachs%26aulast%3DPeters-Golden%26aufirst%3DM.%26aulast%3DHenderson%26aufirst%3DW.%2BR.%26atitle%3DLeukotrienes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D357%26spage%3D1841%26epage%3D1854%26doi%3D10.1056%2FNEJMra071371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Gennaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">The leukotrienes: immune-modulating lipid mediators of disease</span>. <i>Adv. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-394300-2.00002-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FB978-0-12-394300-2.00002-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23063073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtV2hsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2012&pages=51-92&author=A.+Di%0AGennaroauthor=J.+Z.+Haeggstrom&title=The+leukotrienes%3A+immune-modulating+lipid+mediators+of+disease&doi=10.1016%2FB978-0-12-394300-2.00002-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The leukotrienes: immune-modulating lipid mediators of disease</span></div><div class="casAuthors">Di Gennaro, Antonio; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-92</span>CODEN:
                <span class="NLM_cas:coden">ADIMAV</span>;
        ISSN:<span class="NLM_cas:issn">0065-2776</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The leukotrienes are important lipid mediators with immune modulatory and proinflammatory properties.  Classical bioactions of leukotrienes include chemotaxis, endothelial adherence, and activation of leukocytes, chemokine prodn., as well as contraction of smooth muscles in the microcirculation and respiratory tract.  When formed in excess, these compds. play a pathogenic role in several acute and chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease.  An increasing no. of diseases have been linked to inflammation implicating the leukotrienes as potential mediators.  For example, recent investigations using genetic, morphol., and biochem. approaches have pointed to the involvement of leukotrienes in cardiovascular diseases including atherosclerosis, myocardial infarction, stroke, and abdominal aortic aneurysm.  Moreover, new insights have changed our previous notion of leukotrienes as mediators of inflammatory reactions to mols. that can fine-tune the innate and adaptive immune response.  Here, we review the most recent understanding of the leukotriene cascade with emphasis on recently identified roles in immune reactions and pathophysiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnJiBdkcXX6LVg90H21EOLACvtfcHk0liAFxtrjJpxoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtV2hsLs%253D&md5=729c0bf2cdb69123f4c0e2cd7abae06f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-394300-2.00002-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-394300-2.00002-8%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGennaro%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DThe%2520leukotrienes%253A%2520immune-modulating%2520lipid%2520mediators%2520of%2520disease%26jtitle%3DAdv.%2520Immunol.%26date%3D2012%26volume%3D116%26spage%3D51%26epage%3D92%26doi%3D10.1016%2FB978-0-12-394300-2.00002-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Gennaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Targeting leukotriene B4 in inflammation</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1517/14728222.2013.843671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1517%2F14728222.2013.843671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=24090264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWqtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=79-93&author=A.+Di%0AGennaroauthor=J.+Z.+Haeggstrom&title=Targeting+leukotriene+B4+in+inflammation&doi=10.1517%2F14728222.2013.843671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting leukotriene B4 in inflammation</span></div><div class="casAuthors">Di Gennaro, Antonio; Haeggstroem, Jesper Z.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-93</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Leukotriene (LT) B4 is a powerful proinflammatory lipid mediator and triggers adherence to the endothelium, activates and recruits leukocytes to the site of injury.  When formed in excess, LTB4 plays a pathogenic role and may sustain chronic inflammation in diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease.  Recent investigations have also indicated that LTB4 is involved in cardiovascular diseases.  Areas covered: As the 5-lipoxygenase pathway involves several discrete, tightly coupled, enzymes, which convert the substrate, 'step by step', into bioactive products, several different strategies have been used to target LTB4 as a means to treat inflammation.  Here, we discuss recent findings regarding the development of selective enzyme inhibitors and antagonists for LTB4 receptors, as well as their application in preclin. and clin. studies.  Expert opinion: Components of the 5-lipoxygenase pathway have received considerable attention as candidate drug targets resulting in one new class of medications against asthma, i.e., the antileukotrienes.  However, efforts to specifically target LTB4 have not yet been fruitful in the clin. setting, in spite of very promising preclin. data.  Recently, crystal structures along with hitherto unknown functions of key enzymes in the leukotriene cascade have emerged, offering new opportunities for drug development and, with time, pharmacol. intervention in LTB4-mediated pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC8FhaNUW8M7Vg90H21EOLACvtfcHk0ljkYtOuvcbz1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWqtrbI&md5=7ac4ca614b0a2fbe8126492736883783</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F14728222.2013.843671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2013.843671%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BGennaro%26aufirst%3DA.%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DTargeting%2520leukotriene%2520B4%2520in%2520inflammation%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2014%26volume%3D18%26spage%3D79%26epage%3D93%26doi%3D10.1517%2F14728222.2013.843671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase</span>. <i>Curr. Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1173</span>– <span class="NLM_lpage">1182</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=19876785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnt1Khtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1173-1182&author=A.+M.+Fourie&title=Modulation+of+inflammatory+disease+by+inhibitors+of+leukotriene+A4+hydrolase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase</span></div><div class="casAuthors">Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Investigational Drugs (BioMed Central)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">COIDAZ</span>;
        ISSN:<span class="NLM_cas:issn">2040-3429</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Leukotriene A4 hydrolase (LTA4H) is a ubiquitously expressed enzyme that catalyzes the final step in the synthesis of leukotriene B4 (LTB4), a potent proinflammatory lipid mediator derived from arachidonic acid.  Although LTB4 was identified 30 years ago, several recent findings have refocused attention on this mediator as a target for inflammatory and autoimmune diseases.  While LTB4 was once thought to be a chemoattractant and activator only of leukocytes mediating acute, innate inflammatory responses, LTB4 receptors have since been discovered on multiple cell types, including T-lymphocytes and antigen-presenting dendritic cells.  Thus, the inhibition of LTB4 synthesis demonstrates potential for targeting chronic, autoimmune-driven inflammation.  In addn. to genetic data in animals and humans linking the LTB4 pathway to cardiovascular disease, variants in the LTA4H gene have been linked with susceptibility to asthma.  Several companies have initiated drug discovery efforts to identify potent, selective LTA4H inhibitors.  Selected mols. have demonstrated oral efficacy in preclin. models of asthma, inflammatory bowel disease and arthritis, suggesting therapeutic potential for multiple indications.  This review focuses on developments with therapeutic relevance for inhibitors of LTA4H as anti-inflammatory drugs, and particularly in the treatment of respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprm0-IV6joSrVg90H21EOLACvtfcHk0ljkYtOuvcbz1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnt1Khtbs%253D&md5=0983f70fcf38f28f689f66cb1af7f7c1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DModulation%2520of%2520inflammatory%2520disease%2520by%2520inhibitors%2520of%2520leukotriene%2520A4%2520hydrolase%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2009%26volume%3D10%26spage%3D1173%26epage%3D1182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haeggstrom, J. Z.</span></span> <span> </span><span class="NLM_article-title">Leukotriene biosynthetic enzymes as therapeutic targets</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">2680</span>– <span class="NLM_lpage">2690</span>, <span class="refDoi"> DOI: 10.1172/JCI97945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1172%2FJCI97945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30108195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BB3c7otFCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=2680-2690&author=J.+Z.+Haeggstrom&title=Leukotriene+biosynthetic+enzymes+as+therapeutic+targets&doi=10.1172%2FJCI97945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene biosynthetic enzymes as therapeutic targets</span></div><div class="casAuthors">Haeggstrom Jesper Z</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2680-2690</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukotrienes are powerful immune-regulating lipid mediators with established pathogenic roles in inflammatory allergic diseases of the respiratory tract - in particular, asthma and hay fever.  More recent work indicates that these lipids also contribute to low-grade inflammation, a hallmark of cardiovascular, neurodegenerative, and metabolic diseases as well as cancer.  Biosynthesis of leukotrienes involves oxidative metabolism of arachidonic acid and proceeds via a set of soluble and membrane enzymes that are primarily expressed by cells of myeloid origin.  In activated immune cells, these enzymes assemble at the endoplasmic and perinuclear membrane, constituting a biosynthetic complex.  This Review describes recent advances in our understanding of the components of the leukotriene-synthesizing enzyme machinery, emerging opportunities for pharmacological intervention, and the development of new medicines exploiting both antiinflammatory and pro-resolving mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRpINUyhQuIGxpATR2EQURfW6udTcc2eYxsxeu7syIbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7otFCltQ%253D%253D&md5=e4fe4a2a01c986c3cc3f87537042ef95</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI97945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI97945%26sid%3Dliteratum%253Aachs%26aulast%3DHaeggstrom%26aufirst%3DJ.%2BZ.%26atitle%3DLeukotriene%2520biosynthetic%2520enzymes%2520as%2520therapeutic%2520targets%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2018%26volume%3D128%26spage%3D2680%26epage%3D2690%26doi%3D10.1172%2FJCI97945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T. E.</span></span> <span> </span><span class="NLM_article-title">Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1038/nri2294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fnri2294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=18437155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=349-361&author=C.+N.+Serhanauthor=N.+Chiangauthor=T.+E.+Van+Dyke&title=Resolving+inflammation%3A+dual+anti-inflammatory+and+pro-resolution+lipid+mediators&doi=10.1038%2Fnri2294"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators</span></div><div class="casAuthors">Serhan, Charles N.; Chiang, Nan; Van Dyke, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-361</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Active resoln. of acute inflammation is a previously unrecognized interface between innate and adaptive immunity.  Once thought to be a passive process, the resoln. of inflammation is now shown to involve active biochem. programs that enable inflamed tissues to return to homeostasis.  This Review presents new cellular and mol. mechanisms for the resoln. of inflammation, revealing key roles for eicosanoids, such as lipoxins, and recently discovered families of endogenous chem. mediators, termed resolvins and protectins.  These mediators have anti-inflammatory and pro-resoln. properties, thereby protecting organs from collateral damage, stimulating the clearance of inflammatory debris and promoting mucosal antimicrobial defense.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAVfszaqPwhrVg90H21EOLACvtfcHk0ljkYtOuvcbz1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbw%253D&md5=058b12867becddc68602238a6128c6df</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnri2294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2294%26sid%3Dliteratum%253Aachs%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DChiang%26aufirst%3DN.%26aulast%3DVan%2BDyke%26aufirst%3DT.%2BE.%26atitle%3DResolving%2520inflammation%253A%2520dual%2520anti-inflammatory%2520and%2520pro-resolution%2520lipid%2520mediators%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D349%26epage%3D361%26doi%3D10.1038%2Fnri2294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoubian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory and pro-resolving lipid mediators</span>. <i>Annu. Rev. Pathol.: Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1146/annurev.pathmechdis.3.121806.151409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1146%2Fannurev.pathmechdis.3.121806.151409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=18233953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsFersLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=279-312&author=C.+N.+Serhanauthor=S.+Yacoubianauthor=R.+Yang&title=Anti-inflammatory+and+pro-resolving+lipid+mediators&doi=10.1146%2Fannurev.pathmechdis.3.121806.151409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory and proresolving lipid mediators</span></div><div class="casAuthors">Serhan, Charles N.; Yacoubian, Stephanie; Yang, Rong</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pathology: Mechanisms of Disease</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">279-312</span>CODEN:
                <span class="NLM_cas:coden">ARPMCU</span>;
        ISSN:<span class="NLM_cas:issn">1553-4006</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The popular view that all lipid mediators are pro-inflammatory arises largely from the finding that nonsteroidal anti-inflammatory drugs block the biosynthesis of prostaglandins.  The resoln. of inflammation was widely held as a passive event until recently, with the characterization of novel biochem. pathways and lipid-derived mediators that are actively turned on in resoln. and that possess potent anti-inflammatory and proresolving actions.  A lipid-mediator informatics approach was employed to systematically identify new families of endogenous local-acting mediators from omega-3 polyunsatd. fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in resolving exudates, which also contain lipoxins and aspirin-triggered lipoxins generated from arachidonic acid.  Given their potent bioactions, these new chem. mediator families were termed resolvins and protectins.  Here, we review the recent advances in our understanding of the biosynthesis and stereospecific actions of these new proresolving mediators, which have also proven to be organ protective and antifibrotic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqro738WYmTdrVg90H21EOLACvtfcHk0lg9r10ZEClBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsFersLw%253D&md5=8dcc9d14debaffce326d06f4a68de873</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pathmechdis.3.121806.151409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pathmechdis.3.121806.151409%26sid%3Dliteratum%253Aachs%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DYacoubian%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DR.%26atitle%3DAnti-inflammatory%2520and%2520pro-resolving%2520lipid%2520mediators%26jtitle%3DAnnu.%2520Rev.%2520Pathol.%253A%2520Mech.%2520Dis.%26date%3D2008%26volume%3D3%26spage%3D279%26epage%3D312%26doi%3D10.1146%2Fannurev.pathmechdis.3.121806.151409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunford, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundeen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coles, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>321</i></span>,  <span class="NLM_fpage">1154</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.115436</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1124%2Fjpet.106.115436" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17371808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=321&publication_year=2007&pages=1154-1160&author=N.+L.+Raoauthor=P.+J.+Dunfordauthor=X.+Xueauthor=X.+Jiangauthor=K.+A.+Lundeenauthor=F.+Colesauthor=J.+P.+Rileyauthor=K.+N.+Williamsauthor=C.+A.+Griceauthor=J.+P.+Edwardsauthor=L.+Karlssonauthor=A.+M.+Fourie&title=Anti-inflammatory+activity+of+a+potent%2C+selective+leukotriene+A4+hydrolase+inhibitor+in+comparison+with+the+5-lipoxygenase+inhibitor+zileuton&doi=10.1124%2Fjpet.106.115436"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton</span></div><div class="casAuthors">Rao, Navin L.; Dunford, Paul J.; Xue, Xiaohua; Jiang, Xiaohui; Lundeen, Katherine A.; Coles, Fawn; Riley, Jason P.; Williams, Kacy N.; Grice, Cheryl A.; Edwards, James P.; Karlsson, Lars; Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">321</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1154-1160</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Leukotriene A4 hydrolase (LTA4H) catalyzes prodn. of the proinflammatory lipid mediator, leukotriene (LT) B4, which is implicated in a no. of inflammatory diseases.  We have identified a potent and selective inhibitor of both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H (IC50, approx. 10 nM).  In a murine model of arachidonic acid-induced ear inflammation, the LTA4H inhibitor, JNJ-26993135 (1-[4-(benzothiazol-2-yloxy)-benzyl]-piperidine-4-carboxylic acid), dose-dependently inhibited ex vivo LTB4 prodn. in blood, in parallel with dose-dependent inhibition of neutrophil influx (ED50, 1-3 mg/kg) and ear edema.  In murine whole blood and in zymosan-induced peritonitis, JNJ-26993135 selectively inhibited LTB4 prodn., without affecting cysteinyl leukotriene prodn., while maintaining or increasing prodn. of the anti-inflammatory mediator, lipoxin (LX) A4.  The 5-lipoxygenase (5-LO) inhibitor zileuton showed inhibition of LTB4, LTC4, and LXA4 prodn.  Although zileuton inhibited LTB4 prodn. in the peritonitis model more effectively than the LTA4H inhibitor, the influx of neutrophils into the peritoneum after 1 and 2 h was significantly higher in zileuton- vs. JNJ-26993135-treated animals.  This difference may have been mediated by the increased LXA4 levels in the presence of the LTA4H inhibitor.  The selective inhibition of LTB4 prodn. by JNJ-26993135, while increasing levels of the anti-inflammatory mediator, LXA4, may translate to superior therapeutic efficacy vs. 5-LO or 5-LO-activating protein inhibitors in LTB4-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM4FqRH-INZ7Vg90H21EOLACvtfcHk0lg9r10ZEClBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFeqsLo%253D&md5=a74aea05870846dd51c7660c08762521</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.115436&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.115436%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DN.%2BL.%26aulast%3DDunford%26aufirst%3DP.%2BJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DLundeen%26aufirst%3DK.%2BA.%26aulast%3DColes%26aufirst%3DF.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DK.%2BN.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DKarlsson%26aufirst%3DL.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DAnti-inflammatory%2520activity%2520of%2520a%2520potent%252C%2520selective%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%2520in%2520comparison%2520with%2520the%25205-lipoxygenase%2520inhibitor%2520zileuton%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D321%26spage%3D1154%26epage%3D1160%26doi%3D10.1124%2Fjpet.106.115436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caliskan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banoglu, E.</span></span> <span> </span><span class="NLM_article-title">Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1517/17460441.2013.735228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1517%2F17460441.2013.735228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23095029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFShsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=49-63&author=B.+Caliskanauthor=E.+Banoglu&title=Overview+of+recent+drug+discovery+approaches+for+new+generation+leukotriene+A4+hydrolase+inhibitors&doi=10.1517%2F17460441.2013.735228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors</span></div><div class="casAuthors">Caliskan, Burcu; Banoglu, Erden</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: LTA4H is a bifunctional enzyme with hydrolase and aminopeptidase activities.  The hydrolase function of this enzyme specifically catalyzes the rate-limiting step in the conversion of LTA4 to LTB4, one of the most potent chemoattractant and activator of neutrophils.  The wealth of in vitro and in vivo data favors in support of LTA4H as an appealing target for the discovery and development of anti-inflammatory drugs.Areas covered: The authors provide an overview of the recent advances on LTA4H inhibitors since 2000.  The review details the medicinal chem. efforts leading to the generation of novel inhibitor chemotypes with desirable drug-like properties as well as the advantages and disadvantages of LTA4H as a desirable therapeutic target.  Expert opinion: Most of the LTA4H inhibitors block pro-inflammatory LTB4 biosynthesis by concomitant inhibition of both the hydrolase and aminopeptidase activities of LTA4H.  However, the degrdn. of another endogenous chemoattractant substrate (PGP) by aminopeptidase function of LTA4H was shown, introducing a new anti-inflammatory mission for this pro-inflammatory enzyme.  LTA4H inhibitors were also shown to maintain anti-inflammatory lipoxin formation.  Hence, the data on new LTA4H inhibitors should be cautiously interpreted with regard to potential repercussions of preventing PGP degrdn. as well as for the clin. benefits of concomitant lipoxin formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk4naHC_qarbVg90H21EOLACvtfcHk0lg9r10ZEClBig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFShsr7F&md5=93e3c122ba2fe19eea79df358022705a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.735228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.735228%26sid%3Dliteratum%253Aachs%26aulast%3DCaliskan%26aufirst%3DB.%26aulast%3DBanoglu%26aufirst%3DE.%26atitle%3DOverview%2520of%2520recent%2520drug%2520discovery%2520approaches%2520for%2520new%2520generation%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D49%26epage%3D63%26doi%3D10.1517%2F17460441.2013.735228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roinestad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Recent advances in clinical development of leukotriene B4 pathway drugs</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.smim.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=29042030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=65-73&author=L.+Bhattauthor=K.+Roinestadauthor=T.+Vanauthor=E.+B.+Springman&title=Recent+advances+in+clinical+development+of+leukotriene+B4+pathway+drugs&doi=10.1016%2Fj.smim.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in clinical development of leukotriene B4 pathway drugs</span></div><div class="casAuthors">Bhatt, L.; Roinestad, K.; Van, T.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The LTB4 pathway is an attractive target for therapeutic drug development.  Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the rate limiting enzyme in the prodn. of LTB4.  An initial wave of effort culminated in the 1990s.  Over the past 15 years, a second wave of more selective drug candidates, including at least 5 BLT antagonists and 6 LTA4H inhibitors, have reached Phase 2 clin. trials.  Despite the extensive efforts to discover and develop LTB4 pathway targeting drugs, only one has reached the market to date.  Recently discovered complexities in the pathway and challenges in matching pathway intervention with therapeutic effect could explain the limited clin. success of LTB4 pathway drugs, even though there is a large body of scientific evidence linking LTB4 to human diseases and demonstrating efficacy of these compds. in a wide array of preclin. models.  Herein, we describe the clin. programs for the most prominent recent examples from each broad class and discuss the clin. outcomes and their implications for future development of LTB4 pathway drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomAJhLJFJTE7Vg90H21EOLACvtfcHk0lh2QmdP7nOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN&md5=a45e8c63d30430dbd71821c36b90c4ae</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DRoinestad%26aufirst%3DK.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DRecent%2520advances%2520in%2520clinical%2520development%2520of%2520leukotriene%2520B4%2520pathway%2520drugs%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.smim.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>For details,
see <a href="https://trials.boehringer-ingelheim.com/public/trial_results_documents/1334/_english_13341c2248492COpdf.pdf" class="extLink">https://trials.boehringer-ingelheim.com/public/trial_results_documents/1334/_english_13341c2248492COpdf.pdf</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Ftrials.boehringer-ingelheim.com%2Fpublic%2Ftrial_results_documents%2F1334%2F_english_13341c2248492COpdf.pdf+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandanayaka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyvan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enache, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onua, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halldorsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorlaksdottir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigthorsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinnsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zembower, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andresson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-[(2<i>S</i>)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1021/jm900838g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900838g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2hurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=573-585&author=V.+Sandanayakaauthor=B.+Mamatauthor=R.+K.+Mishraauthor=J.+Wingerauthor=M.+Krohnauthor=L.+M.+Zhouauthor=M.+Keyvanauthor=L.+Enacheauthor=D.+Sullinsauthor=E.+Onuaauthor=J.+Zhangauthor=G.+Halldorsdottirauthor=H.+Sigthorsdottirauthor=A.+Thorlaksdottirauthor=G.+Sigthorssonauthor=M.+Thorsteinnsdottirauthor=D.+R.+Daviesauthor=L.+J.+Stewartauthor=D.+E.+Zembowerauthor=T.+Andressonauthor=A.+S.+Kiselyovauthor=J.+Singhauthor=M.+E.+Gurney&title=Discovery+of+4-%5B%282S%29-2-%7B%5B4-%284-chlorophenoxy%29phenoxy%5Dmethyl%7D-1-pyrrolidinyl%5Dbutanoic+acid+%28DG-051%29+as+a+novel+leukotriene+A4+hydrolase+inhibitor+of+leukotriene+B4+biosynthesis&doi=10.1021%2Fjm900838g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-[(2S)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis</span></div><div class="casAuthors">Sandanayaka, Vincent; Mamat, Bjorn; Mishra, Rama K.; Winger, Jennifer; Krohn, Michael; Zhou, Li-Ming; Keyvan, Monica; Enache, Livia; Sullins, David; Onua, Emmanuel; Zhang, Jun; Halldorsdottir, Gudrun; Sigthorsdottir, Heida; Thorlaksdottir, Audur; Sigthorsson, Gudmundur; Thorsteinnsdottir, Margret; Davies, Douglas R.; Stewart, Lance J.; Zembower, David E.; Andresson, Thorkell; Kiselyov, Alex S.; Singh, Jasbir; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">573-585</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Both inhouse human genetic and literature data have converged on the identification of leukotriene 4 hydrolase (LTA4H) as a key target for the treatment of cardiovascular disease.  We combined fragment-based crystallog. screening with an iterative medicinal chem. effort to optimize inhibitors of LTA4H.  Ligand efficiency was followed throughout our structure-activity studies.  As applied within the context of LTA4H inhibitor design, the chem. team was able to design a potent compd. 20 (DG-051, I) (Kd = 26 nM) with high aq. soly. (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clin. evaluation for the treatment of myocardial infarction and stroke.  The structural biol.-chem. interaction described in this paper provides a sound alternative to conventional screening techniques.  This is the first example of a gene-to-clinic paradigm enabled by a fragment-based drug discovery effort.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoySRkJb-vbd7Vg90H21EOLACvtfcHk0lh2QmdP7nOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2hurvE&md5=29fc128c8ee8e7f24849da18f923cffe</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm900838g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900838g%26sid%3Dliteratum%253Aachs%26aulast%3DSandanayaka%26aufirst%3DV.%26aulast%3DMamat%26aufirst%3DB.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DWinger%26aufirst%3DJ.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DL.%2BM.%26aulast%3DKeyvan%26aufirst%3DM.%26aulast%3DEnache%26aufirst%3DL.%26aulast%3DSullins%26aufirst%3DD.%26aulast%3DOnua%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHalldorsdottir%26aufirst%3DG.%26aulast%3DSigthorsdottir%26aufirst%3DH.%26aulast%3DThorlaksdottir%26aufirst%3DA.%26aulast%3DSigthorsson%26aufirst%3DG.%26aulast%3DThorsteinnsdottir%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DZembower%26aufirst%3DD.%2BE.%26aulast%3DAndresson%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDiscovery%2520of%25204-%255B%25282S%2529-2-%257B%255B4-%25284-chlorophenoxy%2529phenoxy%255Dmethyl%257D-1-pyrrolidinyl%255Dbutanoic%2520acid%2520%2528DG-051%2529%2520as%2520a%2520novel%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%2520of%2520leukotriene%2520B4%2520biosynthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D573%26epage%3D585%26doi%3D10.1021%2Fjm900838g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barchuk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertelsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkoff, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnathan, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurmond, R.</span></span> <span> </span><span class="NLM_article-title">Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2014.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.pupt.2014.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=25018015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFymsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2014&pages=15-23&author=W.+Barchukauthor=J.+Lambertauthor=R.+Fuhrauthor=J.+Z.+Jiangauthor=K.+Bertelsenauthor=A.+Fourieauthor=X.+Liuauthor=P.+E.+Silkoffauthor=E.+S.+Barnathanauthor=R.+Thurmond&title=Effects+of+JNJ-40929837%2C+a+leukotriene+A4+hydrolase+inhibitor%2C+in+a+bronchial+allergen+challenge+model+of+asthma&doi=10.1016%2Fj.pupt.2014.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma</span></div><div class="casAuthors">Barchuk, W.; Lambert, J.; Fuhr, R.; Jiang, J. Z.; Bertelsen, K.; Fourie, A.; Liu, X.; Silkoff, P. E.; Barnathan, E. S.; Thurmond, R.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-23</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Leukotriene B4 (LTB4) is a chemotactic mediator implicated in the pathogenesis of asthma.  JNJ-40929837 is an oral inhibitor of LTA4 hydrolase, which catalyzes LTB4 prodn.  We evaluated the effects of JNJ-40929837 in a human bronchial allergen challenge (BAC) model.  In this double-blind, 3-period crossover study, 22 patients with mild, atopic asthma were randomized to one of three treatments per period: 100 mg/day JNJ-40929837 for 6 days followed by 50 mg/day on day 7; 10 mg/day montelukast for 6 days; and matched placebo.  The BAC was performed on day 6 of each treatment period.  Primary outcome was BAC-induced late asthmatic response (LAR) measured by maximal percent redn. in forced expiratory vol. (FEV1) in one second.  Secondary outcomes included early asthmatic response (EAR) by maximal percent redn. in FEV1, EAR and LAR evaluated by area under the FEV1/time curve (AUC0-2, AUC3-10, resp.), change in baseline FEV1 after 5-day treatment, safety, and correlation of JNJ-40929837 to the divalent cation ionophore A23187-stimulated whole blood LTB4 levels and sputum basal LTB4 levels.  No significant differences were obsd. in the primary or secondary FEV1 endpoints with JNJ-40929837 vs. placebo.  Compared with placebo (n = 17, LS mean = 27.7), there was no significant attenuation of the maximal percent redn. in the LAR FEV1 with JNJ-40929837 (n = 16, LS mean = 28.6, P = 0.63) but montelukast (n = 17, LS mean = 22.6, P = 0.01) significantly attenuated the LAR.  JNJ-40929837 substantially inhibited LTB4 prodn. in whole blood, decreased sputum LTB4 levels and was well-tolerated.  The no. of adverse events leading to study withdrawal was the same in JNJ-40929837 and placebo groups.  In conclusion, JNJ-40929837 demonstrated target engagement in blood and sputum.  No significant impact in response to allergen inhalation was obsd. with JNJ-40929837 vs. placebo.This study is registered at ClinicalTrials.gov: NCT01241422.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9Pv2-mB8Ag7Vg90H21EOLACvtfcHk0lh2QmdP7nOCpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFymsLjK&md5=894edcc79d795811670b454e8acda213</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2014.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2014.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DBarchuk%26aufirst%3DW.%26aulast%3DLambert%26aufirst%3DJ.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DJ.%2BZ.%26aulast%3DBertelsen%26aufirst%3DK.%26aulast%3DFourie%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSilkoff%26aufirst%3DP.%2BE.%26aulast%3DBarnathan%26aufirst%3DE.%2BS.%26aulast%3DThurmond%26aufirst%3DR.%26atitle%3DEffects%2520of%2520JNJ-40929837%252C%2520a%2520leukotriene%2520A4%2520hydrolase%2520inhibitor%252C%2520in%2520a%2520bronchial%2520allergen%2520challenge%2520model%2520of%2520asthma%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D29%26spage%3D15%26epage%3D23%26doi%3D10.1016%2Fj.pupt.2014.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D.</span></span> <span> </span><span class="NLM_article-title">Testicular distribution and toxicity of a novel LTA4H inhibitor in rats</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2014.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.taap.2014.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=24769091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosl2hsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2014&pages=26-30&author=P.+D.+Wardauthor=D.+La&title=Testicular+distribution+and+toxicity+of+a+novel+LTA4H+inhibitor+in+rats&doi=10.1016%2Fj.taap.2014.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Testicular distribution and toxicity of a novel LTA4H inhibitor in rats</span></div><div class="casAuthors">Ward, P. D.; La, D.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-30</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">JNJ 40929837, a novel leukotriene A4 hydrolase inhibitor in drug development, was reported to induce testicular toxicity in rats.  The mechanism of toxicity was considered to be rodent specific and not relevant to humans.  To further investigate this finding in rats, the distribution and toxicokinetics of JNJ 40929837 and its two metabolites, M1 and M2, were investigated.  A quant. whole body autoradiog. study showed preferential distribution and retention of JNJ 40929837-derived radioactivity in the testes consistent with the obsd. site of toxicity.  Subsequent studies with unlabeled JNJ 40929837 showed different metabolite profiles between the plasma and testes.  Following a single oral 50 mg/kg dose of JNJ 40929837, M2 was the primary metabolite in plasma whereas M1 was the primary metabolite in testes.  The exposure of M1 was 386-fold higher in the testes compared to plasma whereas M2 had limited exposure in testes.  Furthermore, the Tmax of M1 was 48 h in testes suggesting a large accumulation potential of this metabolite in testes compared to plasma.  Following six months of repeated daily oral dosing, M1 accumulated approx. five-fold in the testes whereas the parent did not accumulate.  These results indicate that the toxicokinetic profiles of JNJ 40929837 and its two metabolites in testes are markedly different compared to plasma and support the importance of understanding the toxicokinetic profiles of compds. and their metabolites in organs/tissues where toxicity is obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9lpMCIw4BcrVg90H21EOLACvtfcHk0lj36PH8o9Y9hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosl2hsbs%253D&md5=1b9aefd05547e7a0e9d9a270c04bee4c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2014.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2014.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DP.%2BD.%26aulast%3DLa%26aufirst%3DD.%26atitle%3DTesticular%2520distribution%2520and%2520toxicity%2520of%2520a%2520novel%2520LTA4H%2520inhibitor%2520in%2520rats%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2014%26volume%3D278%26spage%3D26%26epage%3D30%26doi%3D10.1016%2Fj.taap.2014.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mershon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span> <span> </span><span class="NLM_article-title">EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - study design and patient demographics</span>. <i>Contemp. Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">86</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/j.cct.2018.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.cct.2018.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30056216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ivFOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=86-94&author=J.+S.+Elbornauthor=S.+Ahujaauthor=E.+Springmanauthor=J.+Mershonauthor=R.+Grosswaldauthor=S.+M.+Rowe&title=EMPIRE-CF%3A+a+phase+II+randomized+placebo-controlled+trial+of+once-daily%2C+oral+acebilustat+in+adult+patients+with+cystic+fibrosis+-+study+design+and+patient+demographics&doi=10.1016%2Fj.cct.2018.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics</span></div><div class="casAuthors">Elborn J Stuart; Ahuja Sanjeev; Springman Eric; Mershon John; Grosswald Ralph; Rowe Steven M</div><div class="citationInfo"><span class="NLM_cas:title">Contemporary clinical trials</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">86-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Inflammation causes irreparable damage in the cystic fibrosis (CF) lung.  Despite high standards of care and the advent of new therapies, inflammation continues to cause significant loss of lung function and morbidity.  Acebilustat is a once-daily, oral molecule with anti-inflammatory activity through the inhibition of LTA4 hydrolase and modulation of LTB4.  It has potential to reduce lung function decline and pulmonary exacerbations in patients with CF and is currently being tested in a Phase II multicenter, randomized, double-blind, placebo-controlled, parallel-group study (EMPIRE-CF).  Strict inclusion criteria based on modeling of the Cystic Fibrosis Foundation Patient Registry data were selected to enrich the trial with patients most likely to benefit from chronic anti-inflammatory therapy that reduces lung function decline. 200 patients between 18 and 30 years of age, with an FEV1 percent predicted (pp) ≥50%, and ≥1 exacerbation in the past year have been enrolled.  Patients are randomized 1:1:1 to placebo, acebilustat 50 mg or 100 mg for 48 weeks, taken concomitantly with their current standard of care, and stratified based on concomitant CFTR modulator use, baseline FEV1pp (50% to 75% and >75%), and number of exacerbations in the past year (1 or >1).  The primary endpoints are absolute change from baseline in FEV1pp and safety outcomes.  Secondary endpoints include rate of pulmonary exacerbations and time to first pulmonary exacerbation.  Biomarkers of inflammation will also be assessed.  EMPIRE-CF is expected to identify the optimal patient population, dose, duration and endpoints for future acebilustat trials, and widen understanding of the drug's efficacy in patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsW06namU1-SjiVMCqkKxVfW6udTcc2eZx3QaxXG9rsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ivFOgtg%253D%253D&md5=9d3cd61558f5fd31f0d8f7fe72dcbb59</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.cct.2018.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cct.2018.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%26aulast%3DMershon%26aufirst%3DJ.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26atitle%3DEMPIRE-CF%253A%2520a%2520phase%2520II%2520randomized%2520placebo-controlled%2520trial%2520of%2520once-daily%252C%2520oral%2520acebilustat%2520in%2520adult%2520patients%2520with%2520cystic%2520fibrosis%2520-%2520study%2520design%2520and%2520patient%2520demographics%26jtitle%3DContemp.%2520Clin.%2520Trials%26date%3D2018%26volume%3D72%26spage%3D86%26epage%3D94%26doi%3D10.1016%2Fj.cct.2018.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Phase I studies of acebilustat: pharmacokinetics, pharmacodynamics, food effect, and CYP3A induction</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1111/cts.12426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fcts.12426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=27792868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=20-27&author=J.+S.+Elbornauthor=L.+Bhattauthor=R.+Grosswaldauthor=S.+Ahujaauthor=E.+B.+Springman&title=Phase+I+studies+of+acebilustat%3A+pharmacokinetics%2C+pharmacodynamics%2C+food+effect%2C+and+CYP3A+induction&doi=10.1111%2Fcts.12426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction</span></div><div class="casAuthors">Elborn, J. S.; Bhatt, L.; Grosswald, R.; Ahuja, S.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-27</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Acebilustat is a new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases.  It is an inhibitor of leukotriene A4 hydrolase; therefore, prodn. of leukotriene B4 (LTB4) in biol. fluids provides a direct measure of the pharmacodynamic (PD) response to acebilustat treatment.  Here we compare the pharmacokinetics (PK) and PD between CF patients and healthy volunteers, and investigate the food effect and CYP3A4 induction in healthy volunteers.  No significant differences between study populations were obsd. for peak plasma level (Cmax) or exposure (AUC).  In healthy volunteers, a shift in time to Cmax (Tmax) was obsd. after a high-fat meal, but there was no change in AUC.  LTB4 prodn. was reduced in the blood of both populations and in sputum from CF patients.  Acebilustat did not induce CYP3A4.  These results support continued clin. study of once-daily oral acebilustat in CF at doses of 50 and 100 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWWsgOa7asJLVg90H21EOLACvtfcHk0lj36PH8o9Y9hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12ksw%253D%253D&md5=53db82198031280fc06ead4a6fa8f55c</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fcts.12426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12426%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520I%2520studies%2520of%2520acebilustat%253A%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520food%2520effect%252C%2520and%2520CYP3A%2520induction%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D20%26epage%3D27%26doi%3D10.1111%2Fcts.12426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elborn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horsley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacGregor, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosswald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1111/cts.12428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1111%2Fcts.12428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=27806191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12ltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&pages=28-34&author=J.+S.+Elbornauthor=A.+Horsleyauthor=G.+MacGregorauthor=D.+Biltonauthor=R.+Grosswaldauthor=S.+Ahujaauthor=E.+B.+Springman&title=Phase+I+studies+of+acebilustat%3A+biomarker+response+and+safety+in+patients+with+cystic+fibrosis&doi=10.1111%2Fcts.12428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis</span></div><div class="casAuthors">Elborn, J. S.; Horsley, A.; MacGregor, G.; Bilton, D.; Grosswald, R.; Ahuja, S.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">There is a significant unmet need for safe and effective anti-inflammatory treatment for cystic fibrosis.  The aim of this study was to evaluate the safety of acebilustat, a leukotriene A4 hydrolase inhibitor, and its effect on inflammation biomarkers in patients with cystic fibrosis.  Seventeen patients with mild to moderate cystic fibrosis were enrolled and randomized into groups receiving placebo or doses of 50 mg or 100 mg acebilustat administered orally, once daily for 15 days.  Sputum neutrophil counts were reduced by 65% over baseline values in patients treated with 100 mg acebilustat.  A modestly significant 58% redn. vs. placebo in sputum elastase was obsd. with acebilustat treatment.  Favorable trends were obsd. for redn. of serum C-reactive protein and sputum neutrophil DNA in acebilustat-treated patients.  No changes in pulmonary function were obsd.  Acebilustat was safe and well tolerated.  The results of this study support further clin. development of acebilustat for treatment of cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSdSxMFr8ErVg90H21EOLACvtfcHk0lj752JaG5IUZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12ltA%253D%253D&md5=8eee0575c0951be7c91cf87fc0904034</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fcts.12428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12428%26sid%3Dliteratum%253Aachs%26aulast%3DElborn%26aufirst%3DJ.%2BS.%26aulast%3DHorsley%26aufirst%3DA.%26aulast%3DMacGregor%26aufirst%3DG.%26aulast%3DBilton%26aufirst%3DD.%26aulast%3DGrosswald%26aufirst%3DR.%26aulast%3DAhuja%26aufirst%3DS.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DPhase%2520I%2520studies%2520of%2520acebilustat%253A%2520biomarker%2520response%2520and%2520safety%2520in%2520patients%2520with%2520cystic%2520fibrosis%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2017%26volume%3D10%26spage%3D28%26epage%3D34%26doi%3D10.1111%2Fcts.12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span>For details,
see <a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Fwww.rcsb.org%2F+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>For details,
see <a href="https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/" class="extLink">https://www.3ds.com/products-services/biovia/products/data-science/pipeline-pilot/</a> (accessed <span class="NLM_year">2020</span>-12-2).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=For+details%2C%0Asee+https%3A%2F%2Fwww.3ds.com%2Fproducts-services%2Fbiovia%2Fproducts%2Fdata-science%2Fpipeline-pilot%2F+%28accessed+2020-12-2%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niesen, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span> <span> </span><span class="NLM_article-title">The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1038%2Fnprot.2007.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17853878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2212-2221&author=F.+H.+Niesenauthor=H.+Berglundauthor=M.+Vedadi&title=The+use+of+differential+scanning+fluorimetry+to+detect+ligand+interactions+that+promote+protein+stability&doi=10.1038%2Fnprot.2007.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability</span></div><div class="casAuthors">Niesen, Frank H.; Berglund, Helena; Vedadi, Masoud</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2212-2221</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Differential scanning fluorometry (DSF) is a rapid and inexpensive screening method to identify low-mol.-wt. ligands that bind and stabilize purified proteins.  The temp. at which a protein unfolds is measured by an increase in the fluorescence of a dye with affinity for hydrophobic parts of the protein, which are exposed as the protein unfolds.  A simple fitting procedure allows quick calcn. of the transition midpoint; the difference in the temp. of this midpoint in the presence and absence of ligand is related to the binding affinity of the small mol., which can be a low-mol.-wt. compd., a peptide or a nucleic acid.  DSF is best performed using a conventional real-time PCR instrument.  Ligand solns. from a storage plate are added to a soln. of protein and dye, distributed into the wells of the PCR plate and fluorescence intensity measured as the temp. is raised gradually.  Results can be obtained in a single day.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomViqp6Tq7krVg90H21EOLACvtfcHk0lj752JaG5IUZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb7N&md5=8a74dbb348ab81179614ab4ae5797d94</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.321%26sid%3Dliteratum%253Aachs%26aulast%3DNiesen%26aufirst%3DF.%2BH.%26aulast%3DBerglund%26aufirst%3DH.%26aulast%3DVedadi%26aufirst%3DM.%26atitle%3DThe%2520use%2520of%2520differential%2520scanning%2520fluorimetry%2520to%2520detect%2520ligand%2520interactions%2520that%2520promote%2520protein%2520stability%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2212%26epage%3D2221%26doi%3D10.1038%2Fnprot.2007.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergsdorf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. K.</span></span> <span> </span><span class="NLM_article-title">A guide to run affinity screens using differential scanning fluorimetry and surface plasmon resonance assays</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>610</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2018.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fbs.mie.2018.09.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=30390797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKrsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=610&publication_year=2018&pages=135-165&author=C.+Bergsdorfauthor=S.+K.+Wright&title=A+guide+to+run+affinity+screens+using+differential+scanning+fluorimetry+and+surface+plasmon+resonance+assays&doi=10.1016%2Fbs.mie.2018.09.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">A guide to run affinity screens using differential scanning fluorimetry and surface plasmon resonance assays</span></div><div class="casAuthors">Bergsdorf, Christian; Wright, S. Kirk</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">610</span>
        (<span class="NLM_cas:issue">Modern Approaches in Drug Discovery</span>),
    <span class="NLM_cas:pages">135-165</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The implementation of high-throughput biochem. and cellular assays has enabled the screening of large compd. libraries which has become an important and often times the main source of new chem. matter that serve as starting point for medicinal chem. efforts.  In addn., biophys. methods measuring the phys. interaction (affinity) between a low mol. wt. ligand and a target protein became an integral part of hit validation/optimization to rule out false positives due to assay artifacts.  Recent advances in throughput, robustness, and sensitivity of biophys. affinity screening methods have broadened their application in hit identification and validation such that they can now complement classical functional readouts.  As a result, new target classes can be accessed that have not been amenable to functional assays.  In this chapter, two affinity screening methods, differential scanning fluorimetry and surface plasmon resonance, which are broadly utilized in both academia and pharmaceutical industry are discussed in respect to their use in hit identification and validation.  These methods exemplify how assays which differ in complexity, throughput, and information content can support the hit identification/validation process.  This chapter focuses on the practical aspects and caveats of these techniques in order to enable the reader to establish their own affinity-based screens in both formats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyuSs53WKzPrVg90H21EOLACvtfcHk0lj752JaG5IUZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKrsrzF&md5=3595b2a989df03ad6fb9e6b5eab98f80</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2018.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2018.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DBergsdorf%26aufirst%3DC.%26aulast%3DWright%26aufirst%3DS.%2BK.%26atitle%3DA%2520guide%2520to%2520run%2520affinity%2520screens%2520using%2520differential%2520scanning%2520fluorimetry%2520and%2520surface%2520plasmon%2520resonance%2520assays%26jtitle%3DMethods%2520Enzymol.%26date%3D2018%26volume%3D610%26spage%3D135%26epage%3D165%26doi%3D10.1016%2Fbs.mie.2018.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pristupa, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niznik, H. B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=8302271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaK2cXhsFemu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1994&pages=125-135&author=Z.+B.+Pristupaauthor=J.+M.+Wilsonauthor=B.+J.+Hoffmanauthor=S.+J.+Kishauthor=H.+B.+Niznik&title=Pharmacological+heterogeneity+of+the+cloned+and+native+human+dopamine+transporter%3A+disassociation+of+%5B3H%5DWIN+35%2C428+and+%5B3H%5DGBR+12%2C935+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding</span></div><div class="casAuthors">Pristupa, Zdenek B.; Wilson, Julie M.; Hoffman, Beth J.; Kish, Stephen J.; Niznik, Hyman B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-35</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Controversy exists as to whether the functional state of the dopamine (DA) transporter is identical to sites mediating the specific binding of selective DA transporter radioligands.  Therefore, the authors compared the pharmacol. profile of numerous dopamine transport substrates and inhibitors on [3H]DA uptake with the binding of [3H]WIN 35,428 and [3H]GBR 12,935 to COS-7 cells transiently expressing the cloned human DA transporter.  [3H]DA uptake and [3H]WIN 35,428 binding was specific, saturable, and to a single class of binding sites with an estd. Km/Vmax of ∼2 μM and 6 pmol/min/105 cells for DA uptake and Kd/Bmax values of ∼10 nM and 113 fmol/105 cells for [3H]WIN 35,428.  [3H]DA uptake was inhibited in a concn.-dependent and uniphasic manner by dopaminergic agents with an appropriate rank order of potency for the DA transporter.  Although most uptake blockers inhibited [3H]WIN 35,428 binding in a uniphasic manner, WIN 35,428, Lu 19,005, D-amphetamine, and DA clearly displayed the presence of both high and low affinity components.  Comparison of the Ki values for the inhibition of [3H]DA uptake with [3H]WIN 35,428 binding reveals that, for uptake blockers and D-amphetamine, it is the high affinity component that shares pharmacol. identity with effects on DA uptake (r = 0.9985), whereas for DA it is the low affinity site.  In striking contrast, however, [3H]GBR 12,935 binding to COS-7 cells could not be made to exhibit a pharmacol. profile indicative of the DA transporter and suggests that the site regulating functional [3H]DA uptake may not be identical with sites labeled by [3H]GBR 12,935 in these cells.  Moreover, these sites appear unrelated to those previously described in native membranes as "piperazine acceptor" or P 450 proteins.  Comparison of Ki values and rank order of potency for the inhibition of [3H]WIN 35,428 or [3H]GBR 12,935 binding to human caudate membranes reveals pharmacol. homol., but not identity, with that of the cloned DA uptake process.  Taken together, these data suggest that 1) [3H]WIN 35,428 recognizes two sites of the DA transporter, of which only one appears to represent the functional state of the protein, and 2) [3H]WIN 35,428 and [3H]GBR 12,935 do not appear to bind the same functional form/state of the DA transporter.  Whether the nonidentity of binding sites is a manifestation of some post-translational regulatory event (e.g., phosphorylation/accessory binding protein) or caused by the existence of multiple mol. forms of the DA transporter is currently unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU2Vc8HuOAsLVg90H21EOLACvtfcHk0ljirawjp_e8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhsFemu7c%253D&md5=a6ce271aad17d6f7f282bd716bbd1ddf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPristupa%26aufirst%3DZ.%2BB.%26aulast%3DWilson%26aufirst%3DJ.%2BM.%26aulast%3DHoffman%26aufirst%3DB.%2BJ.%26aulast%3DKish%26aufirst%3DS.%2BJ.%26aulast%3DNiznik%26aufirst%3DH.%2BB.%26atitle%3DPharmacological%2520heterogeneity%2520of%2520the%2520cloned%2520and%2520native%2520human%2520dopamine%2520transporter%253A%2520disassociation%2520of%2520%255B3H%255DWIN%252035%252C428%2520and%2520%255B3H%255DGBR%252012%252C935%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1994%26volume%3D45%26spage%3D125%26epage%3D135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlayson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnbull, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">January, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. S.</span></span> <span> </span><span class="NLM_article-title">[3H]Dofetilide binding to herg transfected membranes: a potential high throughput preclinical screen</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>430</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(01)01362-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FS0014-2999%2801%2901362-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=11698075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotFWhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2001&pages=147-148&author=K.+Finlaysonauthor=L.+Turnbullauthor=C.+T.+Januaryauthor=J.+Sharkeyauthor=J.+S.+Kelly&title=%5B3H%5DDofetilide+binding+to+herg+transfected+membranes%3A+a+potential+high+throughput+preclinical+screen&doi=10.1016%2FS0014-2999%2801%2901362-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen</span></div><div class="casAuthors">Finlayson, Keith; Turnbull, Lorna; January, Craig T.; Sharkey, John; Kelly, John S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">430</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-148</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The pharmacol. characteristics of [3H]dofetilide binding were examd. in membranes prepd. from human embryonic kidney (HEK293) cells stably expressing human ether-a-go-go related gene (HERG) K+ channels.  The class III antiarrhythmic compds. dofetilide, clofilium, 4'-[[1-[2-(6-methyl-2-pyridyl)ethyl]-4-piperidyl]carbonyl]methanesulfonanilide (E-4031), N-methyl-N-[2-[methyl-(1-methyl-1H-benzimidazol-2-yl)amino]ethyl]-4-[(methylsulfonyl)amino]benzene-sulfonamide (WAY-123,398) and d-sotalol all inhibited [3H]dofetilide binding.  In addn., the structurally unrelated compds. pimozide, terfenadine and haloperidol, all of which prolong the QT interval in man, also inhibited binding.  These data indicate that a [3H]dofetilide binding assay using HERG membranes may help identify compds. that prolong the QT interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr09GxPknr35bVg90H21EOLACvtfcHk0ljirawjp_e8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotFWhs74%253D&md5=9849fe1d07c00f00be2ba076ecc7d93b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2801%2901362-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252801%252901362-0%26sid%3Dliteratum%253Aachs%26aulast%3DFinlayson%26aufirst%3DK.%26aulast%3DTurnbull%26aufirst%3DL.%26aulast%3DJanuary%26aufirst%3DC.%2BT.%26aulast%3DSharkey%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%2BS.%26atitle%3D%255B3H%255DDofetilide%2520binding%2520to%2520herg%2520transfected%2520membranes%253A%2520a%2520potential%2520high%2520throughput%2520preclinical%2520screen%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2001%26volume%3D430%26spage%3D147%26epage%3D148%26doi%3D10.1016%2FS0014-2999%2801%2901362-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1124%2Fdmd.110.037911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=21383203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs&doi=10.1124%2Fdmd.110.037911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span></div><div class="casAuthors">Zimmerlin, Alfred; Trunzer, Markus; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although reversible CYP3A inhibition testing is well established for predicting the drug-drug interaction potential of clin. candidates, time-dependent inhibition (TDI) has become the focus of drug designers only recently.  Failure of several late-stage clin. candidates has been attributed to TDI, and this mechanism is also suspected to play a role in liver toxicities often obsd. in preclin. species.  Measurement of enzyme inactivation rates (kinact and KI) is tech. challenging, and a great deal of variability can be found in the literature.  In this article, we have evaluated the TDI potential for 400 registered drugs using a high-throughput assay format based on detn. of the inactivation rate (kobs) at a single concn. of test compd. (10 μM).  The advantages of this new assay format are highlighted by comparison with data generated using the IC50 shift assay, a current std. approach for preliminary assessment of TDI.  With use of an empirically defined pos./neg. kobs bin of 0.02 min-1, only 4% of registered drugs were found to be pos.  This proportion increased to more than 20% when inhouse lead optimization mols. were considered, emphasizing the importance of identifying this property in selection of promising drug candidates.  Finally, it is suggested that the data and technol. described here may be a good basis for building structure-activity relationships and in silico modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobYvW4ft03jbVg90H21EOLACvtfcHk0ljirawjp_e8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D&md5=d21b39e85ab9410b7addfc820c1a4e18</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037911%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1039%26epage%3D1046%26doi%3D10.1124%2Fdmd.110.037911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tilton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">3052</span>– <span class="NLM_lpage">3071</span>, <span class="refDoi"> DOI: 10.1002/jps.20913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1002%2Fjps.20913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=17722003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht12jtrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2007&pages=3052-3071&author=L.+Zhouauthor=L.+Yangauthor=S.+Tiltonauthor=J.+Wang&title=Development+of+a+high+throughput+equilibrium+solubility+assay+using+miniaturized+shake-flask+method+in+early+drug+discovery&doi=10.1002%2Fjps.20913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery</span></div><div class="casAuthors">Zhou, Liping; Yang, Linhong; Tilton, Suzanne; Wang, Jianling</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3052-3071</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Increasingly, pharmaceutical and biotech companies have begun to realize the importance of obtaining soly. information in early drug discovery as it is one of the crit. parameters for lead selection and optimization.  This report introduces a high-throughput equil. soly. (HT-Eq sol) assay using a novel miniaturized shake-flask approach and streamlined HPLC anal.  The new HT-Eq sol assay, validated and optimized via a test set of 85 marketed drugs and Novartis internal compds., shows an excellent correlation to the conventional shake-flask thermodn. soly. data generated inhouse and the equil. soly. results reported in literature.  It therefore offers a fast, reliable and cost-effective screening tool for soly. assessment in early drug discovery, allowing for prioritization of drug candidates using aq. soly. in conjunction with other profiling information and efficacy data.  Our work demonstrates that presence of a small amt. of DMSO (0.5-5%) will result in significant overestimation of equil. soly. (up to 6 folds).  In addn., monitoring of drug dissoln. process using the current approach as well as the interplay between equil. soly. data and those from kinetic soly. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLEKUmI4vDMLVg90H21EOLACvtfcHk0ljirawjp_e8Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht12jtrrO&md5=e04d5b859372d08551b4a6af19e23fb5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjps.20913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20913%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTilton%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520a%2520high%2520throughput%2520equilibrium%2520solubility%2520assay%2520using%2520miniaturized%2520shake-flask%2520method%2520in%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2007%26volume%3D96%26spage%3D3052%26epage%3D3071%26doi%3D10.1002%2Fjps.20913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broddefalk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtenas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemurell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whatling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amilon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundqvist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindstedt, E. L.</span></span> <span> </span><span class="NLM_article-title">Discovery and early clinical development of an inhibitor of 5-lipoxygenase activating protein (AZD5718) for treatment of coronary artery disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4312</span>– <span class="NLM_lpage">4324</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b02004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b02004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvF2gu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4312-4324&author=D.+Pettersenauthor=J.+Broddefalkauthor=H.+Emtenasauthor=M.+A.+Hayesauthor=M.+Lemurellauthor=M.+Swansonauthor=J.+Ulanderauthor=C.+Whatlingauthor=C.+Amilonauthor=H.+Ericssonauthor=A.+Westin+Erikssonauthor=K.+Granbergauthor=A.+T.+Plowrightauthor=I.+Shamovskyauthor=A.+Dellsenauthor=M.+Sundqvistauthor=M.+Nagardauthor=E.+L.+Lindstedt&title=Discovery+and+early+clinical+development+of+an+inhibitor+of+5-lipoxygenase+activating+protein+%28AZD5718%29+for+treatment+of+coronary+artery+disease&doi=10.1021%2Facs.jmedchem.8b02004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease</span></div><div class="casAuthors">Pettersen, Daniel; Broddefalk, Johan; Emtenaes, Hans; Hayes, Martin A.; Lemurell, Malin; Swanson, Marianne; Ulander, Johan; Whatling, Carl; Amilon, Carl; Ericsson, Hans; Westin Eriksson, Annika; Granberg, Kenneth; Plowright, Alleyn T.; Shamovsky, Igor; Dellsen, Anita; Sundqvist, Monica; Naagaard, Mats; Lindstedt, Eva-Lotte</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4312-4324</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the prodn. of proinflammatory and vasoactive leukotrienes.  As such, they are hypothesized to have therapeutic benefit for the treatment of diseases that involve chronic inflammation including coronary artery disease.  Herein, we disclose the medicinal chem. discovery and the early clin. development of the FLAP inhibitor AZD5718 (12).  Multiparameter optimization included securing adequate potency in human whole blood, navigation away from Ames mutagenic amine fragments while balancing metabolic stability and PK properties allowing for clin. relevant exposures after oral dosing.  The superior safety profile of AZD5718 compared to earlier front-runner compds. allowed us to perform a phase 1 clin. study in which AZD5718 demonstrated a dose dependent and greater than 90% suppression of leukotriene prodn. over 24 h.  Currently, AZD5718 is evaluated in a phase 2a study for treatment of coronary artery disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn10AbsxceKbVg90H21EOLACvtfcHk0li9aGlJgeimwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvF2gu7k%253D&md5=2f4eb866bc093f89ab36d97369eec718</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b02004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b02004%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DD.%26aulast%3DBroddefalk%26aufirst%3DJ.%26aulast%3DEmtenas%26aufirst%3DH.%26aulast%3DHayes%26aufirst%3DM.%2BA.%26aulast%3DLemurell%26aufirst%3DM.%26aulast%3DSwanson%26aufirst%3DM.%26aulast%3DUlander%26aufirst%3DJ.%26aulast%3DWhatling%26aufirst%3DC.%26aulast%3DAmilon%26aufirst%3DC.%26aulast%3DEricsson%26aufirst%3DH.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26aulast%3DGranberg%26aufirst%3DK.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DDellsen%26aufirst%3DA.%26aulast%3DSundqvist%26aufirst%3DM.%26aulast%3DNagard%26aufirst%3DM.%26aulast%3DLindstedt%26aufirst%3DE.%2BL.%26atitle%3DDiscovery%2520and%2520early%2520clinical%2520development%2520of%2520an%2520inhibitor%2520of%25205-lipoxygenase%2520activating%2520protein%2520%2528AZD5718%2529%2520for%2520treatment%2520of%2520coronary%2520artery%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4312%26epage%3D4324%26doi%3D10.1021%2Facs.jmedchem.8b02004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzpatrick, F.</span></span> <span> </span><span class="NLM_article-title">Enzymatic hydration of leukotriene A4. purification and characterization of a novel epoxide hydrolase from human erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">12832</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)38953-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2FS0021-9258%2817%2938953-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=2995393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADyaL2MXmtV2msLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=12832-7&author=J.+McGeeauthor=F.+Fitzpatrick&title=Enzymatic+hydration+of+leukotriene+A4.+purification+and+characterization+of+a+novel+epoxide+hydrolase+from+human+erythrocytes&doi=10.1016%2FS0021-9258%2817%2938953-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Enzymic hydration of leukotriene A4.  Purification and characterization of a novel epoxide hydrolase from human erythrocytes</span></div><div class="casAuthors">McGee, James; Fitzpatrick, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">12832-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Human erythrocytes contained a sol. cytosolic epoxide hydrolase for stereospecific enzymic hydration of leukotriene A4 into leukotriene B4.  The enzyme was purified 1100-fold, to apparent electrophoretic homogeneity, by conventional DEAE-Sephacel fractionation followed by high-performance anion-exchange and chromatofocusing procedures.  Its characteristics include a mol. wt. of 54,000, a pI of 4.9, an apparent Km of 7-36 μM for hydration of leukotriene A4, and a pH optimum of 7-8.  The enzyme was partially inactivated on initial exposure to leukotriene A4.  There was slow but detectable enzymic hydration (rates on the order of pmol/min/mg) of certain arachidonic acid epoxides including (±)-14,15-oxido-5,8,11-eicosatrienoic acid and (±)-11,12-oxido-5,8,14-eicosatrienoic acid, but not of others, including 5,6-oxido-8,11,14-eicosatrienoic acid.  Human erythrocyte epoxide hydrolase did not hydrate either styrene oxide or trans-stilbene oxide.  In terms of its phys. properties and substrate preference for leukotriene A4, the erythrocyte enzyme differs from previously described epoxide hydrolases.  Human erythrocytes represent a novel source for an extrahepatic, cytosolic epoxide hydrolase with a potential physiol. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiqGTP2_pyk7Vg90H21EOLACvtfcHk0lgCKTA7X_Ck7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtV2msLk%253D&md5=ce741ac81c849f240c3aeb4de1c95ba0</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2938953-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252938953-6%26sid%3Dliteratum%253Aachs%26aulast%3DMcGee%26aufirst%3DJ.%26aulast%3DFitzpatrick%26aufirst%3DF.%26atitle%3DEnzymatic%2520hydration%2520of%2520leukotriene%2520A4.%2520purification%2520and%2520characterization%2520of%2520a%2520novel%2520epoxide%2520hydrolase%2520from%2520human%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D12832%26epage%3D7%26doi%3D10.1016%2FS0021-9258%2817%2938953-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanaoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigrovic, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audoly, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austen, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span> <span> </span><span class="NLM_article-title">Neutrophil-derived leukotriene B4 is required for inflammatory arthritis</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">837</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1084/jem.20052371</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1084%2Fjem.20052371" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=16567388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjsl2isrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2006&pages=837-842&author=M.+Chenauthor=B.+K.+Lamauthor=Y.+Kanaokaauthor=P.+A.+Nigrovicauthor=L.+P.+Audolyauthor=K.+F.+Austenauthor=D.+M.+Lee&title=Neutrophil-derived+leukotriene+B4+is+required+for+inflammatory+arthritis&doi=10.1084%2Fjem.20052371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil-derived leukotriene B4 is required for inflammatory arthritis</span></div><div class="casAuthors">Chen, Mei; Lam, Bing K.; Kanaoka, Yoshihide; Nigrovic, Peter A.; Audoly, Laurent P.; Austen, K. Frank; Lee, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">837-842</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Neutrophils serve as a vanguard of the acute innate immune response to invading pathogens.  Neutrophils are also abundant at sites of autoimmune inflammation, such as the rheumatoid joint, although their pathophysiol. role is incompletely defined and relevant effector functions remain obscure.  Using genetic and pharmacol. approaches in the K/BxN serum transfer model of arthritis, we find that autoantibody-driven erosive synovitis is critically reliant on the generation of leukotrienes, and more specifically on leukotriene B4 (LTB4), for disease induction as well as perpetuation.  Pursuing the cellular source for this mediator, we find via reconstitution expts. that mast cells are a dispensable source of leukotrienes, whereas arthritis susceptibility can be restored to leukotriene-deficient mice by i.v. administration of wild-type neutrophils.  These expts. demonstrate a nonredundant role for LTB4 in inflammatory arthritis and define a neutrophil mediator involved in orchestrating the synovial eruption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQxyyQ20JRbVg90H21EOLACvtfcHk0lgCKTA7X_Ck7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjsl2isrs%253D&md5=d2b74595b60d56bb7d8d3850da3a98ed</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1084%2Fjem.20052371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20052371%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DB.%2BK.%26aulast%3DKanaoka%26aufirst%3DY.%26aulast%3DNigrovic%26aufirst%3DP.%2BA.%26aulast%3DAudoly%26aufirst%3DL.%2BP.%26aulast%3DAusten%26aufirst%3DK.%2BF.%26aulast%3DLee%26aufirst%3DD.%2BM.%26atitle%3DNeutrophil-derived%2520leukotriene%2520B4%2520is%2520required%2520for%2520inflammatory%2520arthritis%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2006%26volume%3D203%26spage%3D837%26epage%3D842%26doi%3D10.1084%2Fjem.20052371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsson, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zembower, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">4694</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/jm900259h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900259h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BD1MXoslCntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4694-4715&author=D.+R.+Daviesauthor=B.+Mamatauthor=O.+T.+Magnussonauthor=J.+Christensenauthor=M.+H.+Haraldssonauthor=R.+Mishraauthor=B.+Peaseauthor=E.+Hansenauthor=J.+Singhauthor=D.+Zembowerauthor=H.+Kimauthor=A.+S.+Kiselyovauthor=A.+B.+Burginauthor=M.+E.+Gurneyauthor=L.+J.+Stewart&title=Discovery+of+leukotriene+A4+hydrolase+inhibitors+using+metabolomics+biased+fragment+crystallography&doi=10.1021%2Fjm900259h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography</span></div><div class="casAuthors">Davies, Douglas R.; Mamat, Bjorn; Magnusson, Olafur T.; Christensen, Jeff; Haraldsson, Magnus H.; Mishra, Rama; Pease, Brian; Hansen, Erik; Singh, Jasbir; Zembower, David; Kim, Hidong; Kiselyov, Alex S.; Burgin, Alex B.; Gurney, Mark E.; Stewart, Lance J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4694-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe a novel fragment library termed fragments of life (FOL) for structure-based drug discovery.  The FOL library includes natural small mols. of life, derivs. thereof, and biaryl protein architecture mimetics.  The choice of fragments facilitates the interrogation of protein active sites, allosteric binding sites, and protein-protein interaction surfaces for fragment binding.  We screened the FOL library against leukotriene A4 hydrolase (LTA4H) by X-ray crystallog.  A diverse set of fragments including derivs. of resveratrol, nicotinamide, and indole were identified as efficient ligands for LTA4H.  These fragments were elaborated in a small no. of synthetic cycles into potent inhibitors of LTA4H representing multiple novel chemotypes for modulating leukotriene biosynthesis.  Anal. of the fragment-bound structures also showed that the fragments comprehensively recapitulated key chem. features and binding modes of several reported LTA4H inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRKrUSDopfiLVg90H21EOLACvtfcHk0lg7qyl71sFNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXoslCntbo%253D&md5=017d54b1dc012e3dcdf7194c04ef8cff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm900259h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900259h%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DMamat%26aufirst%3DB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DHaraldsson%26aufirst%3DM.%2BH.%26aulast%3DMishra%26aufirst%3DR.%26aulast%3DPease%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DE.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DZembower%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520leukotriene%2520A4%2520hydrolase%2520inhibitors%2520using%2520metabolomics%2520biased%2520fragment%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4694%26epage%3D4715%26doi%3D10.1021%2Fjm900259h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanis, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacani, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blevitt, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chrovian, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Leon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grice, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry-Bayle, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Dutra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santillán, A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiener, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. L.</span></span> <span> </span><span class="NLM_article-title">Azabenzthiazole inhibitors of leukotriene A4 hydrolase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7504</span>– <span class="NLM_lpage">7511</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.bmcl.2012.10.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=23127888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aru7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7504-7511&author=V.+M.+Tanisauthor=G.+M.+Bacaniauthor=J.+M.+Blevittauthor=C.+C.+Chrovianauthor=S.+Crawfordauthor=A.+De+Leonauthor=A.+M.+Fourieauthor=L.+Gomezauthor=C.+A.+Griceauthor=K.+Hermanauthor=A.+M.+Kearneyauthor=A.+M.+Landry-Bayleauthor=A.+Lee-Dutraauthor=J.+Nelsonauthor=J.+P.+Rileyauthor=A.+Santill%C3%A1nauthor=J.+J.+Wienerauthor=X.+Xueauthor=A.+L.+Young&title=Azabenzthiazole+inhibitors+of+leukotriene+A4+hydrolase&doi=10.1016%2Fj.bmcl.2012.10.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Azabenzthiazole inhibitors of leukotriene A4 hydrolase</span></div><div class="casAuthors">Tanis, Virginia M.; Bacani, Genesis M.; Blevitt, Jonathan M.; Chrovian, Christa C.; Crawford, Shelby; De Leon, Aimee; Fourie, Anne M.; Gomez, Laurent; Grice, Cheryl A.; Herman, Krystal; Kearney, Aaron M.; Landry-Bayle, Adrienne M.; Lee-Dutra, Alice; Nelson, Jay; Riley, Jason P.; Santillan, Alejandro; Wiener, John J. M.; Xue, Xiaohua; Young, Arlene L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7504-7511</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, benzthiazole contg. LTA4H inhibitors were discovered that were potent (1-3), but were assocd. with the potential for a hERG liability.  Utilizing medicinal chem. first principles (e.g., introducing rigidity, lowering c Log D) a new benzthiazole series was designed, congeners of 1-3, which led to compds. 7a, 7c, 12a-d which exhibited LTA4H IC50 = 3-6 nM and hERG Dofetilide Binding IC50 = 8.9-> >10 μM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt7wPhfnUv2bVg90H21EOLACvtfcHk0lg7qyl71sFNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aru7zJ&md5=c621215851acb4598d945faac3e12be0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.036%26sid%3Dliteratum%253Aachs%26aulast%3DTanis%26aufirst%3DV.%2BM.%26aulast%3DBacani%26aufirst%3DG.%2BM.%26aulast%3DBlevitt%26aufirst%3DJ.%2BM.%26aulast%3DChrovian%26aufirst%3DC.%2BC.%26aulast%3DCrawford%26aufirst%3DS.%26aulast%3DDe%2BLeon%26aufirst%3DA.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26aulast%3DGomez%26aufirst%3DL.%26aulast%3DGrice%26aufirst%3DC.%2BA.%26aulast%3DHerman%26aufirst%3DK.%26aulast%3DKearney%26aufirst%3DA.%2BM.%26aulast%3DLandry-Bayle%26aufirst%3DA.%2BM.%26aulast%3DLee-Dutra%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DRiley%26aufirst%3DJ.%2BP.%26aulast%3DSantill%25C3%25A1n%26aufirst%3DA.%26aulast%3DWiener%26aufirst%3DJ.%2BJ.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYoung%26aufirst%3DA.%2BL.%26atitle%3DAzabenzthiazole%2520inhibitors%2520of%2520leukotriene%2520A4%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7504%26epage%3D7511%26doi%3D10.1016%2Fj.bmcl.2012.10.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span> </span><span class="NLM_article-title">Diamine derivatives as inhibitors of leukotriene A4
hydrolase</span>. US <span class="NLM_patent">2007/155726</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Diamine+derivatives+as+inhibitors+of+leukotriene+A4%0Ahydrolase.+US+2007%2F155726%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26atitle%3DDiamine%2520derivatives%2520as%2520inhibitors%2520of%2520leukotriene%2520A4%250Ahydrolase%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penno, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laguerre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasler, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gass, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wettstein-Ling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raulf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, J. C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesche, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röhn, T. A.</span></span> <span> </span><span class="NLM_article-title">Lipidomics profiling of hidradenitis suppurativa skin lesions reveals lipoxygenase pathway dysregulation and accumulation of proinflammatory leukotriene B4</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">2421</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.1016/j.jid.2020.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=10.1016%2Fj.jid.2020.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=32387270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlOjtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2020&pages=2421-2432&author=C.+A.+Pennoauthor=P.+Jagerauthor=C.+Laguerreauthor=F.+Haslerauthor=A.+Hofmannauthor=S.+K.+Gassauthor=B.+Wettstein-Lingauthor=D.+J.+Schaeferauthor=A.+Avrameasauthor=F.+Raulfauthor=G.+Wieczorekauthor=J.+C.+U.+Lehmannauthor=C.+Loescheauthor=L.+Rothauthor=T.+A.+R%C3%B6hn&title=Lipidomics+profiling+of+hidradenitis+suppurativa+skin+lesions+reveals+lipoxygenase+pathway+dysregulation+and+accumulation+of+proinflammatory+leukotriene+B4&doi=10.1016%2Fj.jid.2020.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4</span></div><div class="casAuthors">Penno, Carlos A.; Jager, Petra; Laguerre, Claire; Hasler, Franziska; Hofmann, Andreas; Gass, Stephanie K.; Wettstein-Ling, Barbara; Schaefer, Dirk J.; Avrameas, Alexandre; Raulf, Friedrich; Wieczorek, Grazyna; Lehmann, Joachim C. U.; Loesche, Christian; Roth, Lukas; Rohn, Till A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2421-2432.e10</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hidradenitis suppurativa (HS) is a chronic, recurring inflammatory dermatosis characterized by abscesses, deep-seated nodules, sinus tracts, and fibrosis in skin lesions around hair follicles of the axillary, inguinal, and anogenital regions.  Whereas the exact pathogenesis remains poorly defined, clear evidence suggests that HS is a multifactorial inflammatory disease characterized by innate and adaptive immune components.  Bioactive lipids are important regulators of cutaneous homeostasis, inflammation, and resoln. of inflammation.  Alterations in the lipid mediator profile can lead to malfunction and cutaneous inflammation.  We used targeted lipidomics to analyze selected omega-3 and omega-6 polyunsatd. fatty acids in skin of patients with HS and of healthy patients.  Lesional HS skin displayed enrichment of 5-lipoxygenase (LO)-derived metabolites, esp. leukotriene B4.  In addn., 15-LO-derived metabolites were underrepresented in HS lesions.  Changes in the lipid mediator profile were accompanied by transcriptomic dysregulation of the 5-LO and 15-LO pathways.  Hyperactivation of the 5-LO pathway in lesional macrophages identified these cells as potential sources of leukotriene B4, which may cause neutrophil influx and activation.  Furthermore, leukotriene B4-induced mediators and pathways were elevated in HS lesions, suggesting a contribution of this proinflammatory lipid meditator to the pathophysiol. of HS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1Nh26aY3EnrVg90H21EOLACvtfcHk0lg7qyl71sFNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlOjtrfM&md5=97fa46a26120c196c6b85ca8aab0b77d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.jid.2020.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jid.2020.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPenno%26aufirst%3DC.%2BA.%26aulast%3DJager%26aufirst%3DP.%26aulast%3DLaguerre%26aufirst%3DC.%26aulast%3DHasler%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DA.%26aulast%3DGass%26aufirst%3DS.%2BK.%26aulast%3DWettstein-Ling%26aufirst%3DB.%26aulast%3DSchaefer%26aufirst%3DD.%2BJ.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DRaulf%26aufirst%3DF.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DLehmann%26aufirst%3DJ.%2BC.%2BU.%26aulast%3DLoesche%26aufirst%3DC.%26aulast%3DRoth%26aufirst%3DL.%26aulast%3DR%25C3%25B6hn%26aufirst%3DT.%2BA.%26atitle%3DLipidomics%2520profiling%2520of%2520hidradenitis%2520suppurativa%2520skin%2520lesions%2520reveals%2520lipoxygenase%2520pathway%2520dysregulation%2520and%2520accumulation%2520of%2520proinflammatory%2520leukotriene%2520B4%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2020%26volume%3D140%26spage%3D2421%26epage%3D2432%26doi%3D10.1016%2Fj.jid.2020.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV2','PDB','7AV2'); return false;">PDB: 7AV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV1','PDB','7AV1'); return false;">PDB: 7AV1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV0','PDB','7AV0'); return false;">PDB: 7AV0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AUZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AUZ','PDB','7AUZ'); return false;">PDB: 7AUZ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01955">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80382"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01955?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01955</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis of compounds <b>2</b>–<b>23</b>; structural biology data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_001.pdf">jm0c01955_si_001.pdf (2.0 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01955/suppl_file/jm0c01955_si_002.csv">jm0c01955_si_002.csv (3.37 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID codes: <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV2">7AV2</a>; <b>2</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV1">7AV1</a>; (<i><b>R</b></i>)-<b>13</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AV0">7AV0</a>; (<i><b>S</b></i>)-<b>22</b> = LYS006, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7AUZ">7AUZ</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01955&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01955%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01955" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679929e35957d95a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
